candesartan has been researched along with Hypertension in 597 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the blood pressure-lowering and cholesterol-lowering effects of a fixed-dose combination therapy using candesartan (CND)/rosuvastatin (RSV) compared with CND or RSV monotherapy in patients with hypertension and hypercholesterolemia." | 9.30 | Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study. ( Ahn, JC; Ahn, SH; Chang, K; Cho, KI; Chung, WJ; Gyu Park, C; Hong, BK; Hong, TJ; Kim, BH; Kim, SH; Kim, SY; Kim, W; Kim, YJ; Lee, JY; Park, YH; Ryu, JK; Shin, JH; Sohn, IS; Yu, CW, 2019) |
| "The Effects of Angiotensin Receptor Blockers on Diastolic Function in Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE trial is a multicenter, randomized, open-labeled, and assessor(s)-blinded, active controlled using candesartan, parallel-group clinical trial, to compare changes in left ventricular (LV) diastolic dysfunction between HFpEF patients with hypertension who have received candesartan or azilsartan for 48 weeks." | 9.27 | Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction ( Abe, Y; Ajioka, M; Anzai, T; Aonuma, K; Asakura, M; Hamasaki, T; Hayashi, T; Hiramitsu, S; Kawai, H; Kimura, K; Kioka, H; Kitakaze, M; Lim, YJ; Matsuoka, K; Motoki, H; Nagata, Y; Nakamura, S; Ohte, N; Ozaki, Y; Sasaoka, T; Takahama, H; Tamaki, S, 2018) |
| " Three hundred sixty-two individuals were screened, and 290 patients aged 19 to 75 years with mild to moderate hypertension (diastolic blood pressure [DBP], 90-110 mm Hg) were randomly assigned to 60 to 120 mg/d of fimasartan or 8 mg/d of candesartan after a 2-week placebo run-in period." | 9.22 | A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension. ( Cha, GS; Cha, TJ; Chae, SC; Chun, KJ; Hong, GR; Hur, SH; Hwang, JY; Kim, DI; Kim, DS; Kim, KS; Kim, MH; Lee, JH; Lee, SG; Yang, DH, 2016) |
| "The objective of this study was to investigate the efficacy of the fixed-dose combination olmesartan/amlodipine 40/10 mg in patients with moderate essential hypertension not controlled on candesartan 32 mg." | 9.19 | Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2014) |
| "SCAST was a randomized- and placebo-controlled, double-masked trial of candesartan given for 7 days, in 2029 patients with acute stroke and systolic blood pressure ≥140 mm Hg." | 9.19 | Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2014) |
| "Scandinavian Candesartan Acute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan in 2029 patients with acute stroke and raised blood pressure." | 9.17 | Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial. ( Bath, PM; Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2013) |
| "The purpose of this post hoc subgroup analysis was to compare the incidence of major adverse cardiovascular events (MACE) of patients treated with candesartan and amlodipine with that of those with candesartan and non-amlodipine CCBs in hypertensive patients with coronary artery disease (CAD)." | 9.17 | Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. ( Hagiwara, N; Haruta, S; Kawada-Watanabe, E; Koyanagi, R; Ogawa, H; Takagi, A; Yamaguchi, J, 2013) |
| "As part of a randomized, double-blind study of azilsartan (20-40 mg once daily) and candesartan (8-12 mg once daily) in Japanese patients with essential hypertension, an exploratory analysis was performed using ambulatory BP monitoring (ABPM) at baseline and Week 14." | 9.17 | Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension. ( Enya, K; Igeta, M; Ikeda, Y; Kario, K; Rakugi, H, 2013) |
| "A direct switch of candesartan to the fixed-dose combination olmesartan/amlodipine in uncontrolled hypertension is a frequent clinical requirement but is not covered by current labeling." | 9.17 | Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2013) |
| " Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy." | 9.16 | Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012) |
| "The aim of the present study was to clarify the influence of candesartan-based therapy on subsequent carcinogenesis and cancer death in patients with coronary artery disease with hypertension in a substudy of a multicenter, prospective, randomized, controlled trial." | 9.16 | Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy). ( Hagiwara, N; Koyanagi, R; Ogawa, H; Oka, T; Sugiura, R, 2012) |
| "The Candesartan Cooperative Research of Therapy Design for Early Morning Hypertension in CHIBA was designed to investigate whether switching from angiotensin II receptor blockers (ARBs) except candesartan to candesartan might be effective in Japanese patients with morning hypertension." | 9.16 | Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. ( Hasegawa, H; Kameda, Y; Kobayashi, Y; Komuro, I; Kubota, A; Takano, H, 2012) |
| "The aim of this study was to evaluate the effects of imidapril and candesartan on fibrinolysis and insulin sensitivity in normoweight hypertensive patients." | 9.15 | Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. ( Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Salvadeo, SA; Santoro, T; Zoppi, A, 2011) |
| " We report the experience from DIRECT (DIabetic REtinopathy and Candesartan Trials), three placebo-controlled studies designed to examine the effects of an ARB, candesartan, on diabetic retinopathy." | 9.15 | Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. ( Bilous, R; Chaturvedi, N; Fuller, JH; Hainer, JW; Jansson, SO; Klein, R; Malm, A; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2011) |
| "The GIFU substudy of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was conducted to compare the long-term effects of candesartan and amlodipine on office- and home-measured blood pressure (BP), QTc dispersion and left ventricular mass index (LVMI) in high-risk Japanese patients with hypertension." | 9.15 | Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients. ( Fujiwara, H; Matsuno, Y; Minatoguchi, S, 2011) |
| " 512 patients with moderate to severe primary hypertension were randomly assigned to an 8-week treatment with either ARB (candesartan)-based regimen (n=257) or ACE inhibitor (imidapril)-based regimen (n=255)." | 9.15 | Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. ( Cheng, X; Fu, M; Gu, Y; Guo, XM; Jia, XJ; Liao, YH; Wang, L; Wang, M; Wei, F; Wei, YM; Yu, SQ; Zhou, ZH; Zhu, F, 2011) |
| "There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure." | 9.15 | The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. ( Bath, PM; Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, GD; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2011) |
| "In patients with hypertension and obesity showing insulin resistance, treatment with telmisartan significantly improved the hyperinsulin response to glucose loading." | 9.15 | Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). ( Matsuura, K; Mori, Y; Tanaka, T; Utsunomiya, K; Yokoyama, J, 2011) |
| "To evaluate the relationship between plasma plasminogen activator inhibitor-1 (PAI-1) and angiotensin II (Ang II) changes during treatment with imidapril and candesartan in hypertensive patients with metabolic syndrome." | 9.15 | Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2011) |
| "Participants enrolled in this trial were outpatients with essential hypertension after cardiac surgery who had received candesartan for more than one year." | 9.15 | Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study. ( Hata, M; Sezai, A; Shiono, M; Soma, M; Unosawa, S; Wakui, S; Yoshitake, I, 2011) |
| "Hypertensive patients (n = 196) with echocardigraphically documented left ventricular hypertrophy were randomized to candesartan 8-16 mg/day (n = 91) or enalapril 10-20 mg/day (n = 105) with possible addition of hydrochlorothiazide (12." | 9.14 | Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-co ( Ciulla, MM; Cuspidi, C; Esposito, A; Magrini, F; Muiesan, ML; Paliotti, R; Rosei, EA; Zanchetti, A, 2009) |
| "Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)." | 9.14 | Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009) |
| "Data from 4632 men and women (sex ratio 1:1, mean age 54 years) with mild to moderate hypertension, who participated in one of seven randomized, double-blind, placebo-controlled studies with candesartan-HCT for 8-12 weeks, were entered in a common database." | 9.14 | A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension. ( Elmfeldt, D; Karlson, BW; Olofsson, B; Zetterstrand, S, 2009) |
| "A total of 50 stable outpatients with essential hypertension who had received candesartan for more than 1 year were randomized into two groups: control group (n=25): continuous candesartan treatment at a stable dose; and olmesartan group (n=25): candesartan (8 mg day(-1)) was changed to olmesartan given at a dose of 20 mg day(-1)." | 9.14 | Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. ( Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T, 2010) |
| "We compared the effects of telmisartan with those of candesartan, on insulin sensitivity, the serum levels of various adipocytokines and oxidative stress." | 9.14 | Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. ( Awata, T; Ikebukuro, K; Inukai, K; Ito, D; Katayama, S; Kurihara, S; Ono, H; Sumita, T; Watanabe, M, 2010) |
| "The Scandinavian Candesartan Acute Stroke Trial is an international randomised, placebo-controlled, double-blind trial of candesartan in acute stroke." | 9.14 | Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003). ( Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, G; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2010) |
| " Hypertensive patients with impaired glucose tolerance were randomly divided into two groups: group A (n = 6), which received 8 mg/day of oral candesartan for three months, and controls (n = 6)." | 9.13 | Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. ( Aizawa, Y; Nakagawa, O; Suzuki, K, 2008) |
| "We investigated the effect of treatment of hypertension on cognition with the angiotensin-receptor-blocker, candesartan, in a placebo-controlled, double-blind, randomized controlled trial at one center participating in the Study on Cognition and Prognosis in the Elderly." | 9.13 | Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. ( Ford, GA; Harrington, F; McKeith, IG; Saxby, BK; Wesnes, KA, 2008) |
| " Patients with systolic-diastolic or isolated systolic hypertension (n = 1758) received indapamide (1." | 9.12 | Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. ( Asmar, R; Calvo, C; London, G; Schmieder, R, 2006) |
| "The patients with essential hypertension were randomly divided into 2 groups; 1 group was treated with an ARB, candesartan (8 mg/day), for 1 year (ARB group) and other group was treated with the ARB for the first 6 months and with the ARB plus SPRL (25 mg/day) for the next 6 months (combination group)." | 9.12 | Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. ( Date, T; Kawai, M; Mochizuki, S; Seki, S; Shimizu, M; Taniguchi, I; Taniguchi, M; Yoshida, S, 2006) |
| "The aim of this study was to evaluate the annhypertensive efficacy and tolerability of the angiotensin-converting enzyme inhibitor imidapril and the angiotensin II type 1 receptor antagonist candesartan in mild to moderate essential hypertension." | 9.12 | A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicent ( Anglada, MP; Contreras, EM; Esquerra, EA; Martínez, JO; Palma Gámiz, JL; Pêgo, M; Sagastagoitia Gorostiza, JD, 2006) |
| "Forty-nine patients with untreated mild to moderate essential hypertension were recruited in a randomized double-blind study to receive a daily dose either of 8 mg candesartan or 5 mg amlodipine for 16 weeks." | 9.12 | Effects of amlodipine and candesartan on oxidized LDL level in patients with mild to moderate essential hypertension. ( Fischer, K; Kampus, P; Muda, P; Ristimäe, T; Teesalu, R; Zilmer, K; Zilmer, M, 2006) |
| "We evaluated the long-term efficacy of losartan and low-dose hydrochlorothiazide combination therapy in the treatment of hypertension." | 9.12 | Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension. ( Abe, C; Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Takahashi, T, 2007) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 9.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "We administered placebo, losartan 100 mg/day, irbesartan 300 mg/day, and candesartan 16 mg/day during 2 months to 122 patients with mild to moderate hypertension." | 9.11 | Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. ( Ahn, JY; Ahn, TH; Chung, WJ; Han, SH; Jin, DK; Kang, WC; Kim, HS; Koh, KK; Park, GS; Shin, EK, 2004) |
| "Twenty-three elderly patients with systolic hypertension completed a double-blind crossover study comparing placebo, candesartan (C) 16 mg, C32 mg, lisinopril (L) 20 mg, L40 mg and C16 mg + L20 mg." | 9.11 | Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. ( Anderson, A; Bertram, D; MacInnis, RJ; Morgan, T, 2004) |
| "The aim of this study was to test the hypothesis that the angiotensin II type 1 receptor blocker (ARB) candesartan can reduce the risk of stroke in elderly patients with isolated systolic hypertension (ISH)." | 9.11 | Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). ( Elmfeldt, D; Farsang, C; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2004) |
| "Forty-nine middle-aged patients with untreated stage I-II essential hypertension were recruited in a randomized double-blind double-dummy study to receive a daily dose either of 8 mg candesartan (n = 25) or 5 mg amlodipine (n = 24) for 16 weeks." | 9.11 | Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin concentrations in patients with essential hypertension. ( Fischer, K; Kairane, C; Kampus, P; Muda, P; Ristimäe, T; Teesalu, R; Zilmer, K; Zilmer, M, 2005) |
| "The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme consists of three randomised, double-masked, parallel, placebo-controlled studies to determine the impact of treatment with candesartan on diabetic retinopathy." | 9.10 | The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. ( Chaturvedi, N; Sjoelie, AK; Svensson, A, 2002) |
| "Both candesartan and a low dose of hydrochlorothiazide are effective and well-tolerated antihypertensive agents in isolated systolic hypertension with additive effects in combination." | 9.10 | Candesartan and hydrochlorothiazide in isolated systolic hypertension. ( Arnolda, LF; Molloy, D; Upton, J; Wing, LM, 2003) |
| "The aim of this study was to evaluate, in patients with chronic renal failure in hemodialysis and arterial hypertension, the effectiveness of a new angiotensin II receptor antagonist, the candesartan cilexitil, comparing it with losartan, the first of this new class of drugs." | 9.09 | [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Russo, PE; Tagliamonte, E, 1999) |
| "The goal of this multicenter, double-blind, randomized, parallel-group study was to compare the effects of losartan potassium (hereafter referred to as losartan), candesartan cilexitil (hereafter referred to as candesartan), and losartan/hydrochlorothiazide (HCTZ) in patients with mild to moderate hypertension (sitting diastolic blood pressure [SiDBP] 95-115 mm Hg)." | 9.09 | Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. ( Barragan, J; Bernhardi, DC; Bunt, T; Cabrera, WJ; Dumortier, T; Grossman, E; Jacovides, A; Jelakovic, B; Manolis, AJ; Matadamas, N; Mejia, AD; Mendiola, A; Smith, RD; Watanabe, LA; Woo, KS; Zhu, JR, 2000) |
| "To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes." | 9.09 | Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. ( Cooper, ME; Mogensen, CE; Neldam, S; Oren, S; Tikkanen, I; Viskoper, R; Watts, RW, 2000) |
| "Candesartan, an AT(1) receptor antagonist, has been reported to have no association with persistent cough in subjects with hypertension, but there has been no study on the safety of its administration to hypertensive patients with symptomatic asthma." | 9.09 | Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. ( Abe, S; Hashimoto, M; Oashi, K; Saikai, T; Suzuki, K; Tanaka, H; Tanaka, S; Teramoto, S, 2001) |
| "The UK National Health Service (NHS) currently spends in excess of £250 million per annum on angiotensin II receptor blockers (ARBs) for the treatment of hypertension and heart failure; with candesartan currently dominating the market." | 8.87 | Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. ( Bodalia, PN; Grosso, AM; Hingorani, AD; Macallister, RJ; Moon, JC; Scott, MA, 2011) |
| " Several clinical trials have compared candesartan with losartan in the management of essential hypertension." | 8.87 | A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. ( , 2011) |
| "Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential hypertension." | 8.85 | Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. ( Falvey, H; Lowy, A; Müller, E; Nixon, RM, 2009) |
| " Candesartan, a long-acting angiotensin receptor antagonist, has been shown to be an effective, and well-tolerated therapy, in both the early and late phases of cardiovascular disease (prehypertension, hypertension, left ventricular hypertrophy and heart failure)." | 8.84 | Candesartan: from left ventricular hypertrophy to heart failure, a global approach. ( Barrios, V; Calderon, A; Escobar, C, 2007) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 8.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "These findings suggest that 5-ALA-HCl does not affect the antihypertensive agents-induced hypotensive effect, but enhances the bupivacaine-induced hypotensive effect, especially in SHRs, indicating that 5-ALA may contribute to anesthesia-induced hypotension via suppression of sympathetic nerve activity in patients with hypertension." | 8.31 | 5-Aminolevulinic acid hydrochloride enhances bupivacaine-induced hypotension in spontaneously hypertensive rats. ( Abe, M; Fukuda, N; Hara, T; Ishizuka, M; Ito, H; Katakawa, M; Otsuka, N, 2023) |
| "Elastin deficiency causes vascular stiffening, a leading risk for hypertension and chronic kidney disease (CKD)." | 7.85 | Elastin insufficiency causes hypertension, structural defects and abnormal remodeling of renal vascular signaling. ( Jie, L; Osei-Owusu, P; Owens, EA; Reyes, BAS; Van Bockstaele, EJ, 2017) |
| "A chronic increase in circulating angiotensin II (Ang II) activates an aldosterone-mineralocorticoid receptor-ouabain neuromodulatory pathway in the brain that increases neuronal activation in hypothalamic nuclei, such as the paraventricular nucleus (PVN) and causes progressive hypertension." | 7.79 | Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension. ( Gabor, A; Leenen, FH, 2013) |
| "This study investigated whether the angiotensin II type-1 receptor blocker (ARB) candesartan affects markers of oxidative stress in type 2 diabetes mellitus (DM) patients with essential hypertension (EH)." | 7.79 | Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension. ( Miura, Y; Mizuno, K; Ono, Y; Takahashi, M; Watanabe, T, 2013) |
| "4%) when using candesartan compared with losartan in the primary treatment of hypertension." | 7.77 | Health-care costs of losartan and candesartan in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Henriksson, M; Kjeldsen, S; Levin, LÅ; Russell, D; Stålhammar, J, 2011) |
| "A probabilistic cost-benefit model was constructed for a cohort of patients with moderate hypertension, based on a standardised titration and maintenance algorithm using either olmesartan or candesartan, combined with thiazide and calcium channel blocker where required." | 7.77 | Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens. ( Belsey, JD, 2011) |
| "The aim of the study was to elucidate normalizing effect of candesartan on disturbed thrombocytic hemostasis in patients with arterial hypertension and metabolic syndrome." | 7.77 | [Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan]. ( Medvedev, IN; Simonenko, VB; Tolmachev, VV, 2011) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 7.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| " Our aims were to survey the changes in plasma lipid profile in patients with hypertension over a one-year period, and to examine the correlations between these values and the time after the start of ARB monotherapy with candesartan." | 7.76 | Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. ( Asai, S; Kitamura, N; Nakayama, T; Nishida, Y; Soma, M; Takahashi, Y, 2010) |
| " This study was designed to examine the effect of an ARB candesartan on subclinical atherosclerosis assessed by cardio-ankle vascular index (CAVI) in comparison with calcium channel blockers (CCBs) alone in hypertensive patients with metabolic syndrome (MetS)." | 7.76 | Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome. ( Bokuda, K; Ichihara, A; Itoh, H; Kinouchi, K; Mito, A; Sakoda, M, 2010) |
| " We investigated whether exaggerated BPV aggravates hypertensive cardiac remodeling and function by activating inflammation and angiotensin II-mediated mechanisms." | 7.75 | Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. ( Anegawa, T; Hirooka, Y; Ikeda, A; Imaizumi, T; Kai, H; Kajimoto, H; Kato, S; Koga, M; Kudo, H; Mifune, H; Mori, T; Takayama, N; Yasuoka, S, 2009) |
| "We have shown that candesartan decreases the acute stroke-induced elevation of mean arterial blood pressure (MAP) in Wistar rats and improves functional outcome." | 7.74 | Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. ( Elewa, HF; Fagan, SC; Johnson, MH; Kozak, A; Kozak, W, 2008) |
| "An understanding of aminopeptidase A in hypertension is important, given its ability to cleave the N-terminal aspartic acid of potent vasoconstrictor angiotensin II." | 7.74 | The effect of recombinant aminopeptidase A on hypertension in spontaneously hypertensive rats: its effect in comparison with candesartan. ( Hattori, A; Ishii, M; Ishiura, S; Kobayashi, H; Mizutani, S; Murohara, T; Numaguchi, Y; Tsujimoto, M; Wright, JW, 2008) |
| " In this sub-analysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, we aimed to compare the effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese elderly patients with high-risk hypertension and to determine their optimal target blood pressures (BPs)." | 7.74 | The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Fukiyama, K; Fukui, T; Matsuoka, H; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Shimamoto, K; Ueshima, K, 2008) |
| "To test the functional consequences of blocking the local renin-angiotensin system (RAS), we investigated the effects of an angiotensin II type 1 receptor blocker (ARB), candesartan, on the systemic gene expression profile of five important organs (brain, heart, kidney, liver and adipose tissues) in the stroke-prone spontaneously hypertensive rat (SHRSP), an established model of essential hypertension and cardiovascular disorders, and its normotensive control, the Wistar Kyoto (WKY) rat." | 7.74 | Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats. ( Birukawa, N; Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y; Serizawa, M, 2008) |
| " To elucidate the potential role of local renin-angiotensin system in aldosterone-induced cardiovascular injury, we investigated the effects of selective mineralocorticoid receptor (MR) antagonist eplerenone (EPL), angiotensin (Ang) II type 1 receptor antagonist candesartan (ARB), and superoxide dismutase mimetic tempol (TEM) on the development of hypertension, vascular injury, oxidative stress, and inflammatory-related gene expression in aldosterone-treated hypertensive rats." | 7.74 | Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. ( Hirata, Y; Hirono, Y; Kobayashi, N; Sakurada, M; Shichiri, M; Sugiyama, T; Suzuki, N; Takai, S; Yoshimoto, T, 2007) |
| "These results indicate that easily determined characteristics such as ethnicity, gender, body weight, as well as pretreatment levels of BP and PRA predict a substantial fraction of the BP response to candesartan and support the notion that characteristics associated with a poor response to diuretic therapy are associated with better responses to an angiotensin receptor blocker (ARB)." | 7.74 | Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. ( Baranco-Pryor, E; Boerwinkle, E; Canzanello, VJ; Chapman, AB; Rahbari-Oskoui, F; Schwartz, GL; Turner, ST, 2008) |
| "Our objective was to compare the efficacy and duration of action of 4 angiotensin II receptor blockers (ARBs)--losartan (25-100 mg), candesartan (2-12 mg), valsartan (40-80 mg), and telmisartan (10-40 mg)-in patients with essential hypertension using self-measurement of blood pressure at home (home BP) and to examine the differential effect of the four ARBs on home pulse pressure (home PP)." | 7.73 | Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. ( Asayama, K; Hashimoto, J; Imai, Y; Kikuya, M; Metoki, H; Nishimura, T; Ohkubo, T; Totsune, K, 2005) |
| "This study was designed to examine the hypothesis that a calcium channel blocker nifedipine (CCB) could enhance the cardioprotective effect of an angiotensin-ll receptor blocker candesartan (ARB) in the treatment for heart failure." | 7.73 | Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure. ( Hayashi, T; Horimoto, H; Inamoto, S; Kitaura, Y; Mieno, S; Mori, T; Okabe, M; Okuda, N, 2005) |
| "We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function." | 7.73 | Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. ( Fujii, H; Inenaga, T; Kawano, Y; Nakahama, H; Nakamura, S; Yoshihara, F, 2005) |
| "To determine whether BP lowering with candesartan, initiated at reperfusion, can reduce neurovascular damage and improve outcome in a model of hypertension after experimental ischemic stroke." | 7.73 | Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. ( Ergul, A; Fagan, SC; Hess, DC; Hill, WD; Johnson, MH; Kozak, A; Pollock, DM; Xu, L, 2006) |
| "To define alterations in the blood flow velocities of the ophthalmic artery (OA), central retinal artery (CRA), posterior ciliary artery (PCA) in essential hypertension and to evaluate the effect of a new antihypertensive drug, candesartan which is an angiotensin II receptor antagonist, on the blood flow velocity in hypertensive patients." | 7.72 | Effect of hypertension and candesartan on the blood flow velocity of the extraocular vessels in hypertensive patients. ( Ahmetoğlu, A; Dinç, H; Erdöl, H; Gökçe, M; Gümele, HR; Simşek, A, 2003) |
| "Recent studies have shown that angiotensin-converting enzyme (ACE) inhibitors attenuate endothelin-1 (ET-1)-induced hypertension, but the mechanisms for this effect have not been clarified." | 7.72 | Enalapril attenuates endothelin-1-induced hypertension via increased kinin survival. ( Elmarakby, AA; Morsing, P; Pollock, DM, 2003) |
| " While taking candesartan for hypertension, a 53-year-old woman with known ACE inhibitor intolerance developed angioedema." | 7.71 | Angioedema associated with candesartan. ( Lo, KS, 2002) |
| "To investigate the roles of brain angiotensin II and C-type natriuretic peptide (CNP) in the hypertensive mechanism of deoxycorticosterone acetate (DOCA)-salt hypertension." | 7.70 | Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats. ( Nanbu, A; Nishimura, M; Ohtsuka, K; Sakamoto, M; Takahashi, H; Yoshimura, M, 1998) |
| "Candesartan (8 mg/d) was administered for 2 weeks to eight patients with essential hypertension to investigate the effect of an angiotensin II receptor antagonist on insulin sensitivity." | 7.70 | Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. ( Higashiura, K; Miyazaki, Y; Shimamoto, K; Ura, N, 1999) |
| "To examine the role of brain angiotensin II in the development of salt-induced hypertension in Dahl-Iwai salt-sensitive (DIS) rats." | 7.69 | Brain angiotensin II contributes to the development of hypertension in Dahl-Iwai salt-sensitive rats. ( Fukiyama, K; Matayoshi, R; Muratani, H; Sesoko, S; Takishita, S; Teruya, H, 1995) |
| "Candesartan or amlodipine was added when BP did not fall lower than 135/85 mmHg." | 6.78 | Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. ( Aoyama, T; Goto, M; Goto, N; Hiei, K; Iwasa, M; Kawai, N; Kida, K; Kobayashi, H; Kojima, S; Minagawa, T; Minatoguchi, S; Oda, M; Sugishita, F; Takai, K; Tanaka, R; Watanabe, I; Yamamoto, N; Yasue, T, 2013) |
| " Patients' dosing histories were compiled electronically (MEMS, AARDEX)." | 6.72 | Management of patients with uncontrolled arterial hypertension--the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZ. ( Mengden, T; Tousset, E; Uen, S; Vetter, H, 2006) |
| "Patients with hypertension have structural and functional changes in conductance and resistance vessels." | 6.72 | Effect of candesartan on coronary flow reserve in patients with systemic hypertension. ( Barrios, V; Campuzano, R; Catalán, P; García-Lledó, A; Guzman, G; Marfil, T; Megías, A; Moya, JL; Muriel, A; Ruiz-Leria, S; Tarancón, B; Tomás, JP, 2006) |
| "Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin." | 6.71 | Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. ( Bombelli, M; Dell'Oro, R; Facchini, A; Grassi, G; Mancia, G; Scopelliti, F; Seravalle, G; Trevano, FQ, 2003) |
| "Candesartan cilexetil was found to be equally effective as enalapril in reducing SBP, DBP and LVMI in hypertensives with LVH, according to both ITT and PP analyses." | 6.70 | Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. ( Agabiti-Rosei, E; Cuspidi, C; Di Biagio, C; Magnani, B; Muiesan, ML; Salvetti, M; Valagussa, L; Zanchetti, A, 2002) |
| "Stroke is a major cause of mortality and disability worldwide." | 6.49 | Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. ( Ito, T; Kawahara, K; Kikuchi, K; Maruyama, I; Miura, N; Morimoto-Yamashita, Y; Murai, Y; Tanaka, E; Tancharoen, S, 2013) |
| "Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor." | 6.42 | [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. ( Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004) |
| "Candesartan is a selective angiotensin II Type I (AT(1)) receptor blocker which binds tightly to, and dissociates slowly from the receptor." | 6.42 | Candesartan for the treatment of hypertension and heart failure. ( Ostergren, J, 2004) |
| "Candesartan (Cand) is an angiotensin receptor antagonist widely used for hypertension treatment." | 5.91 | Effect of the structural modification of Candesartan with Zinc on hypertension and left ventricular hypertrophy. ( Calleros, L; De Giusti, V; Ferrer, EG; Griera, M; Islas, MS; Jaquenod de Giusti, C; Martinez, VR; Martins Lima, A; Portiansky, EL; Rodriguez Puyol, M; Stergiopulos, N; Velez Rueda, JO; Williams, PAM, 2023) |
| "Candesartan treatment also increased the amount of fecal short-chain fatty acids (SCFAs) including acetic acid, propionic acid, and butyric acid in SHRs." | 5.51 | Candesartan attenuates hypertension-associated pathophysiological alterations in the gut. ( Chen, Y; Cui, J; Ding, L; Du, X; Tang, X; Wang, P; Wang, W; Wu, D; Yin, J; Zhang, T, 2019) |
| "Obesity has been strongly associated with the development and aggravation of hypertension and chronic kidney disease." | 5.36 | Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. ( Chang, YS; Chung, HW; Chung, S; Kim, BS; Kim, GH; Kim, HW; Lee, JH; Lim, JH; Park, CW; Shin, SJ; Youn, DY, 2010) |
| "Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity." | 5.36 | Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010) |
| "Salt-sensitive (SS) hypertension is a vascular diathesis characterized by reduced cardiovascular and renal nitric oxide bioavailability and local upregulation of ANG II." | 5.35 | Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species. ( Jaimes, EA; Pearse, DD; Puzis, L; Raij, L; Zhou, MS, 2008) |
| "Candesartan has been reported to produce nitric oxide (NO) and to decrease oxidative stress in animal studies." | 5.35 | Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. ( Fujiwara, H; Hiei, K; Kawasaki, H; Minatoguchi, S; Mizukusa, T; Ono, H; Takahashi, H; Tsukamoto, T; Uno, T; Watanabe, K; Yamada, Y, 2008) |
| " Chronic administration of a subdepressor dose of an angiotensin II type 1 receptor blocker candesartan reduced the pressure overload-induced dihydroethidium and 4-HNE signals at day 3." | 5.33 | Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. ( Fukui, D; Imaizumi, T; Kai, H; Kudo, H; Kuwahara, F; Mori, T; Sugi, Y; Tahara, N; Takayama, N; Takemiya, K; Tokuda, K; Yasukawa, H, 2006) |
| "Candesartan treatment normalized blood pressure and the shift toward higher blood pressures at both the upper and lower limits of cerebrovascular autoregulation in SHR." | 5.31 | Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. ( Ito, T; Nishimura, Y; Saavedra, JM, 2000) |
| "Only losartan treatment reduced ex vivo platelet adhesion to a synthetic surface." | 5.31 | Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. ( Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L, 2001) |
| "The aim of this study was to evaluate the blood pressure-lowering and cholesterol-lowering effects of a fixed-dose combination therapy using candesartan (CND)/rosuvastatin (RSV) compared with CND or RSV monotherapy in patients with hypertension and hypercholesterolemia." | 5.30 | Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study. ( Ahn, JC; Ahn, SH; Chang, K; Cho, KI; Chung, WJ; Gyu Park, C; Hong, BK; Hong, TJ; Kim, BH; Kim, SH; Kim, SY; Kim, W; Kim, YJ; Lee, JY; Park, YH; Ryu, JK; Shin, JH; Sohn, IS; Yu, CW, 2019) |
| "The Effects of Angiotensin Receptor Blockers on Diastolic Function in Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE trial is a multicenter, randomized, open-labeled, and assessor(s)-blinded, active controlled using candesartan, parallel-group clinical trial, to compare changes in left ventricular (LV) diastolic dysfunction between HFpEF patients with hypertension who have received candesartan or azilsartan for 48 weeks." | 5.27 | Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction ( Abe, Y; Ajioka, M; Anzai, T; Aonuma, K; Asakura, M; Hamasaki, T; Hayashi, T; Hiramitsu, S; Kawai, H; Kimura, K; Kioka, H; Kitakaze, M; Lim, YJ; Matsuoka, K; Motoki, H; Nagata, Y; Nakamura, S; Ohte, N; Ozaki, Y; Sasaoka, T; Takahama, H; Tamaki, S, 2018) |
| "A combination of a calcium channel blocker and angiotensin receptor blocker (lacidipine 2 mg, 4 mg, and candesartan 4mg, 8mg, 16mg) was prescribed to 30 patients with essential hypertension of grades 1-3, 30 to 65 years old (mean age - 54." | 5.27 | Beneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patients. ( Ashcheulova, T; Gerasimchuk, N; Honchar, O; Kovalyova, O, 2018) |
| "The ACE phenotype was determined in plasma of 14 patients with hypertension treated chronically for 4 weeks with 40 mg enalapril (E) or 20 mg E + 16 mg candesartan (EC) and in 20 patients with hypertension treated acutely with a single dose (20 mg) of E with or without pretreatment with hydrochlorothiazide." | 5.24 | ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors. ( Danilov, SM; Dull, RO; Schwartz, DE; Tovsky, SI, 2017) |
| " Three hundred sixty-two individuals were screened, and 290 patients aged 19 to 75 years with mild to moderate hypertension (diastolic blood pressure [DBP], 90-110 mm Hg) were randomly assigned to 60 to 120 mg/d of fimasartan or 8 mg/d of candesartan after a 2-week placebo run-in period." | 5.22 | A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension. ( Cha, GS; Cha, TJ; Chae, SC; Chun, KJ; Hong, GR; Hur, SH; Hwang, JY; Kim, DI; Kim, DS; Kim, KS; Kim, MH; Lee, JH; Lee, SG; Yang, DH, 2016) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) showed no beneficial clinical effects of blood pressure lowering with the angiotensin receptor blocker candesartan in the acute phase of stroke." | 5.20 | Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis. ( Bath, PM; Berge, E; Jusufovic, M; Karlson, BW; Sandset, EC, 2015) |
| " The Genetics of Drug Responsiveness in Essential Hypertension (GENRES) study is a double-blind, placebo-controlled cross-over study where each subject received amlodipine, bisoprolol,hydrochlorothiazide, and losartan, each as a monotherapy, in a randomized order." | 5.20 | Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs. ( Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Donner, KM; Frau, F; Glorioso, N; Glorioso, V; Gong, Y; Gums, JG; Hiltunen, TP; Johnson, JA; Kontula, KK; Ripatti, S; Saarela, J; Salvi, E; Sarin, AP; Turner, ST; Zaninello, R, 2015) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of blood pressure-lowering treatment with candesartan in acute stroke." | 5.20 | Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC; Sandset, PM, 2015) |
| "The objective of this study was to investigate the efficacy of the fixed-dose combination olmesartan/amlodipine 40/10 mg in patients with moderate essential hypertension not controlled on candesartan 32 mg." | 5.19 | Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2014) |
| "The present study by using the telemedicine system clearly demonstrated that telmisartan has a strong effect on reducing morning home BP, and a good effect on lipid metabolism in patients with metabolic syndrome." | 5.19 | Effectiveness of using long-acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hypertension monitoring by using telemedicine system (FUJIYAMA study). ( Kinoshita, S; Nakamoto, H; Nishida, E; Ryuzaki, M; Sone, M, 2014) |
| "DISTINCT (reDefining Intervention with Studies Testing Innovative Nifedipine GITS - Candesartan Therapy) aimed to determine the dose-response and tolerability of nifedipine GITS and/or candesartan cilexetil therapy in participants with hypertension." | 5.19 | Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results. ( Cha, G; Gil-Extremera, B; Haller, H; Harvey, P; Heyvaert, F; Kjeldsen, SE; Lewin, AJ; Mancia, G; Sica, D; Villa, G, 2014) |
| "SCAST was a randomized- and placebo-controlled, double-masked trial of candesartan given for 7 days, in 2029 patients with acute stroke and systolic blood pressure ≥140 mm Hg." | 5.19 | Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke. ( Bath, PM; Berge, E; Jusufovic, M; Sandset, EC, 2014) |
| "Scandinavian Candesartan Acute Stroke Trial was a randomized-controlled and placebo-controlled trial of candesartan in 2029 patients with acute stroke and raised blood pressure." | 5.17 | Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial. ( Bath, PM; Berge, E; Hornslien, AG; Sandset, EC; Wyller, TB, 2013) |
| "We analyzed 145 out-patients with essential hypertension in primary prevention enrolled in the Natrilix SR Versus Candesartan and Amlodipine in the Reduction of Systolic Blood Pressure in Hypertensive Patients (X-CELLENT) study, a multicenter, randomized, double-blinded, placebo-controlled trial." | 5.17 | Effects of antihypertensive drugs on central blood pressure in humans: a preliminary observation. ( Agnoletti, D; Blacher, J; Borghi, C; Safar, ME; Zhang, Y, 2013) |
| "The purpose of this post hoc subgroup analysis was to compare the incidence of major adverse cardiovascular events (MACE) of patients treated with candesartan and amlodipine with that of those with candesartan and non-amlodipine CCBs in hypertensive patients with coronary artery disease (CAD)." | 5.17 | Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. ( Hagiwara, N; Haruta, S; Kawada-Watanabe, E; Koyanagi, R; Ogawa, H; Takagi, A; Yamaguchi, J, 2013) |
| "As part of a randomized, double-blind study of azilsartan (20-40 mg once daily) and candesartan (8-12 mg once daily) in Japanese patients with essential hypertension, an exploratory analysis was performed using ambulatory BP monitoring (ABPM) at baseline and Week 14." | 5.17 | Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension. ( Enya, K; Igeta, M; Ikeda, Y; Kario, K; Rakugi, H, 2013) |
| "A direct switch of candesartan to the fixed-dose combination olmesartan/amlodipine in uncontrolled hypertension is a frequent clinical requirement but is not covered by current labeling." | 5.17 | Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1). ( Bramlage, P; Fimmers, R; Gansz, A; Lüders, S; Nadal, J; Schmieder, RE; Schrader, J; Sturm, CD; Zemmrich, C, 2013) |
| "Patients aged 30 to 59 years with untreated stage 1 essential hypertension and a family history of hypertension were treated with the antihypertensive agents candesartan (n = 124) or nifedipine CR (n = 120)." | 5.17 | Feasibility of regression of hypertension using contemporary antihypertensive agents. ( Itoh, H; Julius, S; Murakami, M; Nakaya, H; Ryuzaki, M; Sasamura, H; Sato, Y; Takahashi, F; Takeuchi, M; Tomotsugu, N, 2013) |
| "Of the pleiotropic effect related parameters investigated, urinary 8-isoprostane, fasting serum insulin and homeostasis model assessment of insulin resistance index were more suppressed after 4 weeks treatment with irbesartan than after candesartan and valsartan therapy, respectively." | 5.17 | Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers. ( Ando, H; Fujimura, A; Hosohata, K; Saito, T; Ushijima, K, 2013) |
| " Hypertensive patients with type 2 diabetes mellitus and albuminuria (≥30 mg g(-1) creatinine) were enroled in the study, and were either started on or switched to candesartan (8 mg per day) monotherapy." | 5.16 | Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria. ( Dohi, Y; Ichikawa, T; Ito, M; Kato, T; Kimura, G; Kojima, M; Komada, T; Machida, H; Miyazaki, T; Nakatani, K; Ninomiya, T; Okura, T; Sugiyama, M; Watanabe, Y, 2012) |
| "The aim of the present study was to clarify the influence of candesartan-based therapy on subsequent carcinogenesis and cancer death in patients with coronary artery disease with hypertension in a substudy of a multicenter, prospective, randomized, controlled trial." | 5.16 | Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy). ( Hagiwara, N; Koyanagi, R; Ogawa, H; Oka, T; Sugiura, R, 2012) |
| "The Candesartan Cooperative Research of Therapy Design for Early Morning Hypertension in CHIBA was designed to investigate whether switching from angiotensin II receptor blockers (ARBs) except candesartan to candesartan might be effective in Japanese patients with morning hypertension." | 5.16 | Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension. ( Hasegawa, H; Kameda, Y; Kobayashi, Y; Komuro, I; Kubota, A; Takano, H, 2012) |
| "The Scandinavian Candesartan Acute Stroke Trial (SCAST) found no benefits of candesartan in acute stroke." | 5.16 | Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. ( Bath, PM; Berge, E; Kjeldsen, SE; Murray, GD; Sandset, EC, 2012) |
| "In this open-label, single-arm switch study reflecting clinical practice, patients with moderate hypertension not controlled by the free combination of CAN 32 + HCT 25 achieved a clinically and statistically significant reduction of blood pressure from the single pill combination of ALIS 300/HCT 25, and the optional addition of amlodipine." | 5.15 | Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (± amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg. ( Benduhn, H; Klebs, S; Schweizer, J; Ulmer, HJ, 2011) |
| "The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is an open-label randomized comparison between an ARB (candesartan) and a CCB (amlodipine) in the treatment of paroxysmal AF associated with hypertension." | 5.15 | Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). ( Aizawa, Y; Atarashi, H; Fukatani, M; Hirai, M; Hirayama, A; Inoue, H; Kamakura, S; Kato, T; Kodama, I; Koretsune, Y; Kumagai, K; Kurachi, Y; Mitamura, H; Nakaya, H; Ogawa, S; Ohe, T; Ohtsu, H; Okumura, K; Saikawa, T; Sakurai, M; Sato, T; Sugi, K; Watanabe, E; Yamashita, T; Yamazaki, T, 2011) |
| "The aim of this study was to evaluate the effects of imidapril and candesartan on fibrinolysis and insulin sensitivity in normoweight hypertensive patients." | 5.15 | Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. ( Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Salvadeo, SA; Santoro, T; Zoppi, A, 2011) |
| " We report the experience from DIRECT (DIabetic REtinopathy and Candesartan Trials), three placebo-controlled studies designed to examine the effects of an ARB, candesartan, on diabetic retinopathy." | 5.15 | Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials. ( Bilous, R; Chaturvedi, N; Fuller, JH; Hainer, JW; Jansson, SO; Klein, R; Malm, A; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2011) |
| "The GIFU substudy of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial was conducted to compare the long-term effects of candesartan and amlodipine on office- and home-measured blood pressure (BP), QTc dispersion and left ventricular mass index (LVMI) in high-risk Japanese patients with hypertension." | 5.15 | Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients. ( Fujiwara, H; Matsuno, Y; Minatoguchi, S, 2011) |
| " 512 patients with moderate to severe primary hypertension were randomly assigned to an 8-week treatment with either ARB (candesartan)-based regimen (n=257) or ACE inhibitor (imidapril)-based regimen (n=255)." | 5.15 | Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. ( Cheng, X; Fu, M; Gu, Y; Guo, XM; Jia, XJ; Liao, YH; Wang, L; Wang, M; Wei, F; Wei, YM; Yu, SQ; Zhou, ZH; Zhu, F, 2011) |
| "There was no indication that careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure." | 5.15 | The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. ( Bath, PM; Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, GD; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2011) |
| "In patients with hypertension and obesity showing insulin resistance, treatment with telmisartan significantly improved the hyperinsulin response to glucose loading." | 5.15 | Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE). ( Matsuura, K; Mori, Y; Tanaka, T; Utsunomiya, K; Yokoyama, J, 2011) |
| "To evaluate the relationship between plasma plasminogen activator inhibitor-1 (PAI-1) and angiotensin II (Ang II) changes during treatment with imidapril and candesartan in hypertensive patients with metabolic syndrome." | 5.15 | Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome. ( Derosa, G; Fogari, R; Lazzari, P; Maffioli, P; Mugellini, A; Zoppi, A, 2011) |
| "Participants enrolled in this trial were outpatients with essential hypertension after cardiac surgery who had received candesartan for more than one year." | 5.15 | Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study. ( Hata, M; Sezai, A; Shiono, M; Soma, M; Unosawa, S; Wakui, S; Yoshitake, I, 2011) |
| " High-risk patients aged ≥18 years with previously uncontrolled hypertension were started on candesartan 32 mg in a fixed-dose combination with either 12." | 5.15 | Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU Soon. ( Bramlage, P; Hübner, R; Mengden, T, 2011) |
| "One hundred and five patients eligible for coronary artery bypass graft surgery (65-85 years old, all suffering from hypertension and coronary artery disease, with stable kidney function) were randomized to candesartan (8 mg od) or placebo for between 8 and 11 days prior to surgery." | 5.14 | ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting. ( Erdmann, E; Flesch, M; Geissler, HJ; Kessler, G; Knipp, S; Massoudy, P; Philipp, T; Wilhelm, H, 2009) |
| "Hypertensive patients (n = 196) with echocardigraphically documented left ventricular hypertrophy were randomized to candesartan 8-16 mg/day (n = 91) or enalapril 10-20 mg/day (n = 105) with possible addition of hydrochlorothiazide (12." | 5.14 | Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-co ( Ciulla, MM; Cuspidi, C; Esposito, A; Magrini, F; Muiesan, ML; Paliotti, R; Rosei, EA; Zanchetti, A, 2009) |
| "Angiographically documented CAD patients with hypertension were randomly assigned to receive either candesartan-based (n= 1024) or non-ARB-based pharmacotherapy including angiotensin-converting enzyme-inhibitors (n = 1025)." | 5.14 | Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in ( Hagiwara, N; Haze, K; Honda, T; Hosoda, S; Kasanuki, H; Nagashima, M; Ogawa, H; Origasa, H; Sumiyoshi, T; Urashima, M; Yamaguchi, J, 2009) |
| "Data from 4632 men and women (sex ratio 1:1, mean age 54 years) with mild to moderate hypertension, who participated in one of seven randomized, double-blind, placebo-controlled studies with candesartan-HCT for 8-12 weeks, were entered in a common database." | 5.14 | A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension. ( Elmfeldt, D; Karlson, BW; Olofsson, B; Zetterstrand, S, 2009) |
| "To evaluate the effect of ACE inhibitor enalapril, AR blocker candesartan and their combination on left ventricular hypertrophy (LVH) and content of biochemical markers of collagen balance in patients with hypertensive LV hypertrophy." | 5.14 | [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy]. ( Ageev, FT; Ovchinnikov, AG; Serbul, VM, 2009) |
| " A total of 154 untreated hypertensive patients, aged 40 to 66 years, with World Health Organization stage I or II hypertension and left ventricular hypertrophy, were randomized to receive placebo, candesartan (32 mg), each of these plus aspirin (300 mg/d), or the same preparations in a reverse order, for 3 weeks, with a 3-week washout period between treatments." | 5.14 | Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial. ( Chiariello, M; De Rosa, ML, 2009) |
| "This study examined the influence of diabetes on left ventricular hypertrophy (LVH) detected by different electrocardiographic (ECG) criteria and its changes induced by a 12-month candesartan-based regimen." | 5.14 | Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study. ( Barrios, S; Barrios, V; Calderón, A; Echarri, R; Escobar, C; Navarro-Cid, J, 2009) |
| " Patients with essential hypertension and a blood pressure > 140/90 mmHg on ARB monotherapy (losartan 50 mg/day or candesartan 8 mg/day) were randomly assigned to a nifedipine controlled release (CR) group (n = 15) or amlodipine group (n = 11)." | 5.14 | Additive antihypertensive and antihypertrophic effects of long-acting Ca blockers in uncontrolled hypertensive patients with angiotensin-receptor blocker based treatment. ( Ando, C; Inoue, Y; Kodama, S; Mihara, H; Miyoshi, K; Niimura, H; Okamura, K; Sumi, S; Tojyo, H; Tsuchiya, Y; Urata, H; Yamanouchi, Y, 2009) |
| "A total of 50 stable outpatients with essential hypertension who had received candesartan for more than 1 year were randomized into two groups: control group (n=25): continuous candesartan treatment at a stable dose; and olmesartan group (n=25): candesartan (8 mg day(-1)) was changed to olmesartan given at a dose of 20 mg day(-1)." | 5.14 | Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension. ( Fujii, M; Horie, M; Kawahara, C; Nishiyama, K; Tsutamoto, T; Yamaji, M; Yamamoto, T, 2010) |
| "The aim of this study was to assess the effects of angiotensin receptor blocker (ARB)-based therapy on cardiovascular events in high-risk hypertensive patients with coronary artery disease (CAD) and impaired renal function in post hoc analysis of HIJ-CREATE (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease)." | 5.14 | Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function. ( Hagiwara, N; Haze, K; Honda, T; Kasanuki, H; Kawana, M; Ogawa, H; Origasa, H; Shiga, T; Sumiyoshi, T; Takagi, A, 2010) |
| "In a previous study involving 18 hypertensive patients with type 2 diabetes mellitus, we found that replacement of valsartan and candesartan by telmisartan significantly improved insulin sensitivity and significantly increased serum adiponectin levels in the patients." | 5.14 | Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. ( Kondo, K; Nomura, Y; Oiso, Y; Ozaki, N; Sobajima, H, 2010) |
| "The aim of this study is to compare the effects of candesartan and olmesartan on insulin sensitivity-related parameters, before and after antihypertensive therapy." | 5.14 | Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Fogari, E; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA, 2010) |
| "We compared the effects of telmisartan with those of candesartan, on insulin sensitivity, the serum levels of various adipocytokines and oxidative stress." | 5.14 | Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. ( Awata, T; Ikebukuro, K; Inukai, K; Ito, D; Katayama, S; Kurihara, S; Ono, H; Sumita, T; Watanabe, M, 2010) |
| "The Scandinavian Candesartan Acute Stroke Trial is an international randomised, placebo-controlled, double-blind trial of candesartan in acute stroke." | 5.14 | Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003). ( Berge, E; Boysen, G; Jatuzis, D; Kõrv, J; Lüders, S; Murray, G; Richter, PS; Roine, RO; Sandset, EC; Terént, A; Thijs, V, 2010) |
| "The Trial of Preventing Hypertension (TROPHY) demonstrated the feasibility of possibly reducing the incidence of hypertension with the angiotensin receptor blocker candesartan compared with placebo." | 5.13 | An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY). ( Cain, VA; Egan, BM; Julius, S; Michelson, EL; Nesbitt, SD; Williams, SA; Yang, M, 2008) |
| " Hypertensive patients with impaired glucose tolerance were randomly divided into two groups: group A (n = 6), which received 8 mg/day of oral candesartan for three months, and controls (n = 6)." | 5.13 | Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. ( Aizawa, Y; Nakagawa, O; Suzuki, K, 2008) |
| "The aim of the research was to evaluate some clinical and hemodynamic characteristics in patients with diabetes mellitus type 1 and type 2 (DM type 1 and DM type 2), to diagnose diabetic retinopathy (DR) on early stage of its development for the correction of the disease by treating with angiotensin II type 1 receptor blocker (AT I)--Candesartan." | 5.13 | [Positive effects of angiotensin [corrected] receptor blockers on the course of microvascular complications of diabetes mellitus]. ( Kurashvili, GR; Kurashvili, RB; Shelestova, EL; Tsibadze, AD; Tsutskiridze, LR, 2008) |
| "Type 2 diabetic patients with hypertension received either ARB (candesartan), or a calcium channel blocker (CCB; amlodipine or nifedipine) for 12 weeks." | 5.13 | Angiotensin II type-I receptor blocker, candesartan, improves brachial-ankle pulse wave velocity independent of its blood pressure lowering effects in type 2 diabetes patients. ( Ishii, H; Tsukada, T; Yoshida, M, 2008) |
| "A total of 3521 patients with treated or untreated hypertension and sitting diastolic blood pressure (DBP) 90-114 mmHg, entered a single-blind run-in phase with candesartan (16 mg for 2 weeks, followed by 32 mg for 6 weeks)." | 5.13 | Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. ( Bönner, G, 2008) |
| "The authors assessed the effect of an angiotensin receptor blocker (candesartan)-based regimen on electrocardiographic left ventricular hypertrophy (ECG-LVH) in 276 patients with hypertension, including 141 with the metabolic syndrome (MS)." | 5.13 | Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. ( Barrios, S; Barrios, V; Calderón, A; Echarri, R; Escobar, C; Fernandez, R; Ferrer, E; Navarro-Cid, J, 2008) |
| "We investigated the effect of treatment of hypertension on cognition with the angiotensin-receptor-blocker, candesartan, in a placebo-controlled, double-blind, randomized controlled trial at one center participating in the Study on Cognition and Prognosis in the Elderly." | 5.13 | Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial. ( Ford, GA; Harrington, F; McKeith, IG; Saxby, BK; Wesnes, KA, 2008) |
| "Candesartan therapy significantly reduced inflammation and increased adiponectin levels and improved insulin sensitivity in hypertensive patients." | 5.12 | Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. ( Chung, WJ; Han, SH; Koh, KK; Lee, Y; Quon, MJ; Shin, EK, 2006) |
| " Patients with systolic-diastolic or isolated systolic hypertension (n = 1758) received indapamide (1." | 5.12 | Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study. ( Asmar, R; Calvo, C; London, G; Schmieder, R, 2006) |
| "The patients with essential hypertension were randomly divided into 2 groups; 1 group was treated with an ARB, candesartan (8 mg/day), for 1 year (ARB group) and other group was treated with the ARB for the first 6 months and with the ARB plus SPRL (25 mg/day) for the next 6 months (combination group)." | 5.12 | Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy. ( Date, T; Kawai, M; Mochizuki, S; Seki, S; Shimizu, M; Taniguchi, I; Taniguchi, M; Yoshida, S, 2006) |
| "The Japanese Rhythm Management Trial II for Atrial Fibrillation (J-RHYTHM II study) is a randomized comparative evaluation of an angiotensin II type 1 blocker (candesartan) and a dihydropiridine calcium blocker (amlodipine), both combined with antithrombotic therapy, as an antiarrhythmic therapy for the treatment of paroxysmal AF (PAF) associated with hypertension." | 5.12 | Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension. ( Aizawa, Y; Atarashi, H; Fukatani, M; Hirai, M; Hirayama, A; Inoue, H; Kamakura, S; Kato, T; Kodama, I; Koretsune, Y; Kumagai, K; Kurachi, Y; Mitamura, H; Nakaya, H; Ogawa, S; Ohe, T; Ohtsu, H; Okumura, K; Saikawa, T; Sakurai, M; Sugi, K; Watanabe, E; Yamashita, T; Yamazaki, T, 2006) |
| "The aim of this study was to evaluate the annhypertensive efficacy and tolerability of the angiotensin-converting enzyme inhibitor imidapril and the angiotensin II type 1 receptor antagonist candesartan in mild to moderate essential hypertension." | 5.12 | A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicent ( Anglada, MP; Contreras, EM; Esquerra, EA; Martínez, JO; Palma Gámiz, JL; Pêgo, M; Sagastagoitia Gorostiza, JD, 2006) |
| "Thus, losartan may have the possibility to inhibit platelet activation in patients with hypertension independent of blood pressure reduction." | 5.12 | Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers. ( Andoh, Y; Dong, J; Fujii, S; Furumoto, T; Imagawa, S; Ishimori, N; Ohmura, K; Ohmura, Y; Sato, Y; Tsutsui, H, 2007) |
| "We evaluated whether the changes in the insulin sensitivity observed in hypertensive patients following treatment with an angiotensin II receptor blocker (candesartan) or calcium-channel antagonist (amlodipine) might be related to improvement of the endothelial function (END) and/or plasma level of high-sensitive C-reactive protein (CRP) following such treatment." | 5.12 | Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication. ( Koji, Y; Motobe, K; Shiina, K; Tomiyama, H; Yamada, J; Yamashina, A; Yambe, M; Yoshida, M, 2007) |
| "Forty-nine patients with untreated mild to moderate essential hypertension were recruited in a randomized double-blind study to receive a daily dose either of 8 mg candesartan or 5 mg amlodipine for 16 weeks." | 5.12 | Effects of amlodipine and candesartan on oxidized LDL level in patients with mild to moderate essential hypertension. ( Fischer, K; Kampus, P; Muda, P; Ristimäe, T; Teesalu, R; Zilmer, K; Zilmer, M, 2006) |
| "We evaluated the long-term efficacy of losartan and low-dose hydrochlorothiazide combination therapy in the treatment of hypertension." | 5.12 | Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension. ( Abe, C; Akashiba, A; Ishimitsu, T; Kameda, T; Matsuoka, H; Minami, J; Takahashi, T, 2007) |
| "We sought to compare the effect of manidipine versus hydrochlorothiazide (HCTZ) in addition to candesartan on the urinary albumin excretion rate (UAER) in hypertensive patients with type II diabetes and microalbuminuria." | 5.12 | Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria. ( Corradi, L; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A, 2007) |
| "The Study on COgnition and Prognosis in the Elderly (SCOPE) was a multinational, randomised, double-blind study to assess the effects of candesartan 8-16 mg daily on cardiovascular events and cognitive function in elderly patients (aged 70-89 years) with mild to moderate hypertension." | 5.11 | Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE). ( Degl'Innocenti, A; Elmfeldt, D; Hofman, A; Lithell, H; Olofsson, B; Skoog, I; Trenkwalder, P; Wiklund, I; Zanchetti, A, 2004) |
| "We administered placebo, losartan 100 mg/day, irbesartan 300 mg/day, and candesartan 16 mg/day during 2 months to 122 patients with mild to moderate hypertension." | 5.11 | Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. ( Ahn, JY; Ahn, TH; Chung, WJ; Han, SH; Jin, DK; Kang, WC; Kim, HS; Koh, KK; Park, GS; Shin, EK, 2004) |
| "Twenty-three elderly patients with systolic hypertension completed a double-blind crossover study comparing placebo, candesartan (C) 16 mg, C32 mg, lisinopril (L) 20 mg, L40 mg and C16 mg + L20 mg." | 5.11 | Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. ( Anderson, A; Bertram, D; MacInnis, RJ; Morgan, T, 2004) |
| "The aim of this study was to test the hypothesis that the angiotensin II type 1 receptor blocker (ARB) candesartan can reduce the risk of stroke in elderly patients with isolated systolic hypertension (ISH)." | 5.11 | Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). ( Elmfeldt, D; Farsang, C; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2004) |
| "To assess efficacy and tolerability of candesartan cilexetil (CC) plus hydrochlorothiazide (HCTZ) fixed combination vs previous monotherapy (PM) plus HCTZ in hypertension." | 5.11 | Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients. ( Mancia, G; Omboni, S, 2004) |
| "Forty-nine middle-aged patients with untreated stage I-II essential hypertension were recruited in a randomized double-blind double-dummy study to receive a daily dose either of 8 mg candesartan (n = 25) or 5 mg amlodipine (n = 24) for 16 weeks." | 5.11 | Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin concentrations in patients with essential hypertension. ( Fischer, K; Kairane, C; Kampus, P; Muda, P; Ristimäe, T; Teesalu, R; Zilmer, K; Zilmer, M, 2005) |
| "To assess and compare the long-term effects of the combination of candesartan and lisinopril with high-dose lisinopril on systolic blood pressure in patients with hypertension and diabetes." | 5.11 | Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. ( Andersen, NH; Eiskjaer, H; Hansen, KW; Helleberg, K; Knudsen, ST; Mogensen, CE; Poulsen, PL; Poulsen, SH, 2005) |
| "The Study on COgnition and Prognosis in the Elderly (SCOPE) assessed the effect of candesartan on cardiovascular outcomes in elderly patients with mild to moderate hypertension." | 5.11 | The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. ( Elmfeldt, D; Hofman, A; Lithell, H; Olofsson, B; Papademetriou, V; Skoog, I; Trenkwalder, P; Zanchetti, A, 2005) |
| "A randomized clinical trial was used to compare the effects of an angiotensin II type 1 receptor inhibitor, candesartan, singly or in combination with a reducing sodium diet, the DASH diet, on the quality of life (QOL) in outpatients with hypertension." | 5.11 | Assessment of quality of life in a randomized clinical trial of candesartan only or in combination with DASH diet for hypertensive patients. ( Geleris, P; Kirpizidis, H; Stavrati, A, 2005) |
| "The aim of this study was to investigate blood pressure, renal haemodynamics, hormone secretion and the responses to angiotensin II infusion during candesartan cilexetil (candesartan), losartan potassium (losartan) and valsartan treatment in patients with essential hypertension." | 5.10 | Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients. ( Andersson, OK; Elmfeldt, D; Friberg, PR; Fridman, KU; Wysocki, M, 2002) |
| "The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme consists of three randomised, double-masked, parallel, placebo-controlled studies to determine the impact of treatment with candesartan on diabetic retinopathy." | 5.10 | The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design. ( Chaturvedi, N; Sjoelie, AK; Svensson, A, 2002) |
| "To assess whether candesartan-based antihypertensive treatment in elderly patients with mildly to moderately elevated blood pressure confers a reduction in cardiovascular events, cognitive decline and dementia." | 5.10 | The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. ( Elmfeldt, D; Hansson, L; Hofman, A; Lithell, H; Olofsson, B; Skoog, I; Trenkwalder, P; Zanchetti, A, 2003) |
| "The goal of this study was to compare the impacts of perindopril and candesartan on blood pressure, glucose metabolism, serum lipid profile, and metabolic parameters in patients with mild hypertension and type 2 DM during therapy and after a 1-month washout period." | 5.10 | A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus. ( Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, R, 2003) |
| "We administered placebo or candesartan 16 mg daily during two months to 45 patients with mild-to-moderate hypertension." | 5.10 | Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. ( Ahn, JY; Ahn, TH; Choi, IS; Han, SH; Jin, DK; Kim, DS; Kim, HS; Koh, KK; Shin, EK; Shin, MS, 2003) |
| "Both candesartan and a low dose of hydrochlorothiazide are effective and well-tolerated antihypertensive agents in isolated systolic hypertension with additive effects in combination." | 5.10 | Candesartan and hydrochlorothiazide in isolated systolic hypertension. ( Arnolda, LF; Molloy, D; Upton, J; Wing, LM, 2003) |
| "The aim of this study was to evaluate, in patients with chronic renal failure in hemodialysis and arterial hypertension, the effectiveness of a new angiotensin II receptor antagonist, the candesartan cilexitil, comparing it with losartan, the first of this new class of drugs." | 5.09 | [Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan]. ( Cice, G; Di Benedetto, A; Ferrara, L; Iacono, A; Russo, PE; Tagliamonte, E, 1999) |
| "The goal of this multicenter, double-blind, randomized, parallel-group study was to compare the effects of losartan potassium (hereafter referred to as losartan), candesartan cilexitil (hereafter referred to as candesartan), and losartan/hydrochlorothiazide (HCTZ) in patients with mild to moderate hypertension (sitting diastolic blood pressure [SiDBP] 95-115 mm Hg)." | 5.09 | Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. ( Barragan, J; Bernhardi, DC; Bunt, T; Cabrera, WJ; Dumortier, T; Grossman, E; Jacovides, A; Jelakovic, B; Manolis, AJ; Matadamas, N; Mejia, AD; Mendiola, A; Smith, RD; Watanabe, LA; Woo, KS; Zhu, JR, 2000) |
| "To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes." | 5.09 | Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. ( Cooper, ME; Mogensen, CE; Neldam, S; Oren, S; Tikkanen, I; Viskoper, R; Watts, RW, 2000) |
| "The main objective of the CALM (Candesartan And Lisinopril Microalbuminuria) study is to assess the effect of a dual blockade of the renin-angiotensin system--using both an angiotensin converting enzyme inhibitor (ACE-I) and an angiotensin II type 1 receptor blocker--in patients with type 2 diabetes, high blood pressure and microalbuminuria." | 5.09 | [Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy]. ( Philips, JC; Scheen, AJ; Weekers, L, 2001) |
| "Candesartan, an AT(1) receptor antagonist, has been reported to have no association with persistent cough in subjects with hypertension, but there has been no study on the safety of its administration to hypertensive patients with symptomatic asthma." | 5.09 | Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma. ( Abe, S; Hashimoto, M; Oashi, K; Saikai, T; Suzuki, K; Tanaka, H; Tanaka, S; Teramoto, S, 2001) |
| "Patients (n=35), aged >20 years, with hypertension and average baseline LVMI of 89 g/m2 were treated for 24 weeks with candesartan, 16 mg o." | 5.09 | Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects. ( Shiels, A; Spratt, JC; Webb, DJ; Williams, B, 2001) |
| "Trandolapril+candesartan appears to be the most efficacious intervention for reducing albuminuria for normotensive patients, while fosinopril+amlodipine appears to be the most efficacious intervention for reducing albuminuria for hypertensive patients." | 4.95 | Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis. ( Feng, Y; Huang, R; Li, X; Melgiri, ND; Qin, X; Sun, Y; Wang, Y, 2017) |
| "We are presenting a current view on a fixed-dose combination of amlodipine and candesartan in the treatment of hypertension." | 4.93 | [What are the effects of fixed-dose combination of candesartan and amlodipine]. ( Špinar, J; Vítovec, J, 2016) |
| "The UK National Health Service (NHS) currently spends in excess of £250 million per annum on angiotensin II receptor blockers (ARBs) for the treatment of hypertension and heart failure; with candesartan currently dominating the market." | 4.87 | Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis. ( Bodalia, PN; Grosso, AM; Hingorani, AD; Macallister, RJ; Moon, JC; Scott, MA, 2011) |
| " Several clinical trials have compared candesartan with losartan in the management of essential hypertension." | 4.87 | A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. ( , 2011) |
| "Valsartan administered at 160 or 320 mg is more effective at lowering BP than losartan 100 mg and shows comparable efficacy to other ARBs in patients with essential hypertension." | 4.85 | Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. ( Falvey, H; Lowy, A; Müller, E; Nixon, RM, 2009) |
| "In the Trial of Preventing Hypertension (TROPHY), volunteers with "high normal blood pressure" were randomized to 4 years of placebo (n = 381) or 2 years of 16 mg/d of candesartan (n = 391) followed by 2 years of placebo." | 4.84 | Should the results of TROPHY affect the JNC 7 definition of prehypertension? ( Julius, S, 2007) |
| " Candesartan, a long-acting angiotensin receptor antagonist, has been shown to be an effective, and well-tolerated therapy, in both the early and late phases of cardiovascular disease (prehypertension, hypertension, left ventricular hypertrophy and heart failure)." | 4.84 | Candesartan: from left ventricular hypertrophy to heart failure, a global approach. ( Barrios, V; Calderon, A; Escobar, C, 2007) |
| "The Study on Cognition and Prognosis in the Elderly (SCOPE) assessed the effect of candesartan on cardiovascular and cognitive outcomes in elderly patients (aged 70-89 years) with mild to moderate hypertension." | 4.83 | Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review. ( Elmfeldt, D; Zanchetti, A, 2006) |
| "This is the second part in a series of papers dealing with various aspects of clinical pharmacology of the first AT1-receptor antagonist losartan and its therapeutic use in hypertension, diabetic nephropathy, chronic heart failure, and acute phase of myocardial infarction." | 4.82 | [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy]. ( Preobrazhenskiĭ, DV; Sidorenko, BA; Stetsenko, TM; Tarykina, EV; Tsurko, VV, 2003) |
| "In the first study, olmesartan 10 mg/d was compared with losartan 50 mg/d in 316 patients with mild to moderate hypertension (mean baseline diastolic blood pressure [DBP], 95-114 mm Hg)." | 4.82 | Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. ( Stumpe, KO, 2004) |
| "The introduction of Angiotensin II receptor blockers (ARB) in 1995 was another milestone in the pharmacological management of hypertension." | 4.82 | [Angiotensin II receptor blockers--evidence along the cardiovascular continuum]. ( Battegay, E; Zeller, A, 2005) |
| "To determine the mechanism of protective vascular effect of angiotensin receptor blocker(ARB), the effect of candesartan on blood pressure(BP), ultrasonographically assessed carotid intima-media thickness(IMT), plasma superoxide dismutase activity (SOD), and lipid peroxides(LPO) were measured, and compared with the effects of diuretics in 20 patients with essential hypertension." | 4.81 | [Protective vascular effect of angiotensin receptor blocker (ARB)]. ( Yamakado, M, 2002) |
| "These findings suggest that 5-ALA-HCl does not affect the antihypertensive agents-induced hypotensive effect, but enhances the bupivacaine-induced hypotensive effect, especially in SHRs, indicating that 5-ALA may contribute to anesthesia-induced hypotension via suppression of sympathetic nerve activity in patients with hypertension." | 4.31 | 5-Aminolevulinic acid hydrochloride enhances bupivacaine-induced hypotension in spontaneously hypertensive rats. ( Abe, M; Fukuda, N; Hara, T; Ishizuka, M; Ito, H; Katakawa, M; Otsuka, N, 2023) |
| "In our cohorts (losartan, n =15,783; valsartan, n =16,907; candesartan, n =26,178), mean age was 76-78 years, 59-66% were female, 90-92% had hypertension, and 13-15% had heart failure." | 3.96 | Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers. ( Beaudoin, C; Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2020) |
| "Angiotensin receptor blockers (ARBs; including candesartan, losartan, olmesartan and valsartan) are widely used to treat hypertension, heart failure and diabetic neuropathy." | 3.88 | Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study. ( Busby, J; Cardwell, CR; Hughes, C; Johnston, BT; McMenamin, Ú; Spence, A, 2018) |
| " Therefore, in the current study we examined the effects of Candesartan and Compound 21 (C21) (RAS modulators) on aspects of cognition known to diminish with advanced age and accelerate with hypertension and vascular disease." | 3.88 | Role of angiotensin system modulation on progression of cognitive impairment and brain MRI changes in aged hypertensive animals - A randomized double- blind pre-clinical study. ( Ahmed, HA; Arbab, AS; Bunting, KM; Ergul, A; Fagan, SC; Ishrat, T; Patel, A; Pillai, B; Vazdarjanova, A; Waller, JL, 2018) |
| "During the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, patients with hypertension who received amlodipine had similar cardiovascular risks as those who received candesartan." | 3.88 | Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan. ( Ichihara, C; Kitao, H; Konda, M; Kuwabara, Y; Liu, J; Oba, K; Ueshima, K; Yasuno, S, 2018) |
| "Elastin deficiency causes vascular stiffening, a leading risk for hypertension and chronic kidney disease (CKD)." | 3.85 | Elastin insufficiency causes hypertension, structural defects and abnormal remodeling of renal vascular signaling. ( Jie, L; Osei-Owusu, P; Owens, EA; Reyes, BAS; Van Bockstaele, EJ, 2017) |
| "We surveyed consecutive newly diagnosed, untreated patients with hypertension who started the treatment with a mid-level dose of one of seven ARBs (losartan 50 mg, telmisartan 40 mg, candesartan 8 mg, olmesartan 20 mg, valsartan 80 mg, irbesartan 100 mg, or azilsartan 20 mg)." | 3.83 | The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements. ( Asayama, K; Haga, T; Hosaka, M; Imai, Y; Inoue, R; Kikuya, M; Mano, N; Metoki, H; Murakami, T; Obara, T; Ohkubo, T; Satoh, M, 2016) |
| " Although both tempol and candesartan effectively reduced reactive oxygen species production in the kidney, tempol did not decrease blood pressure and exacerbated urine protein and histological damage, such as glomerulosclerosis and interstitial fibrosis, particularly in juxtamedullary nephrons (tempol vs." | 3.80 | Superoxide dismutase mimetic, tempol, aggravates renal injury in advanced-stage stroke-prone spontaneously hypertensive rats. ( Kohagura, K; Nakamura, T; Ohya, Y; Shinzato, T; Sugama, I; Yamazato, M, 2014) |
| "In C57BL/6-mice, hypertension was induced by infusion of 600 ng/kg • min angiotensin II." | 3.80 | Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors. ( Amann, K; Brand, S; Mandel, P; Schupp, N; Zimnol, A, 2014) |
| "A chronic increase in circulating angiotensin II (Ang II) activates an aldosterone-mineralocorticoid receptor-ouabain neuromodulatory pathway in the brain that increases neuronal activation in hypothalamic nuclei, such as the paraventricular nucleus (PVN) and causes progressive hypertension." | 3.79 | Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension. ( Gabor, A; Leenen, FH, 2013) |
| " After surgery, the AAB-induced hypertension (AABIH) rats were treated with losartan 40 mg/kg/day, candesartan 10 mg/kg/day, irbesartan 10 mg/kg/day per os for 16 weeks." | 3.79 | Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats. ( Inamdar, MN; Kulkarni, C; Kulkarni, KS; Moinuddin, G, 2013) |
| "Our results indicate that candesartan protects against hypertension and adipocyte dysfunction in SHRSP." | 3.79 | Effects of angiotensin II type 1 receptor blocker and adiponectin on adipocyte dysfunction in stroke-prone spontaneously hypertensive rats. ( Inoue, T; Ito, H; Takemori, K, 2013) |
| "This study investigated whether the angiotensin II type-1 receptor blocker (ARB) candesartan affects markers of oxidative stress in type 2 diabetes mellitus (DM) patients with essential hypertension (EH)." | 3.79 | Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension. ( Miura, Y; Mizuno, K; Ono, Y; Takahashi, M; Watanabe, T, 2013) |
| "We enrolled 196 patients with hypertension who were already being treated with free-drug combinations of angiotensin-II receptor blocker (ARB) and amlodipine." | 3.79 | Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension. ( Dohi, K; Hiraoka, N; Hoshino, K; Ito, M; Kitai, T; Kumagai, N; Nakamori, S; Nakamura, M; Okamoto, S; Onishi, K; Oota, M; Ueda, Y; Yamada, T; Yazu, T, 2013) |
| "Prevention is an important goal in the treatment of hypertension." | 3.79 | Prehypertension: a possible target for antihypertensive medication. ( Julius, S; Nesbitt, SD, 2000) |
| "Betamethasone is administered to accelerate lung development and improve survival of premature infants but may be associated with hypertension later in life." | 3.78 | Angiotensin-(1-7) deficiency and baroreflex impairment precede the antenatal Betamethasone exposure-induced elevation in blood pressure. ( Chappell, MC; Diz, DI; Rose, JC; Shaltout, HA, 2012) |
| " Combination drugs of the angiotensin receptor blocker and calcium channel blocker, such as olmesartan (OLM)/azelnidipine (AZ) and candesartan (CAN)/amlodipine (AM), are widely used for treating hypertension in Japan." | 3.78 | Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats. ( Hirooka, Y; Kishi, T; Ogawa, K; Shinohara, K; Sunagawa, K; Utsumi, H; Yasukawa, K, 2012) |
| "4%) when using candesartan compared with losartan in the primary treatment of hypertension." | 3.77 | Health-care costs of losartan and candesartan in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Henriksson, M; Kjeldsen, S; Levin, LÅ; Russell, D; Stålhammar, J, 2011) |
| "This study investigated the relation between renal dysfunction and cardiovascular events in patients from the Challenge-DM Study (a large-scale investigation of Japanese diabetic patients with hypertension on candesartan therapy)." | 3.77 | Effects of renal dysfunction on cardiovascular events in diabetic patients with hypertension: challenge-DM Study subgroup analysis. ( Kawamori, R; Matsuoka, H; Saito, Y; Umemura, S, 2011) |
| "A probabilistic cost-benefit model was constructed for a cohort of patients with moderate hypertension, based on a standardised titration and maintenance algorithm using either olmesartan or candesartan, combined with thiazide and calcium channel blocker where required." | 3.77 | Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens. ( Belsey, JD, 2011) |
| "The aim of the study was to elucidate normalizing effect of candesartan on disturbed thrombocytic hemostasis in patients with arterial hypertension and metabolic syndrome." | 3.77 | [Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan]. ( Medvedev, IN; Simonenko, VB; Tolmachev, VV, 2011) |
| " Since angiotensin II increases pendrin-mediated Cl(-) absorption in vitro, we asked whether angiotensin II increases pendrin expression in vivo and whether angiotensin-induced hypertension is pendrin dependent." | 3.77 | Angiotensin II acts through the angiotensin 1a receptor to upregulate pendrin. ( Agazatian, D; Bailey, JL; Coffman, TM; Farley, DB; Hong, S; Inagami, T; Kim, YH; Le, T; Matthews, SW; Pech, V; Verlander, JW; Wall, SM; Weiner, ID; Whitehill, FM, 2011) |
| " The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk differences between losartan and candesartan treatment in patients with hypertension without known CVD." | 3.76 | Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension. ( Bodegard, J; Hasvold, P; Kjeldsen, SE; Olsson, U; Russell, D; Stålhammar, J, 2010) |
| " Our aims were to survey the changes in plasma lipid profile in patients with hypertension over a one-year period, and to examine the correlations between these values and the time after the start of ARB monotherapy with candesartan." | 3.76 | Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. ( Asai, S; Kitamura, N; Nakayama, T; Nishida, Y; Soma, M; Takahashi, Y, 2010) |
| " This study was designed to examine the effect of an ARB candesartan on subclinical atherosclerosis assessed by cardio-ankle vascular index (CAVI) in comparison with calcium channel blockers (CCBs) alone in hypertensive patients with metabolic syndrome (MetS)." | 3.76 | Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome. ( Bokuda, K; Ichihara, A; Itoh, H; Kinouchi, K; Mito, A; Sakoda, M, 2010) |
| " In this study, we investigated the effect of postischemic treatment using the angiotensin II type 1 receptor blocker, candesartan, on brain damage in focal cerebral ischemia." | 3.75 | Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats. ( Kitagawa, K; Okazaki, S; Omura-Matsuoka, E; Oyama, N; Sakoda, S; Sasaki, T; Sugiyama, Y; Terasaki, Y; Yagita, Y, 2009) |
| " We investigated whether exaggerated BPV aggravates hypertensive cardiac remodeling and function by activating inflammation and angiotensin II-mediated mechanisms." | 3.75 | Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. ( Anegawa, T; Hirooka, Y; Ikeda, A; Imaizumi, T; Kai, H; Kajimoto, H; Kato, S; Koga, M; Kudo, H; Mifune, H; Mori, T; Takayama, N; Yasuoka, S, 2009) |
| "We have shown that candesartan decreases the acute stroke-induced elevation of mean arterial blood pressure (MAP) in Wistar rats and improves functional outcome." | 3.74 | Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study. ( Elewa, HF; Fagan, SC; Johnson, MH; Kozak, A; Kozak, W, 2008) |
| "An understanding of aminopeptidase A in hypertension is important, given its ability to cleave the N-terminal aspartic acid of potent vasoconstrictor angiotensin II." | 3.74 | The effect of recombinant aminopeptidase A on hypertension in spontaneously hypertensive rats: its effect in comparison with candesartan. ( Hattori, A; Ishii, M; Ishiura, S; Kobayashi, H; Mizutani, S; Murohara, T; Numaguchi, Y; Tsujimoto, M; Wright, JW, 2008) |
| " In this sub-analysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial, we aimed to compare the effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese elderly patients with high-risk hypertension and to determine their optimal target blood pressures (BPs)." | 3.74 | The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Fukiyama, K; Fukui, T; Matsuoka, H; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Shimamoto, K; Ueshima, K, 2008) |
| " Patients with previously uncontrolled hypertension with at least one further risk factor in which physicians deemed a treatment with 16 mg Candesartan/12." | 3.74 | Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care. ( Bramlage, P; Odoj, P; Schönrock, E, 2008) |
| "To test the functional consequences of blocking the local renin-angiotensin system (RAS), we investigated the effects of an angiotensin II type 1 receptor blocker (ARB), candesartan, on the systemic gene expression profile of five important organs (brain, heart, kidney, liver and adipose tissues) in the stroke-prone spontaneously hypertensive rat (SHRSP), an established model of essential hypertension and cardiovascular disorders, and its normotensive control, the Wistar Kyoto (WKY) rat." | 3.74 | Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats. ( Birukawa, N; Jesmin, S; Kato, N; Liang, YQ; Ochiai, Y; Serizawa, M, 2008) |
| " To elucidate the potential role of local renin-angiotensin system in aldosterone-induced cardiovascular injury, we investigated the effects of selective mineralocorticoid receptor (MR) antagonist eplerenone (EPL), angiotensin (Ang) II type 1 receptor antagonist candesartan (ARB), and superoxide dismutase mimetic tempol (TEM) on the development of hypertension, vascular injury, oxidative stress, and inflammatory-related gene expression in aldosterone-treated hypertensive rats." | 3.74 | Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. ( Hirata, Y; Hirono, Y; Kobayashi, N; Sakurada, M; Shichiri, M; Sugiyama, T; Suzuki, N; Takai, S; Yoshimoto, T, 2007) |
| " We investigated the impact of measurement error in the outcome on results of the trial of preventing hypertension (TROPHY), a trial of candesartan vs." | 3.74 | Carryover effects after cessation of drug treatment: trophies or dreams? ( Lumley, T; Psaty, BM; Rice, KM, 2008) |
| "These results indicate that easily determined characteristics such as ethnicity, gender, body weight, as well as pretreatment levels of BP and PRA predict a substantial fraction of the BP response to candesartan and support the notion that characteristics associated with a poor response to diuretic therapy are associated with better responses to an angiotensin receptor blocker (ARB)." | 3.74 | Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. ( Baranco-Pryor, E; Boerwinkle, E; Canzanello, VJ; Chapman, AB; Rahbari-Oskoui, F; Schwartz, GL; Turner, ST, 2008) |
| "Candesartan, an ARB, improves EPC dysfunction and increases cardiac c-kit expression through the anti-oxidative mechanism in hypertension." | 3.74 | Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension. ( Fukuda, N; Kobayashi, N; Matsumoto, K; Matsumoto, T; Suzuki, R; Tahira, Y; Ueno, T; Yao, EH; Yu, Y, 2008) |
| " Stroke-prone spontaneously hypertensive rats (SHRSP) were orally given pioglitazone, candesartan, or combined pioglitazone and candesartan for 4 weeks to compare their effects on cardiovascular injury." | 3.74 | Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Nakamura, T; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2008) |
| "Our objective was to compare the efficacy and duration of action of 4 angiotensin II receptor blockers (ARBs)--losartan (25-100 mg), candesartan (2-12 mg), valsartan (40-80 mg), and telmisartan (10-40 mg)-in patients with essential hypertension using self-measurement of blood pressure at home (home BP) and to examine the differential effect of the four ARBs on home pulse pressure (home PP)." | 3.73 | Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements. ( Asayama, K; Hashimoto, J; Imai, Y; Kikuya, M; Metoki, H; Nishimura, T; Ohkubo, T; Totsune, K, 2005) |
| "This study was designed to examine the hypothesis that a calcium channel blocker nifedipine (CCB) could enhance the cardioprotective effect of an angiotensin-ll receptor blocker candesartan (ARB) in the treatment for heart failure." | 3.73 | Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure. ( Hayashi, T; Horimoto, H; Inamoto, S; Kitaura, Y; Mieno, S; Mori, T; Okabe, M; Okuda, N, 2005) |
| "We describe a hypertensive nephrosclerosis patient presenting with severe hyperkalemia due to a combination therapy of the angiotensin receptor blocker (ARB) candesartan and spironolactone despite mildly decreased renal function." | 3.73 | Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone. ( Fujii, H; Inenaga, T; Kawano, Y; Nakahama, H; Nakamura, S; Yoshihara, F, 2005) |
| "To determine whether BP lowering with candesartan, initiated at reperfusion, can reduce neurovascular damage and improve outcome in a model of hypertension after experimental ischemic stroke." | 3.73 | Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. ( Ergul, A; Fagan, SC; Hess, DC; Hill, WD; Johnson, MH; Kozak, A; Pollock, DM; Xu, L, 2006) |
| "To define alterations in the blood flow velocities of the ophthalmic artery (OA), central retinal artery (CRA), posterior ciliary artery (PCA) in essential hypertension and to evaluate the effect of a new antihypertensive drug, candesartan which is an angiotensin II receptor antagonist, on the blood flow velocity in hypertensive patients." | 3.72 | Effect of hypertension and candesartan on the blood flow velocity of the extraocular vessels in hypertensive patients. ( Ahmetoğlu, A; Dinç, H; Erdöl, H; Gökçe, M; Gümele, HR; Simşek, A, 2003) |
| "Recent studies have shown that angiotensin-converting enzyme (ACE) inhibitors attenuate endothelin-1 (ET-1)-induced hypertension, but the mechanisms for this effect have not been clarified." | 3.72 | Enalapril attenuates endothelin-1-induced hypertension via increased kinin survival. ( Elmarakby, AA; Morsing, P; Pollock, DM, 2003) |
| " Since we have proposed that perturbation of the interstitial capillary circulation with consequent chronic hypoxia could be critical to the progressive nature of many renal diseases, we developed a dynamic method of measuring renal cortical pO(2) and sought to determine whether agents which block the renal effects of angiotensin II (AII) could affect interstitial microvascular oxygenation in the normal rat kidney." | 3.72 | Angiotensin II blockade augments renal cortical microvascular pO2 indicating a novel, potentially renoprotective action. ( Fine, LG; Norman, JT; Singer, M; Stidwill, R, 2003) |
| "We examined the effect of the dihydropyridine calcium channel blocker (CCB) benidipine, the angiotensin II type 1 receptor blocker (ARB) candesartan, and the combination of these drugs on blood pressure and kidney and vascular function in rats with salt-induced hypertension." | 3.72 | Effects of benidipine and candesartan on kidney and vascular function in hypertensive Dahl rats. ( Ina, Y; Ohno, T; Sato, H; Sonoda, R; Suzuki, K; Yao, K, 2003) |
| "An 89-year-old man with severe hypertension (190/82 mm Hg) and chronic heart failure (New York Heart Association class II) despite treatment with benidipine, doxazosin mesylate (INN, doxazosin), and furosemide was given oral candesartan cilexetil (4 mg/d), an angiotensin II type 1 receptor blocker metabolized via cytochrome p450 (CYP) 2C9." | 3.72 | Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype. ( Hashimoto, H; Hayashi, H; Nishio, S; Ohashi, K; Uchida, S; Watanabe, H; Yamazaki, K, 2003) |
| "Standard ACEI plus candesartan is more effective in reducing systolic blood pressure and proteinuria than a 50% increase in ACEI dose." | 3.72 | Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. ( Fairley, KF; Kincaid-Smith, P; Packham, D, 2004) |
| "The possible role of calcineurin in the attenuation of cardiac hypertrophy and fibrosis by blockade of the angiotensin II type 1 (AT1) receptor was investigated in Dahl salt-sensitive (DS) rats." | 3.71 | AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats. ( Ichihara, S; Iwase, M; Izawa, H; Nagasaka, T; Nagata, K; Nakashima, N; Obata, K; Odashima, M; Somura, F; Yamada, Y; Yokota, M, 2002) |
| " While taking candesartan for hypertension, a 53-year-old woman with known ACE inhibitor intolerance developed angioedema." | 3.71 | Angioedema associated with candesartan. ( Lo, KS, 2002) |
| " In addition to treatment with prednisolone, they were administered anticoagulants(warfarin, or aspirin, or heparin) for APSN and an angiotensin II receptor blocker, candesartan, for the hypertension." | 3.71 | [Two cases of systemic lupus erythematosus accompanied by antiphospholipid syndrome nephropathy without immune complex nephritis]. ( Kawakami, K; Komiya, T; Negoro, N; Okada, S; Okamura, M; Okazaki, M; Sumi, T; Tsukamoto, J; Yoshikawa, J, 2002) |
| " Furthermore, PD 123319 attenuates the development of hypertension in salt-loaded rats neonatally treated with capsaicin, indicating that the AT2 receptor contributes to the increase in blood pressure." | 3.71 | Role of AT1 and AT2 receptor subtypes in salt-sensitive hypertension induced by sensory nerve degeneration. ( Huang, Y; Wang, DH, 2001) |
| "Hypertension induced by long-term infusion of angiotensin II (Ang II) is associated with augmented intrarenal Ang II levels to a greater extent than can be explained on the basis of the circulating Ang II levels." | 3.71 | Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor. ( Benes, E; Hammond, TG; Imig, JD; Navar, LG; Orengo, S; Zhuo, JL, 2002) |
| " Chronic treatment with enalapril or candesartan inhibited the development of hypertension and cardiac hypertrophy equally in SHR." | 3.71 | Comparative effects of candesartan and enalapril on augmented vasoconstrictive responses to endothelin-1 in coronary vessels of spontaneously hypertensive rats. ( Harada, S; Hatta, T; Kawa, T; Kido, H; Miki, S; Moriguchi, J; Morimoto, S; Nakagawa, M; Oguni, A; Sasaki, S; Takeda, K, 2002) |
| "To investigate the roles of brain angiotensin II and C-type natriuretic peptide (CNP) in the hypertensive mechanism of deoxycorticosterone acetate (DOCA)-salt hypertension." | 3.70 | Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats. ( Nanbu, A; Nishimura, M; Ohtsuka, K; Sakamoto, M; Takahashi, H; Yoshimura, M, 1998) |
| "The current study was conducted to determine the potential influence of ibuprofen on the renal and systemic response to AT1 receptor blockade in conscious rats developing spontaneous hypertension." | 3.70 | Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats. ( Morsing, P; Pollock, DM, 1999) |
| "Candesartan (8 mg/d) was administered for 2 weeks to eight patients with essential hypertension to investigate the effect of an angiotensin II receptor antagonist on insulin sensitivity." | 3.70 | Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension. ( Higashiura, K; Miyazaki, Y; Shimamoto, K; Ura, N, 1999) |
| " Perindopril, candesartan cilexetil, or amlodipine alone or the combination of low doses of each agent was administered orally to stroke-prone spontaneously hypertensive rats (SHRSP) for 4 weeks to compare the hypotensive or cardiovascular effects." | 3.70 | Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats. ( Iwao, H; Izumi, Y; Kim, S; Zhan, Y, 2000) |
| "The objectives of the present study were to test the hypothesis that vascular angiotensin II (AII) generation may be negatively regulated by circulating AII in Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR), and to clarify the role of this vascular AII in the sustained hypertension seen in SHR following nephrectomy." | 3.69 | Activated angiotensin II generation and regulation in rat mesenteric arteries following nephrectomy. ( Higaki, J; Higashimori, K; Mikami, H; Ogihara, T; Rakugi, H; Shi, SJ, 1994) |
| "To examine the role of brain angiotensin II in the development of salt-induced hypertension in Dahl-Iwai salt-sensitive (DIS) rats." | 3.69 | Brain angiotensin II contributes to the development of hypertension in Dahl-Iwai salt-sensitive rats. ( Fukiyama, K; Matayoshi, R; Muratani, H; Sesoko, S; Takishita, S; Teruya, H, 1995) |
| "In this study, to investigate the mechanism of hypertension-associated induction of cardiac angiotensinogen in vivo and in vitro, we studied the regulation of angiotensinogen mRNA in the hearts of genetically hypertensive rats and in the rat cardiomyocytes." | 3.69 | Regulation of cardiac angiotensinogen mRNA in vivo and in vitro. ( Hibi, K; Ishigami, T; Ishii, M; Kihara, M; Kobayashi, I; Nyui, N; Sumida, Y; Takagi, N; Tamura, K; Umemura, S; Watanabe, Y; Yabana, M, 1997) |
| "Hypertension is the leading risk factor for premature death worldwide." | 3.30 | Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial. ( Hagström, E; Held, C; Lind, L; Lytsy, P; Marttala, K; Neal, B; Nowrouzi, S; Östlund, O; Sundström, J, 2023) |
| "Candesartan was also superior to lisinopril on the secondary outcome of Hopkins Verbal Learning Test-Revised delayed recall (ES = 0." | 2.94 | Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment: A Randomized Clinical Trial. ( Dee, E; Goldstein, F; Hajjar, I; Levey, A; McDaniel, D; Obideen, M; Okafor, M; Quyyumi, AA; Shokouhi, M, 2020) |
| "The Precision HYpertenSIon Care (PHYSIC) study aims to investigate if there is a consistent between-person variation in blood pressure response to the common blood pressure-lowering drug classes of a clinically relevant magnitude, given the within-person variation in blood pressure." | 2.90 | The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study. ( Ekman, I; Lind, L; Lytsy, P; Marttala, K; Nowrouzi, S; Öhagen, P; Östlund, O; Sundström, J, 2019) |
| "In the Japan Morning Surge-Target Organ Protection (J-TOP) study, which compared bedtime or awakening dosing of candesartan (+diuretics as needed) among subjects with home systolic BP (SBP) higher than 135 mm Hg, we evaluated 180 hypertensive patients who successfully underwent pulse wave analysis by HEM-9000AI and measured their urinary albumin/creatinine ratio (UACR) and left ventricular mass index (LVMI) (n = 144) at baseline and after 6 months of treatment." | 2.80 | Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study. ( Eguchi, K; Hoshide, S; Ishikawa, J; Kario, K; Shimizu, M; Yano, Y, 2015) |
| "Olmesartan is a promising ARB for BP control in hypertensive type 2 diabetics." | 2.79 | Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study. ( Daikuhara, H; Fukunaga, K; Ohshima, T, 2014) |
| " A low dose of HCTZ in combination with candesartan reduces blood pressure effectively without adverse effects on the glucose and lipid profiles." | 2.78 | Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles. ( Fujiwara, W; Ishii, J; Izawa, H; Kinoshita, K; Morimoto, S; Mukaide, D; Nomura, M; Ozaki, Y; Ukai, G; Yokoi, H, 2013) |
| "Candesartan or amlodipine was added when BP did not fall lower than 135/85 mmHg." | 2.78 | Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. ( Aoyama, T; Goto, M; Goto, N; Hiei, K; Iwasa, M; Kawai, N; Kida, K; Kobayashi, H; Kojima, S; Minagawa, T; Minatoguchi, S; Oda, M; Sugishita, F; Takai, K; Tanaka, R; Watanabe, I; Yamamoto, N; Yasue, T, 2013) |
| "To study the impact of the dosing time of an angiotensin II receptor blocker (ARB) titrated by self-measured home blood pressure (HBP) on cardiorenal damage in hypertensives." | 2.75 | Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study. ( Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kario, K; Shimada, K; Shimizu, M; Yano, Y, 2010) |
| " The authors randomly assigned 269 patients who had persistent proteinuria (> or =1 g/d) despite 7 wk of treatment with the highest approved dosage of candesartan (16 mg/d) to 16, 64, or 128 mg/d candesartan for 30 wk." | 2.74 | Supramaximal dose of candesartan in proteinuric renal disease. ( Burgess, E; Chiu, A; Muirhead, N; Pichette, V; Rene de Cotret, P; Tobe, S, 2009) |
| " Because administration of candesartan at appropriate dosage (4-12 mg/day) significantly decreased self-measured morning home BP, candesartan might possess the property to maintain a sustained BP reduction for up to 24 hours after dosing, and might be able to prevent early morning cardiovascular events." | 2.74 | [Evaluation of antihypertensive effect of angiotensin II receptor blockers in patients with essential hypertension by self-measured home blood pressure--HACARARE 300 study]. ( Msanobu, T, 2009) |
| "In vivo, 56 patients with both type 2 diabetes and hypertension were enrolled and randomized to receive either telmisartan (40 mg) or candesartan (8 mg) for 3 months." | 2.73 | Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. ( Ano, N; Atsuda, K; Inoue, G; Irie, J; Kitaoka, A; Shiono, K; Toda, K; Yamada, S, 2008) |
| "Treatment with candesartan in type 2 diabetic patients with mild to moderate retinopathy might induce improvement of retinopathy." | 2.73 | Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. ( Bilous, R; Chaturvedi, N; Fuller, J; Klein, R; Orchard, T; Parving, HH; Porta, M; Sjølie, AK, 2008) |
| "In 404 patients with left ventricular hypertrophy, a significantly larger decrease in left ventricular mass index 3 years after enrollment was observed in candesartan-based (n = 205) than amlodipine-based (n = 199) regimens (-22." | 2.73 | ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial. ( Fujimoto, A; Nakao, K; Ogihara, T; Saruta, T, 2008) |
| "Aldosterone is an important pathogenetic factor, independent of the renin-angiotensin system in cardiovascular and renal disease." | 2.73 | Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. ( Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T, 2007) |
| "Fenofibrate combined with candesartan improves endothelial function and reduces inflammatory markers to a greater extent than monotherapy in hypertriglyceridemic hypertensive patients." | 2.72 | Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. ( Ahn, JY; Chung, WJ; Han, SH; Kim, JA; Koh, KK; Lee, Y; Quon, MJ; Shin, EK, 2006) |
| " Patients' dosing histories were compiled electronically (MEMS, AARDEX)." | 2.72 | Management of patients with uncontrolled arterial hypertension--the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZ. ( Mengden, T; Tousset, E; Uen, S; Vetter, H, 2006) |
| "Patients with hypertension have structural and functional changes in conductance and resistance vessels." | 2.72 | Effect of candesartan on coronary flow reserve in patients with systemic hypertension. ( Barrios, V; Campuzano, R; Catalán, P; García-Lledó, A; Guzman, G; Marfil, T; Megías, A; Moya, JL; Muriel, A; Ruiz-Leria, S; Tarancón, B; Tomás, JP, 2006) |
| "Insulin sensitivity was expressed as insulin resistance index (IRI), calculated as the ratio of the area under the curve (AUC) for glucose to that for insulin." | 2.71 | Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. ( Bombelli, M; Dell'Oro, R; Facchini, A; Grassi, G; Mancia, G; Scopelliti, F; Seravalle, G; Trevano, FQ, 2003) |
| "Twenty-eight patients who had type 1 diabetes and known diabetic renal disease and had a persistently elevated albumin creatinine ratio (ACR) > 10 mg/mmol despite office BP recordings < or = 140/80 mmHg on maximal recommended dose of the ACEI lisinopril were studied." | 2.71 | Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease. ( Bilous, R; Karalliedde, J; Krimholtz, MJ; Thomas, S; Viberti, G, 2005) |
| "Candesartan cilexetil was found to be equally effective as enalapril in reducing SBP, DBP and LVMI in hypertensives with LVH, according to both ITT and PP analyses." | 2.70 | Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. ( Agabiti-Rosei, E; Cuspidi, C; Di Biagio, C; Magnani, B; Muiesan, ML; Salvetti, M; Valagussa, L; Zanchetti, A, 2002) |
| "Candesartan is an angiotensin II subtype 1 (AT1) receptor antagonist that is administered orally as candesartan cilexetil which is converted in the active compound." | 2.69 | Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. ( Buter, H; de Jong, PE; de Zeeuw, D; Navis, GY; Woittiez, AJ, 1999) |
| "Arterial hypertension is a highly manageable disorder due to a variety of drugs available for its treatment." | 2.58 | Noncholestatic acute hepatocellular injury following candesartan administration. ( DeObeso-Gonzalez, E; Flores-Villalba, E; Lammel-Lindemann, JA; Martagón, AJ; Puente-Gallegos, F, 2018) |
| "Stroke is a major cause of mortality and disability worldwide." | 2.49 | Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke. ( Ito, T; Kawahara, K; Kikuchi, K; Maruyama, I; Miura, N; Morimoto-Yamashita, Y; Murai, Y; Tanaka, E; Tancharoen, S, 2013) |
| "Incident cancer cases were compared in patients randomized to ARBs versus controls." | 2.47 | Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. ( , 2011) |
| "Hypertension is a major risk factor for coronary heart disease, stroke, heart failure and renal disease." | 2.47 | An overview of candesartan in clinical practice. ( Khawaja, Z; Wilcox, CS, 2011) |
| "Untreated hypertension is self-accelerating condition through RAS stimulation." | 2.44 | [Role of RAS in prehypertension]. ( Horiuchi, M; Inaba, S; Iwai, M, 2008) |
| " An increase in production of superoxide anion and hydrogen peroxide, reduction of nitric oxide synthesis, and a decrease in bioavailability of antioxidants have been demonstrated in human hypertension." | 2.44 | [Oxidative stress and mild hypertension]. ( Kurabayashi, M; Nakamura, T; Saito, Y, 2008) |
| "Prevention of hypertension is one of the important strategies for decreasing future cardiovascular accidents." | 2.44 | [Prevension of hypertension by angiotensin receptor blockers in human--TROPHY study]. ( Inoue, T; Ohya, Y, 2008) |
| "Prehypertension is a recognized stage of blood pressure but treatment standards have not yet been established." | 2.44 | Treatment options for prehypertension. ( Nesbitt, SD, 2007) |
| "Prehypertension is considered a precursor of stage 1 hypertension and a predictor of excessive cardiovascular risk." | 2.44 | [Significance of treating prehypertension with an angiotensin-receptor blocker--results from TROPHY study]. ( Umemura, S, 2008) |
| "With candesartan-based treatment, compared with control, the relative risk of non-fatal stroke was 0." | 2.43 | The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses. ( Trenkwalder, P, 2006) |
| " It compared the antihypertensive effect between increasing ARB dosage and the addition of controlled-release nifedipine." | 2.43 | [NICE-Combi study: effect of nifedipine in combination with an angiotensin II receptor blocker on BP control and renal protection]. ( Hasebe, N, 2006) |
| "As stroke is characterised by vascular remodelling and dysfunction and by effects on the cerebral circulation, selecting an agent that has a direct vascular protective effect beyond blood pressure control may be desirable." | 2.42 | Stroke prevention: is it possible? If so, which antihypertensive agent should be used? ( Kim, S, 2003) |
| "Arterial hypertension is closely correlated with the occurrence of stroke and also with the loss of cognitive function and dementia." | 2.42 | Neurological protection provided by candesartan: reviewing the latest study results. ( Leys, D, 2003) |
| "Candesartan is a novel high-affinity type 1 AT(1)-receptor blocker characterized by prolonged binding to and slow dissociation from the receptor." | 2.42 | [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension]. ( Ivanova, NA; Preobrazhenskiĭ, DV; Sidorenko, BA; Soplevenko, AV; Stetsenko, TM, 2004) |
| "Candesartan is a selective angiotensin II Type I (AT(1)) receptor blocker which binds tightly to, and dissociates slowly from the receptor." | 2.42 | Candesartan for the treatment of hypertension and heart failure. ( Ostergren, J, 2004) |
| " The selected studies were included in a meta-analysis of the dose-response relationship for each drug." | 2.41 | The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. ( Elmfeldt, D; Meredith, P; Olofsson, B, 2002) |
| " Further research is necessary to determine which AT1RBs and which dosing regimens are optimal." | 2.41 | Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. ( Mancini, GB, 2002) |
| "Arterial hypertension is a major risk factor for microangiopathic diabetic complications and associated with an increased cardiovascular morbidity and mortality." | 2.41 | [Angiotensin II type-1 receptor antagonists and diabetes mellitus]. ( Schernthaner, G; Schnack, C, 2001) |
| "The main goal of the treatment of hypertension is to decrease cardiovascular morbidity and mortality." | 2.40 | Clinical efficacy of a new AT1 blocker. ( Heemann, U; Philipp, T, 1998) |
| "Candesartan is an insurmountable blocker with a slow dissociation from the AT1 receptor, and it has been shown to effectively reduce BP in humans and in a variety of genetic and experimental models of hypertension." | 2.40 | Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection. ( Morsing, P, 1999) |
| "Their use in congestive heart failure and renal disease is under investigation." | 2.40 | Angiotensin-II receptor antagonists: their place in therapy. ( Kirk, JK, 1999) |
| "Candesartan (Atacand) is a novel antagonist of angiotensin II AT1 receptors." | 2.40 | [Pharma-clinics. The drug of the month. Candesartan (Atacand)]. ( Kulbertus, H, 1999) |
| "Candesartan (Cand) is an angiotensin receptor antagonist widely used for hypertension treatment." | 1.91 | Effect of the structural modification of Candesartan with Zinc on hypertension and left ventricular hypertrophy. ( Calleros, L; De Giusti, V; Ferrer, EG; Griera, M; Islas, MS; Jaquenod de Giusti, C; Martinez, VR; Martins Lima, A; Portiansky, EL; Rodriguez Puyol, M; Stergiopulos, N; Velez Rueda, JO; Williams, PAM, 2023) |
| " Candesartan in combination with RDN prolonged trough BP and attenuated renal hemodynamic responses to blood loss." | 1.72 | Renal Denervation in Combination With Angiotensin Receptor Blockade Prolongs Blood Pressure Trough During Hemorrhage. ( Booth, LC; Denton, KM; Head, GA; May, CN; McArdle, Z; Moritz, KM; Schlaich, MP; Singh, RR, 2022) |
| " Repeat dose pharmacokinetic and pharmacodynamic study of the nano-fixed dose combination (FDC) was done in dexamethasone-induced animal model." | 1.56 | Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension. ( Bhandari, RK; Bhatia, A; Kaur, N; Malhotra, S; Pandey, AK; Rather, IIG; Shafiq, N; Sharma, S, 2020) |
| "Simultaneous occurrence of transient global amnesia and Takotsubo syndrome has been only rarely reported." | 1.51 | Simultaneous transient global amnesia and Takotsubo syndrome after death of a relative: a case report. ( Finsterer, J; Stollberger, C, 2019) |
| "Candesartan treatment also increased the amount of fecal short-chain fatty acids (SCFAs) including acetic acid, propionic acid, and butyric acid in SHRs." | 1.51 | Candesartan attenuates hypertension-associated pathophysiological alterations in the gut. ( Chen, Y; Cui, J; Ding, L; Du, X; Tang, X; Wang, P; Wang, W; Wu, D; Yin, J; Zhang, T, 2019) |
| "Hypertension is one of the major risk factors for central nervous system (CNS) disorders like stroke and Alzheimer's disease (AD)." | 1.48 | Angiotensin Receptor Blockade by Inhibiting Glial Activation Promotes Hippocampal Neurogenesis Via Activation of Wnt/β-Catenin Signaling in Hypertension. ( Bhat, SA; Goel, R; Hanif, K; Shukla, R; Shukla, S, 2018) |
| "Treatment with ramipril and candesartan, especially with long-term use, reduced the hydropic swelling of hepatocytes." | 1.48 | PATHOMORPHOLOGY OF THE MYOCARDIUM, KIDNEY AND LIVER IN SPONTANEOUSLY HYPERTENSIVE RATS TREATED WITH SHORT AND LONG-TERM USE RAMIPRIL AND CANDESARTAN. ( Davydenko, I; Maruschak, A; Shorikov, E; Slobodyan, K; Timofiichuk, I, 2018) |
| "Stroke is a leading cause of adult disability worldwide." | 1.46 | Mechanisms of acute neurovascular protection with AT1 blockade after stroke: Effect of prestroke hypertension. ( Ahmed, H; Alhusban, A; Ergul, A; Fagan, SC; Ishrat, T; Johnson, MH; Kozak, A; Pillai, B; Sayed, MA, 2017) |
| " We evaluated the impact of 3 generic angiotensin II receptor blockers commercialization on adverse events: hospitalizations or emergency room consultations." | 1.46 | Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis. ( Blais, C; Guénette, L; Hamel, D; Leclerc, J; Poirier, P; Rochette, L, 2017) |
| "Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels." | 1.43 | Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. ( Piecha, G; Skoczylas, A; Więcek, A, 2016) |
| "Candesartan and tempol treatments also significantly improved conducted vasodilatation." | 1.39 | Spreading vasodilatation in the murine microcirculation: attenuation by oxidative stress-induced change in electromechanical coupling. ( Chaston, DJ; Edwards, FR; Hill, CE; Howitt, L; Matthaei, KI; Sandow, SL, 2013) |
| "Candesartan is an angiotensin II type 1 receptor blocker (ARB) that has been to shown to limit ischemic stroke and improve stroke outcome." | 1.39 | AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator. ( Alhusban, A; Ergul, A; Fagan, SC; Kozak, A, 2013) |
| "Candesartan treatment for 4 weeks significantly reduced these parameters." | 1.39 | Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats. ( Chen, X; Endo, S; Guo, Q; Hu, C; Ito, S; Jiang, Y; Miyata, T; Mori, T; Nakayama, K; Nakayama, M; Ogawa, S; Ohsaki, Y; Yoneki, Y; Zhu, W, 2013) |
| "In the Japan Morning Surge-Target Organ Protection (J-TOP) study, which was an open-label multicenter trial to compare bedtime or awakening dosing of candesartan (+ diuretics as needed) among individuals with home SBP higher than 135 mmHg, we evaluated 254 hypertensive patients who underwent ambulatory BP monitoring, and measured their BNP at baseline and after 6th month of treatment." | 1.38 | Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study. ( Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kario, K; Shimada, K; Shimizu, M; Yano, Y, 2012) |
| "In end-stage renal disease (ESRD) the incidence of genomic damage is increased." | 1.37 | AT1 receptor antagonist candesartan attenuates genomic damage in peripheral blood lymphocytes of patients on maintenance hemodialysis treatment. ( Bahner, U; Grupp, C; Heidland, A; Klassen, A; Rutkowski, P; Schupp, N; Sebeková, K; Stopper, H, 2011) |
| "The regular dose of an angiotensin II type-1 receptor blocker (ARB) in renal transplant patients for hypertension is shown to be safe and effective; however, information on the appropriate dosing of ARBs in renal transplant patients is limited." | 1.37 | Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients. ( Abe, T; Ichimaru, N; Imamura, R; Isaka, Y; Kawada, N; Kitamura, H; Kojima, Y; Kokado, Y; Moriyama, T; Nonomura, N; Okumi, M; Rakugi, H; Takahara, S, 2011) |
| "Obesity has been strongly associated with the development and aggravation of hypertension and chronic kidney disease." | 1.36 | Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats. ( Chang, YS; Chung, HW; Chung, S; Kim, BS; Kim, GH; Kim, HW; Lee, JH; Lim, JH; Park, CW; Shin, SJ; Youn, DY, 2010) |
| "Candesartan-pretreated SHHF (5 mg/kg/day candesartan; weeks 4-8) received during adulthood (20-28 weeks of age) either candesartan at a dose of 1." | 1.36 | Prehypertensive preconditioning improves adult antihypertensive and cardioprotective treatment. ( Baumann, M; Heemann, U; Lutz, J; Roos, M; Sollinger, D, 2010) |
| "Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity." | 1.36 | Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010) |
| "Hypertension is a leading risk factor for the development and progression of diabetic retinopathy and contributes to a variety of other retinal diseases in the absence of diabetes mellitus." | 1.35 | Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability. ( Bursell, SE; Chilcote, TJ; Clermont, AC; Feener, EP; Phipps, JA; Sinha, S, 2009) |
| "Baclofen per se has the potential of lowering blood pressure." | 1.35 | Intrathecal baclofen for autonomic instability due to spinal cord injury. ( Kofler, M; Poustka, K; Saltuari, L, 2009) |
| "Cardiac complications were defined as left ventricular hypertrophy (LVH) and ischemic heart disease (IHD)." | 1.35 | Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial. ( Fujimoto, A; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2009) |
| "Hypertension is commonly identified based on the average of two BPs taken at each of two visits, a practice consistent with current guidelines." | 1.35 | Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study. ( Turner, MJ; van Schalkwyk, JM, 2008) |
| "Salt-sensitive (SS) hypertension is a vascular diathesis characterized by reduced cardiovascular and renal nitric oxide bioavailability and local upregulation of ANG II." | 1.35 | Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species. ( Jaimes, EA; Pearse, DD; Puzis, L; Raij, L; Zhou, MS, 2008) |
| "Candesartan has been reported to produce nitric oxide (NO) and to decrease oxidative stress in animal studies." | 1.35 | Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. ( Fujiwara, H; Hiei, K; Kawasaki, H; Minatoguchi, S; Mizukusa, T; Ono, H; Takahashi, H; Tsukamoto, T; Uno, T; Watanabe, K; Yamada, Y, 2008) |
| "Candesartan treatment of DS rats with established diastolic heart failure reversed cardiac remodeling, improved cardiac relaxation abnormality, and prolonged survival, being accompanied by the attenuation of the increase in cardiac superoxide, reduced nicotinamide-adenine dinucleotide phosphate oxidase, and xanthine oxidoreductase activities." | 1.34 | Role of xanthine oxidoreductase in the reversal of diastolic heart failure by candesartan in the salt-sensitive hypertensive rat. ( Dong, YF; Kataoka, K; Kim-Mitsuyama, S; Matsuba, S; Ogawa, H; Tokutomi, Y; Yamamoto, E; Yamashita, T, 2007) |
| "Hypertension was also accompanied by increased IL-1beta and IL-6 plasma levels." | 1.33 | Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system. ( Cachofeiro, V; Cediel, E; de Las Heras, N; Jiménez, J; Lahera, V; Oubiña, MP; Sanz-Rosa, D; Vegazo, O, 2005) |
| "Diabetes and hypertension are potent risk factors for cerebrovascular disease." | 1.33 | Diabetic brain damage in hypertension: role of renin-angiotensin system. ( Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kario, K; Matsui, Y; Morinari, M; Shimada, K, 2005) |
| "Candesartan (3 mg /kg/d) was given in rat chow for 4 months." | 1.33 | Effects of long-term treatment with candesartan on hemodynamics and organ damage in spontaneously hypertensive rats. ( Chen, YY; Miao, CY; Shen, FM; Su, DF; Xie, HH, 2005) |
| "Candesartan treatment increased Aogen, ACE and AT2 receptor in SHR, and increased ACE and decreased Aogen in WKY rats, without affecting the (pro)renin and AT1 receptors." | 1.33 | AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. ( Delgiacco, E; Dou, J; Ge, L; Imboden, H; Macova, M; Nishioku, T; Pavel, J; Saavedra, JM; Yu, ZX; Zhou, J, 2006) |
| "Atherosclerotic renal artery stenosis is a problem with no consensus on diagnosis or therapy." | 1.33 | Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. ( Cohen, DJ; Cooper, CJ; D'Agostino, R; Dworkin, L; Henrich, W; Jaff, M; Jamerson, K; Kuntz, R; Matsumoto, A; Murphy, TP; Reid, D; Rosenfield, K; Rundback, J; Steffes, M, 2006) |
| "Also, body weight was measured two times, at initial time (before STZ injection) and terminal (at the last day in the experiment)." | 1.33 | Role of AT1 receptors in permeability of the blood-brain barrier in diabetic hypertensive rats. ( Awad, AS, 2006) |
| " Chronic administration of a subdepressor dose of an angiotensin II type 1 receptor blocker candesartan reduced the pressure overload-induced dihydroethidium and 4-HNE signals at day 3." | 1.33 | Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. ( Fukui, D; Imaizumi, T; Kai, H; Kudo, H; Kuwahara, F; Mori, T; Sugi, Y; Tahara, N; Takayama, N; Takemiya, K; Tokuda, K; Yasukawa, H, 2006) |
| "Candesartan treatment reduced (P < 0." | 1.32 | Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function? ( Cachofeiro, V; Cediel, E; de las Heras, N; González Pacheco, FR; Jiménez, J; Lahera, V; Oubina, MP; Sanz-Rosa, D; Vegazo, O, 2003) |
| "Candesartan treatment decreased cardiac PAI-1 expression only in the dark in WKY rats but throughout the day in SHR." | 1.32 | Circadian gene expression of clock genes and plasminogen activator inhibitor-1 in heart and aorta of spontaneously hypertensive and Wistar-Kyoto rats. ( Fujioka, Y; Iwasaki, T; Kawasaki, D; Masai, M; Morimoto, S; Naito, Y; Ohyanagi, M; Okumura, T; Sakoda, T; Tsujino, T, 2003) |
| " Estrogen has been shown to downregulate angiotensin type 1 (AT1) receptor expression and to increase the bioavailability of endothelium-derived NO, which decreases AT1 receptor expression." | 1.32 | Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity. ( Harrison-Bernard, LM; Raij, L; Schulman, IH, 2003) |
| "Treatment with candesartan, but not the combination of hydralazine and hydrochlorothiazide, significantly increased the expression of Cx37 and Cx40, although blood pressure decreased similarly." | 1.32 | Angiotensin II receptor blockade corrects altered expression of gap junctions in vascular endothelial cells from hypertensive rats. ( Abe, I; Fujii, K; Goto, K; Iida, M; Kansui, Y; Nakamura, K; Oniki, H; Shibata, Y, 2004) |
| "Thus candesartan is considered to be a unique, attractive choice of prophylactic agent for migraine complicated by hypertension." | 1.32 | Efficacy of candesartan in the treatment of migraine in hypertensive patients. ( Owada, K, 2004) |
| "Oral treatment with candesartan increased the nonlinearity and reduced the linearity in SHR." | 1.31 | Potentiated sympathetic nervous and renin-angiotensin systems reduce nonlinear correlation between sympathetic activity and blood pressure in conscious spontaneously hypertensive rats. ( Imai, M; Kumagai, H; Matsuura, T; Onami, T; Osaka, M; Sakata, K; Saruta, T, 2002) |
| "Pretreatment with candesartan for 3 days or nicardipine for 28 days was ineffective." | 1.31 | Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. ( Bregonzio, C; Falcón-Neri, A; Ito, T; Saavedra, JM; Terrón, JA; Yamakawa, H, 2002) |
| "Candesartan treatment normalized blood pressure and the shift toward higher blood pressures at both the upper and lower limits of cerebrovascular autoregulation in SHR." | 1.31 | Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. ( Ito, T; Nishimura, Y; Saavedra, JM, 2000) |
| "When hypertension was reduced using captopril or candesartan, retinal KDR expression returned to baseline levels." | 1.31 | Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension. ( Aiello, LP; Clermont, A; Feener, EP; Hata, Y; Pokras, F; Rook, SL; Suzuma, I; Suzuma, K, 2001) |
| "Only losartan treatment reduced ex vivo platelet adhesion to a synthetic surface." | 1.31 | Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan. ( Arriero, MM; Cabestrero, F; Casado, S; de Miguel, LS; Farré, J; García, R; García-Colis, E; Gómez, J; Jiménez, AM; López-Farré, A; Montón, M; Núñez, A; Rico, L, 2001) |
| "Candesartan was intravenously administered 30 min before ischemia." | 1.31 | An angiotensin II type 1 receptor blocker, candesartan, increases myocardial apoptosis in rats with acute ischemia-reperfusion. ( Chen, M; Hamada, M; Hiasa, G; Hiwada, K; Ikeda, S; Suzuki, M, 2001) |
| "Candesartan treatment normalised the lower part of the autoregulatory curve in SHR, and markedly decreased cerebral ischaemia as a consequence of middle cerebral artery occlusion with reperfusion." | 1.31 | Pre-treatment with candesartan protects from cerebral ischaemia. ( Ito, T; Nishimura, Y; Saavedra, J, 2001) |
| " Chronic administration of low-dose candesartan, captopril, or verapamil prevented the arterial hypertension and improved renal hemodynamics, but these levels were not completely normalized." | 1.30 | Pressure natriuresis in nitric oxide-deficient hypertensive rats: effect of antihypertensive treatments. ( Atucha, NM; Cachofeiro, V; Fortepiani, LA; García-Estañ, J; Lahera, V; Ortíz, MC; Rodrigo, E; Ruilope, LM, 1999) |
| "Hydronephrosis was induced by ligation of the left ureter in 8-week-old stroke-prone spontaneously hypertensive rats." | 1.29 | Effects of a calcium antagonist and an angiotensin II receptor antagonist on rat renal arterioles. ( Goto, A; Hayakawa, H; Hirata, Y; Kimura, K; Omata, M; Tojo, A, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 44 (7.37) | 18.2507 |
| 2000's | 333 (55.78) | 29.6817 |
| 2010's | 202 (33.84) | 24.3611 |
| 2020's | 18 (3.02) | 2.80 |
| Authors | Studies |
|---|---|
| Schmidt, B | 1 |
| Schieffer, B | 1 |
| Shah, DI | 1 |
| Sharma, M | 1 |
| Bansal, Y | 1 |
| Bansal, G | 1 |
| Singh, M | 1 |
| Singh, RR | 1 |
| McArdle, Z | 1 |
| Booth, LC | 1 |
| May, CN | 1 |
| Head, GA | 2 |
| Moritz, KM | 1 |
| Schlaich, MP | 2 |
| Denton, KM | 1 |
| Tsubanova, N | 1 |
| Kovpak, A | 1 |
| Zamorskyi, I | 1 |
| Wu, T | 1 |
| Zheng, Y | 1 |
| Huang, Q | 1 |
| Tian, S | 1 |
| Martinez, VR | 1 |
| Martins Lima, A | 1 |
| Stergiopulos, N | 1 |
| Velez Rueda, JO | 1 |
| Islas, MS | 1 |
| Griera, M | 1 |
| Calleros, L | 1 |
| Rodriguez Puyol, M | 1 |
| Jaquenod de Giusti, C | 1 |
| Portiansky, EL | 1 |
| Ferrer, EG | 1 |
| De Giusti, V | 1 |
| Williams, PAM | 1 |
| Sundström, J | 3 |
| Lind, L | 4 |
| Nowrouzi, S | 2 |
| Hagström, E | 1 |
| Held, C | 3 |
| Lytsy, P | 2 |
| Neal, B | 1 |
| Marttala, K | 2 |
| Östlund, O | 2 |
| Fukuda, N | 3 |
| Katakawa, M | 1 |
| Ito, H | 2 |
| Hara, T | 1 |
| Otsuka, N | 1 |
| Ishizuka, M | 1 |
| Abe, M | 1 |
| Hedenmalm, K | 1 |
| Quinten, C | 1 |
| Kurz, X | 1 |
| Bradley, M | 1 |
| Lee, H | 1 |
| Eworuke, E | 1 |
| Tayag, JCS | 1 |
| Ishii, T | 1 |
| Kokuba, S | 1 |
| Hirata, T | 1 |
| Shiohira, H | 1 |
| Nakamura, K | 3 |
| Cunningham, PN | 1 |
| Wang, Z | 2 |
| Grove, ML | 1 |
| Cooper-DeHoff, RM | 2 |
| Beitelshees, AL | 1 |
| Gong, Y | 2 |
| Gums, JG | 2 |
| Johnson, JA | 2 |
| Turner, ST | 5 |
| Boerwinkle, E | 5 |
| Chapman, AB | 5 |
| Kiriakidi, S | 1 |
| Chatzigiannis, C | 1 |
| Papaemmanouil, C | 1 |
| Tzakos, AG | 1 |
| Mavromoustakos, T | 1 |
| Leclerc, J | 2 |
| Blais, C | 2 |
| Rochette, L | 2 |
| Hamel, D | 2 |
| Guénette, L | 2 |
| Beaudoin, C | 1 |
| Poirier, P | 2 |
| Pandey, AK | 1 |
| Shafiq, N | 2 |
| Bhandari, RK | 1 |
| Rather, IIG | 1 |
| Kaur, N | 1 |
| Bhatia, A | 1 |
| Sharma, S | 2 |
| Malhotra, S | 2 |
| Li, Z | 1 |
| Lindner, DP | 1 |
| Bishop, NM | 1 |
| Cipolla, MJ | 1 |
| Kikuchi, N | 2 |
| Ogawa, H | 10 |
| Kawada-Watanabe, E | 2 |
| Arashi, H | 1 |
| Jujo, K | 2 |
| Sekiguchi, H | 1 |
| Yamaguchi, J | 5 |
| Hagiwara, N | 8 |
| Chen, YJ | 1 |
| Chiang, CE | 1 |
| Cheng, HM | 1 |
| Hajjar, I | 3 |
| Okafor, M | 1 |
| McDaniel, D | 1 |
| Obideen, M | 1 |
| Dee, E | 1 |
| Shokouhi, M | 1 |
| Quyyumi, AA | 1 |
| Levey, A | 1 |
| Goldstein, F | 1 |
| Yang, H | 1 |
| Song, X | 1 |
| Wei, Z | 1 |
| Xia, C | 1 |
| Wang, J | 3 |
| Shen, L | 1 |
| Wagmann, L | 1 |
| Vollmer, AC | 1 |
| Lauder, L | 1 |
| Mahfoud, F | 1 |
| Meyer, MR | 1 |
| Xu, L | 2 |
| Hu, G | 2 |
| Qiu, J | 1 |
| Fan, Y | 1 |
| Ma, Y | 1 |
| Miura, T | 2 |
| Kohzuki, M | 2 |
| Ito, O | 2 |
| Mizuno, H | 1 |
| Hoshide, S | 7 |
| Tomitani, N | 1 |
| Kario, K | 10 |
| Danilov, SM | 1 |
| Tovsky, SI | 1 |
| Schwartz, DE | 1 |
| Dull, RO | 1 |
| Alhusban, A | 2 |
| Kozak, A | 4 |
| Pillai, B | 2 |
| Ahmed, H | 1 |
| Sayed, MA | 1 |
| Johnson, MH | 3 |
| Ishrat, T | 2 |
| Ergul, A | 4 |
| Fagan, SC | 5 |
| Owens, EA | 1 |
| Jie, L | 1 |
| Reyes, BAS | 1 |
| Van Bockstaele, EJ | 1 |
| Osei-Owusu, P | 1 |
| Lyamin, NP | 1 |
| Nalivayeva, AV | 1 |
| Mordwintseva, AY | 1 |
| Lammel-Lindemann, JA | 1 |
| Flores-Villalba, E | 1 |
| Martagón, AJ | 1 |
| DeObeso-Gonzalez, E | 1 |
| Puente-Gallegos, F | 1 |
| Bhat, SA | 1 |
| Goel, R | 1 |
| Shukla, S | 1 |
| Shukla, R | 1 |
| Hanif, K | 2 |
| Cechova, S | 1 |
| Dong, F | 1 |
| Chan, F | 1 |
| Kelley, MJ | 1 |
| Ruiz, P | 1 |
| Le, TH | 1 |
| Busby, J | 1 |
| McMenamin, Ú | 1 |
| Spence, A | 1 |
| Johnston, BT | 1 |
| Hughes, C | 1 |
| Cardwell, CR | 1 |
| Tassi, E | 1 |
| Lai, EY | 1 |
| Li, L | 1 |
| Solis, G | 1 |
| Chen, Y | 2 |
| Kietzman, WE | 1 |
| Ray, PE | 1 |
| Riegel, AT | 1 |
| Welch, WJ | 2 |
| Wilcox, CS | 3 |
| Wellstein, A | 1 |
| Ahmed, HA | 1 |
| Bunting, KM | 1 |
| Patel, A | 1 |
| Vazdarjanova, A | 1 |
| Waller, JL | 1 |
| Arbab, AS | 1 |
| Li, H | 1 |
| Zhao, JL | 1 |
| Zhang, YM | 1 |
| Han, SX | 1 |
| Bramlage, P | 6 |
| Schmidt, S | 1 |
| Sims, H | 1 |
| Maruschak, A | 1 |
| Shorikov, E | 1 |
| Timofiichuk, I | 1 |
| Davydenko, I | 1 |
| Slobodyan, K | 1 |
| Liu, J | 1 |
| Yasuno, S | 8 |
| Oba, K | 9 |
| Konda, M | 1 |
| Ichihara, C | 1 |
| Kitao, H | 1 |
| Kuwabara, Y | 1 |
| Ueshima, K | 12 |
| Takahama, H | 1 |
| Asakura, M | 1 |
| Abe, Y | 2 |
| Ajioka, M | 1 |
| Aonuma, K | 1 |
| Anzai, T | 1 |
| Hayashi, T | 4 |
| Hiramitsu, S | 1 |
| Kawai, H | 1 |
| Kioka, H | 1 |
| Kimura, K | 2 |
| Lim, YJ | 1 |
| Matsuoka, K | 1 |
| Motoki, H | 1 |
| Nagata, Y | 1 |
| Nakamura, S | 2 |
| Ohte, N | 1 |
| Ozaki, Y | 2 |
| Sasaoka, T | 1 |
| Tamaki, S | 1 |
| Hamasaki, T | 1 |
| Kitakaze, M | 2 |
| Rong, R | 1 |
| Wang, W | 2 |
| Muroya, Y | 1 |
| Ogawa, Y | 1 |
| Ekman, I | 1 |
| Öhagen, P | 1 |
| Matsuo, Y | 1 |
| Suematsu, Y | 1 |
| Tomita, S | 1 |
| Tashiro, K | 1 |
| Kuwano, T | 1 |
| Kitajima, K | 1 |
| Miura, SI | 1 |
| Ashcheulova, T | 1 |
| Gerasimchuk, N | 1 |
| Kovalyova, O | 1 |
| Honchar, O | 1 |
| Pais, P | 3 |
| Jung, H | 3 |
| Dans, A | 3 |
| Zhu, J | 3 |
| Liu, L | 3 |
| Kamath, D | 1 |
| Bosch, J | 3 |
| Lonn, E | 2 |
| Yusuf, S | 3 |
| Nautiyal, M | 2 |
| Shaltout, HA | 4 |
| Chappell, MC | 5 |
| Diz, DI | 5 |
| Finsterer, J | 1 |
| Stollberger, C | 1 |
| Wu, D | 1 |
| Tang, X | 1 |
| Ding, L | 1 |
| Cui, J | 1 |
| Wang, P | 1 |
| Du, X | 1 |
| Yin, J | 1 |
| Zhang, T | 1 |
| Cho, KI | 1 |
| Kim, BH | 1 |
| Park, YH | 1 |
| Ahn, JC | 1 |
| Kim, SH | 1 |
| Chung, WJ | 5 |
| Kim, W | 1 |
| Sohn, IS | 1 |
| Shin, JH | 1 |
| Kim, YJ | 1 |
| Chang, K | 1 |
| Yu, CW | 1 |
| Ahn, SH | 1 |
| Kim, SY | 1 |
| Ryu, JK | 1 |
| Lee, JY | 1 |
| Hong, BK | 1 |
| Hong, TJ | 1 |
| Gyu Park, C | 1 |
| Howitt, L | 1 |
| Chaston, DJ | 1 |
| Sandow, SL | 1 |
| Matthaei, KI | 1 |
| Edwards, FR | 1 |
| Hill, CE | 1 |
| Gabor, A | 1 |
| Leenen, FH | 1 |
| Levitan, EB | 1 |
| Kaciroti, N | 2 |
| Oparil, S | 2 |
| Julius, S | 12 |
| Muntner, P | 1 |
| Schwartz, GL | 3 |
| Bailey, K | 1 |
| Suzuki, H | 5 |
| Sakamoto, M | 3 |
| Iuchi, H | 2 |
| Ohashi, K | 2 |
| Isaka, T | 2 |
| Sakamoto, N | 2 |
| Kayama, Y | 2 |
| Tojo, K | 2 |
| Yoshimura, M | 4 |
| Utsunomiya, K | 3 |
| Hornslien, AG | 1 |
| Sandset, EC | 7 |
| Bath, PM | 6 |
| Wyller, TB | 1 |
| Berge, E | 7 |
| Sakima, A | 3 |
| Kita, T | 2 |
| Nakada, S | 2 |
| Yokota, N | 2 |
| Tamaki, N | 2 |
| Etoh, T | 2 |
| Shimokubo, T | 2 |
| Kitamura, K | 2 |
| Takishita, S | 5 |
| Ohya, Y | 5 |
| Agnoletti, D | 2 |
| Zhang, Y | 2 |
| Borghi, C | 1 |
| Blacher, J | 2 |
| Safar, ME | 3 |
| Moinuddin, G | 1 |
| Inamdar, MN | 1 |
| Kulkarni, KS | 1 |
| Kulkarni, C | 1 |
| Koyanagi, R | 3 |
| Haruta, S | 1 |
| Takagi, A | 3 |
| Farinde, A | 1 |
| Takemori, K | 1 |
| Inoue, T | 3 |
| Rakugi, H | 6 |
| Enya, K | 2 |
| Igeta, M | 1 |
| Ikeda, Y | 3 |
| Kikuchi, K | 2 |
| Tancharoen, S | 1 |
| Ito, T | 4 |
| Morimoto-Yamashita, Y | 1 |
| Miura, N | 1 |
| Kawahara, K | 1 |
| Maruyama, I | 1 |
| Murai, Y | 1 |
| Tanaka, E | 1 |
| Zemmrich, C | 2 |
| Lüders, S | 5 |
| Gansz, A | 2 |
| Sturm, CD | 2 |
| Fimmers, R | 2 |
| Nadal, J | 2 |
| Schmieder, RE | 2 |
| Schrader, J | 3 |
| Sun, Y | 2 |
| Liao, Y | 1 |
| Yuan, Y | 1 |
| Feng, L | 1 |
| Ma, S | 2 |
| Wei, F | 2 |
| Wang, M | 2 |
| Zhu, F | 2 |
| Harrap, SB | 1 |
| Charchar, FJ | 1 |
| Sasamura, H | 4 |
| Nakaya, H | 4 |
| Tomotsugu, N | 1 |
| Sato, Y | 3 |
| Takahashi, F | 1 |
| Takeuchi, M | 2 |
| Murakami, M | 2 |
| Ryuzaki, M | 3 |
| Itoh, H | 6 |
| Egan, BM | 4 |
| Kaciroti, NA | 3 |
| Nesbitt, SD | 4 |
| Chen, AK | 1 |
| Sugama, I | 1 |
| Kohagura, K | 1 |
| Yamazato, M | 2 |
| Nakamura, T | 4 |
| Shinzato, T | 2 |
| Kinoshita, S | 1 |
| Sone, M | 2 |
| Nishida, E | 1 |
| Nakamoto, H | 1 |
| Ono, Y | 1 |
| Mizuno, K | 1 |
| Takahashi, M | 1 |
| Miura, Y | 2 |
| Watanabe, T | 1 |
| Lin, JW | 1 |
| Chang, CH | 1 |
| Caffrey, JL | 1 |
| Wu, LC | 1 |
| Lai, MS | 1 |
| Daikuhara, H | 2 |
| Fukunaga, K | 1 |
| Ohshima, T | 1 |
| Zimmerman, MA | 1 |
| Harris, RA | 1 |
| Sullivan, JC | 1 |
| Isegawa, K | 1 |
| Hirooka, Y | 6 |
| Kishi, T | 4 |
| Yasukawa, K | 2 |
| Utsumi, H | 2 |
| Sunagawa, K | 4 |
| Sugiura, K | 1 |
| Schilders, JE | 1 |
| Wu, H | 1 |
| Boomsma, F | 1 |
| van den Meiracker, AH | 2 |
| Danser, AH | 2 |
| Kato, H | 1 |
| Shiraishi, T | 1 |
| Ueda, S | 1 |
| Kubo, E | 1 |
| Shima, T | 1 |
| Nagura, M | 1 |
| Yano, H | 1 |
| Izumikawa, Y | 1 |
| Shimada, M | 1 |
| Tomioka, S | 1 |
| Nosaka, H | 1 |
| Kojima, K | 1 |
| Tanemoto, M | 1 |
| Uchida, S | 2 |
| Kjeldsen, SE | 8 |
| Sica, D | 1 |
| Haller, H | 1 |
| Cha, G | 2 |
| Gil-Extremera, B | 2 |
| Harvey, P | 2 |
| Heyvaert, F | 1 |
| Lewin, AJ | 2 |
| Villa, G | 2 |
| Mancia, G | 5 |
| Hasvold, LP | 1 |
| Bodegård, J | 4 |
| Thuresson, M | 2 |
| Stålhammar, J | 4 |
| Hammar, N | 1 |
| Russell, D | 4 |
| Jusufovic, M | 3 |
| Raghunathan, T | 2 |
| Hass, A | 2 |
| Oz, H | 2 |
| Mashavi, M | 1 |
| Shargorodsky, M | 3 |
| Karlson, BW | 2 |
| Shimizu, M | 5 |
| Ishikawa, J | 5 |
| Yano, Y | 4 |
| Eguchi, K | 7 |
| Brand, S | 1 |
| Amann, K | 1 |
| Mandel, P | 1 |
| Zimnol, A | 1 |
| Schupp, N | 2 |
| Hiltunen, TP | 1 |
| Donner, KM | 1 |
| Sarin, AP | 1 |
| Saarela, J | 1 |
| Ripatti, S | 1 |
| Frau, F | 1 |
| Glorioso, V | 1 |
| Zaninello, R | 1 |
| Salvi, E | 1 |
| Glorioso, N | 1 |
| Kontula, KK | 1 |
| Sandset, PM | 1 |
| Luo, H | 1 |
| Wang, X | 3 |
| Chen, C | 1 |
| Zou, X | 1 |
| Li, C | 1 |
| Xu, Z | 1 |
| Yang, X | 1 |
| Shi, W | 1 |
| Zeng, C | 2 |
| Gavish, D | 2 |
| Hosaka, M | 2 |
| Metoki, H | 3 |
| Satoh, M | 2 |
| Ohkubo, T | 3 |
| Asayama, K | 3 |
| Kikuya, M | 3 |
| Inoue, R | 2 |
| Obara, T | 2 |
| Hirose, T | 1 |
| Imai, Y | 3 |
| Arora, A | 1 |
| Jain, S | 1 |
| Khuller, GK | 1 |
| Del Borgo, M | 1 |
| Wang, Y | 2 |
| Bosnyak, S | 1 |
| Khan, M | 1 |
| Walters, P | 1 |
| Spizzo, I | 1 |
| Perlmutter, P | 1 |
| Hilliard, L | 1 |
| Denton, K | 1 |
| Aguilar, MI | 1 |
| Widdop, RE | 3 |
| Jones, ES | 1 |
| Villar, VA | 1 |
| Chen, SY | 1 |
| Konkalmatt, P | 1 |
| Asico, LD | 1 |
| Jones, JE | 1 |
| Yang, Y | 1 |
| Sanada, H | 1 |
| Felder, RA | 1 |
| Eisner, GM | 1 |
| Weir, MR | 3 |
| Armando, I | 1 |
| Jose, PA | 1 |
| Haga, T | 1 |
| Murakami, T | 1 |
| Mano, N | 1 |
| López-Jaramillo, P | 2 |
| Xavier, D | 2 |
| Avezum, A | 2 |
| Leiter, LA | 2 |
| Piegas, LS | 2 |
| Parkhomenko, A | 2 |
| Keltai, M | 2 |
| Keltai, K | 2 |
| Sliwa, K | 2 |
| Chazova, I | 2 |
| Peters, RJ | 2 |
| Yusoff, K | 2 |
| Lewis, BS | 2 |
| Jansky, P | 2 |
| Khunti, K | 2 |
| Toff, WD | 2 |
| Reid, CM | 2 |
| Varigos, J | 2 |
| Accini, JL | 1 |
| McKelvie, R | 2 |
| Pogue, J | 2 |
| Diaz, R | 2 |
| Dagenais, G | 2 |
| Lonn, EM | 1 |
| Molina, DI | 1 |
| Wilkinson, J | 1 |
| Buus, NH | 1 |
| Mulvany, MJ | 2 |
| Eiskjær, H | 1 |
| Christensen, KL | 1 |
| Skov, K | 2 |
| Skoczylas, A | 1 |
| Piecha, G | 1 |
| Więcek, A | 1 |
| Lee, JH | 2 |
| Yang, DH | 1 |
| Hwang, JY | 1 |
| Hur, SH | 1 |
| Cha, TJ | 1 |
| Kim, KS | 1 |
| Kim, MH | 1 |
| Chun, KJ | 1 |
| Cha, GS | 1 |
| Hong, GR | 1 |
| Lee, SG | 1 |
| Kim, DS | 2 |
| Kim, DI | 1 |
| Chae, SC | 1 |
| Vítovec, J | 1 |
| Špinar, J | 1 |
| Cao, X | 1 |
| Nakamura, Y | 1 |
| Wada, T | 4 |
| Izumi-Nakaseko, H | 1 |
| Ando, K | 1 |
| Sugiyama, A | 1 |
| Eaton Md, CB | 2 |
| Kim, MJ | 1 |
| Kim, JH | 2 |
| Kim, IY | 1 |
| Lee, DW | 1 |
| Lee, SB | 1 |
| Huang, R | 1 |
| Feng, Y | 1 |
| Qin, X | 1 |
| Melgiri, ND | 1 |
| Li, X | 1 |
| Savina, NM | 1 |
| Williams, SA | 1 |
| Michelson, EL | 2 |
| Cain, VA | 1 |
| Yang, M | 1 |
| Susic, D | 4 |
| Krousel-Wood, M | 1 |
| Zhou, X | 2 |
| Frohlich, ED | 4 |
| Kozak, W | 1 |
| Elewa, HF | 1 |
| Koh, KK | 7 |
| Quon, MJ | 5 |
| Bae, YI | 1 |
| Yun, SJ | 1 |
| Lee, SC | 1 |
| Park, GT | 1 |
| Lee, JB | 1 |
| Yamada, S | 1 |
| Ano, N | 1 |
| Toda, K | 1 |
| Kitaoka, A | 1 |
| Shiono, K | 1 |
| Inoue, G | 1 |
| Atsuda, K | 1 |
| Irie, J | 1 |
| Kato, S | 2 |
| Onishi, K | 2 |
| Yamanaka, T | 1 |
| Takamura, T | 1 |
| Dohi, K | 2 |
| Yamada, N | 1 |
| Wada, H | 1 |
| Nobori, T | 1 |
| Ito, M | 3 |
| Suzuki, K | 3 |
| Nakagawa, O | 1 |
| Aizawa, Y | 3 |
| Chen, S | 1 |
| Ge, Y | 1 |
| Si, J | 1 |
| Rifai, A | 1 |
| Dworkin, LD | 1 |
| Gong, R | 1 |
| Hamada, T | 2 |
| Ichida, K | 1 |
| Hosoyamada, M | 1 |
| Mizuta, E | 2 |
| Yanagihara, K | 1 |
| Sonoyama, K | 1 |
| Sugihara, S | 1 |
| Igawa, O | 2 |
| Hosoya, T | 3 |
| Ohtahara, A | 1 |
| Shigamasa, C | 1 |
| Yamamoto, Y | 3 |
| Ninomiya, H | 2 |
| Hisatome, I | 2 |
| Inaba, S | 1 |
| Iwai, M | 1 |
| Horiuchi, M | 1 |
| Saito, Y | 2 |
| Kurabayashi, M | 1 |
| Ishii, M | 2 |
| Hattori, A | 1 |
| Numaguchi, Y | 1 |
| Tsujimoto, M | 1 |
| Ishiura, S | 1 |
| Kobayashi, H | 3 |
| Murohara, T | 1 |
| Wright, JW | 1 |
| Mizutani, S | 1 |
| Makita, S | 1 |
| Abiko, A | 1 |
| Naganuma, Y | 1 |
| Moriai, Y | 1 |
| Nakamura, M | 2 |
| Sjølie, AK | 3 |
| Klein, R | 2 |
| Porta, M | 2 |
| Orchard, T | 2 |
| Fuller, J | 1 |
| Parving, HH | 2 |
| Bilous, R | 3 |
| Chaturvedi, N | 4 |
| Fujimoto, A | 11 |
| Sato, T | 5 |
| Fukiyama, K | 8 |
| Azuma, J | 1 |
| Ogihara, T | 18 |
| Saruta, T | 16 |
| Nakao, K | 12 |
| Tsutskiridze, LR | 1 |
| Kurashvili, RB | 1 |
| Tsibadze, AD | 1 |
| Kurashvili, GR | 1 |
| Shelestova, EL | 1 |
| Flesch, M | 1 |
| Knipp, S | 1 |
| Kessler, G | 1 |
| Geissler, HJ | 1 |
| Massoudy, P | 2 |
| Wilhelm, H | 1 |
| Philipp, T | 3 |
| Erdmann, E | 1 |
| Fukui, T | 5 |
| Shimamoto, K | 3 |
| Matsuoka, H | 8 |
| Eriksson, JW | 2 |
| Jansson, PA | 2 |
| Carlberg, B | 1 |
| Hägg, A | 1 |
| Kurland, L | 1 |
| Svensson, MK | 1 |
| Ahlström, H | 1 |
| Ström, C | 1 |
| Lönn, L | 1 |
| Ojbrandt, K | 1 |
| Johansson, L | 2 |
| Schönrock, E | 2 |
| Odoj, P | 2 |
| Takebayashi, T | 1 |
| Uno, H | 1 |
| Ishiguro, K | 3 |
| Koibuchi, N | 1 |
| Nishimatsu, H | 1 |
| Higashikuni, Y | 1 |
| Hirata, Y | 3 |
| Kugiyama, K | 1 |
| Nagai, R | 1 |
| Sata, M | 1 |
| Kato, N | 1 |
| Liang, YQ | 1 |
| Ochiai, Y | 1 |
| Birukawa, N | 1 |
| Serizawa, M | 1 |
| Jesmin, S | 1 |
| Ishii, H | 2 |
| Tsukada, T | 1 |
| Yoshida, M | 2 |
| Hayashi, K | 4 |
| Sakamaki, Y | 2 |
| Han, SH | 6 |
| Lee, Y | 4 |
| Kim, SJ | 1 |
| Koh, Y | 1 |
| Shin, EK | 6 |
| Ikeda, H | 2 |
| Hamamoto, Y | 1 |
| Honjo, S | 1 |
| Nabe, K | 1 |
| Wada, Y | 1 |
| Koshiyama, H | 1 |
| Schork, MA | 2 |
| Padia, SH | 2 |
| Kemp, BA | 2 |
| Howell, NL | 2 |
| Gildea, JJ | 1 |
| Keller, SR | 1 |
| Carey, RM | 2 |
| Phipps, JA | 1 |
| Clermont, AC | 1 |
| Sinha, S | 1 |
| Chilcote, TJ | 1 |
| Bursell, SE | 1 |
| Feener, EP | 2 |
| Zhou, MS | 4 |
| Schulman, IH | 2 |
| Raij, L | 4 |
| Kofler, M | 1 |
| Poustka, K | 1 |
| Saltuari, L | 1 |
| Hu, J | 1 |
| Tiwari, S | 1 |
| Riazi, S | 1 |
| Hu, X | 1 |
| Ecelbarger, CM | 1 |
| Bönner, G | 1 |
| Burgess, E | 1 |
| Muirhead, N | 1 |
| Rene de Cotret, P | 1 |
| Chiu, A | 1 |
| Pichette, V | 1 |
| Tobe, S | 1 |
| Rayugi, H | 1 |
| Ciulla, MM | 1 |
| Paliotti, R | 1 |
| Esposito, A | 1 |
| Cuspidi, C | 2 |
| Muiesan, ML | 2 |
| Rosei, EA | 1 |
| Magrini, F | 1 |
| Zanchetti, A | 9 |
| de Zeeuw, D | 2 |
| Lambers-Heerspink, H | 1 |
| Shigenaga, A | 1 |
| Tamura, K | 5 |
| Dejima, T | 2 |
| Ozawa, M | 2 |
| Wakui, H | 2 |
| Masuda, S | 3 |
| Azuma, K | 1 |
| Tsurumi-Ikeya, Y | 1 |
| Mitsuhashi, H | 1 |
| Okano, Y | 4 |
| Kokuho, T | 1 |
| Sugano, T | 1 |
| Ishigami, T | 2 |
| Toya, Y | 2 |
| Uchino, K | 1 |
| Tokita, Y | 1 |
| Umemura, S | 7 |
| Kasanuki, H | 4 |
| Hosoda, S | 1 |
| Sumiyoshi, T | 2 |
| Honda, T | 4 |
| Haze, K | 2 |
| Nagashima, M | 2 |
| Origasa, H | 2 |
| Urashima, M | 1 |
| Staessen, JA | 1 |
| Richart, T | 1 |
| Birkenhäger, WH | 1 |
| Kuji, T | 1 |
| Tochikubo, O | 3 |
| Nixon, RM | 1 |
| Müller, E | 1 |
| Lowy, A | 1 |
| Falvey, H | 1 |
| Omura-Matsuoka, E | 1 |
| Yagita, Y | 1 |
| Sasaki, T | 1 |
| Terasaki, Y | 1 |
| Oyama, N | 1 |
| Sugiyama, Y | 1 |
| Okazaki, S | 1 |
| Sakoda, S | 1 |
| Kitagawa, K | 1 |
| Zetterstrand, S | 1 |
| Olofsson, B | 8 |
| Elmfeldt, D | 10 |
| Onal, IK | 1 |
| Altun, B | 1 |
| Onal, ED | 1 |
| Kirkpantur, A | 1 |
| Gul Oz, S | 1 |
| Turgan, C | 1 |
| Perrone-Filardi, P | 1 |
| Corrado, L | 1 |
| Brevetti, G | 1 |
| Silvestro, A | 1 |
| Dellegrottaglie, S | 1 |
| Cafiero, M | 1 |
| Caiazzo, G | 1 |
| Petretta, A | 1 |
| Maglione, A | 1 |
| Monda, C | 1 |
| Guerra, G | 1 |
| Marzano, A | 1 |
| Cesarano, P | 1 |
| Gargiulo, P | 1 |
| Chiariello, M | 2 |
| Ovchinnikov, AG | 1 |
| Serbul, VM | 1 |
| Ageev, FT | 1 |
| De Rosa, ML | 2 |
| Borthen, C | 1 |
| Oglaend, B | 1 |
| Eggebøe, T | 1 |
| Ellingsen, CL | 1 |
| Schjøtt, J | 1 |
| Barrios, V | 6 |
| Escobar, C | 5 |
| Calderón, A | 5 |
| Echarri, R | 2 |
| Barrios, S | 2 |
| Navarro-Cid, J | 2 |
| Giordano, U | 1 |
| Cifra, B | 1 |
| Giannico, S | 1 |
| Turchetta, A | 1 |
| Calzolari, A | 1 |
| Kudo, H | 3 |
| Kai, H | 4 |
| Kajimoto, H | 1 |
| Koga, M | 2 |
| Takayama, N | 2 |
| Mori, T | 6 |
| Ikeda, A | 1 |
| Yasuoka, S | 1 |
| Anegawa, T | 1 |
| Mifune, H | 1 |
| Imaizumi, T | 4 |
| Chen, X | 2 |
| Yang, D | 1 |
| He, H | 1 |
| Luo, Z | 1 |
| Feng, X | 1 |
| Cao, T | 1 |
| Ma, L | 1 |
| Yan, Z | 1 |
| Liu, D | 1 |
| Tepel, M | 1 |
| Zhu, Z | 1 |
| Chung, S | 1 |
| Park, CW | 1 |
| Shin, SJ | 1 |
| Lim, JH | 1 |
| Chung, HW | 1 |
| Youn, DY | 1 |
| Kim, HW | 1 |
| Kim, BS | 1 |
| Kim, GH | 1 |
| Chang, YS | 1 |
| Almuntaser, I | 1 |
| Mahmud, A | 1 |
| Brown, A | 1 |
| Murphy, R | 1 |
| King, G | 1 |
| Crean, P | 1 |
| Feely, J | 1 |
| Kodama, S | 1 |
| Inoue, Y | 1 |
| Miyoshi, K | 1 |
| Sumi, S | 1 |
| Okamura, K | 1 |
| Tojyo, H | 1 |
| Ando, C | 1 |
| Niimura, H | 1 |
| Tsuchiya, Y | 1 |
| Mihara, H | 1 |
| Yamanouchi, Y | 1 |
| Urata, H | 1 |
| Msanobu, T | 1 |
| Hasvold, P | 3 |
| Olsson, U | 1 |
| Baumann, M | 1 |
| Sollinger, D | 1 |
| Roos, M | 1 |
| Lutz, J | 1 |
| Heemann, U | 2 |
| Tsutamoto, T | 1 |
| Nishiyama, K | 1 |
| Yamaji, M | 1 |
| Kawahara, C | 1 |
| Fujii, M | 1 |
| Yamamoto, T | 3 |
| Horie, M | 2 |
| Fournie-Zaluski, MC | 1 |
| Roques, BP | 1 |
| Neldam, S | 2 |
| Meredith, PA | 2 |
| Murray, LS | 1 |
| McInnes, GT | 1 |
| Akhmedov, VA | 1 |
| Dolgikh, VT | 1 |
| Naumov, DV | 1 |
| Dvornikov, VE | 1 |
| Derosa, G | 6 |
| Maffioli, P | 3 |
| Salvadeo, SA | 3 |
| Ferrari, I | 2 |
| Gravina, A | 2 |
| Mereu, R | 2 |
| Palumbo, I | 2 |
| D'Angelo, A | 2 |
| Cicero, AF | 4 |
| Moltzer, E | 1 |
| Mattace Raso, FU | 1 |
| Karamermer, Y | 1 |
| Boersma, E | 1 |
| Webb, GD | 1 |
| Simoons, ML | 1 |
| Roos-Hesselink, JW | 1 |
| Varagic, J | 2 |
| Munk, PS | 1 |
| von Brandis, P | 1 |
| Larsen, AI | 1 |
| Hirata, M | 2 |
| Kondo, T | 1 |
| Hirai, M | 3 |
| Yamada, K | 2 |
| Kato, M | 1 |
| Shigemasa, C | 1 |
| Azegami, T | 1 |
| Henriksson, M | 1 |
| Kjeldsen, S | 1 |
| Levin, LÅ | 1 |
| Ishikawa, S | 3 |
| Shimada, K | 5 |
| Shiga, T | 1 |
| Kawana, M | 1 |
| Ozaki, N | 2 |
| Nomura, Y | 1 |
| Sobajima, H | 1 |
| Kondo, K | 1 |
| Oiso, Y | 2 |
| Fogari, E | 1 |
| Baron-Menguy, C | 1 |
| Toutain, B | 1 |
| Cousin, M | 1 |
| Dumont, O | 1 |
| Guihot, AL | 1 |
| Vessières, E | 1 |
| Subra, JF | 1 |
| Custaud, MA | 1 |
| Loufrani, L | 1 |
| Henrion, D | 1 |
| Rose, JC | 2 |
| Figueroa, JP | 1 |
| Averill, DB | 1 |
| Araki, R | 1 |
| Kihara, K | 1 |
| Kamimura, H | 1 |
| Isayama, H | 1 |
| Fujii, Y | 1 |
| Iino, Y | 1 |
| Nishida, Y | 3 |
| Takahashi, Y | 2 |
| Nakayama, T | 2 |
| Soma, M | 4 |
| Kitamura, N | 1 |
| Asai, S | 2 |
| Bokuda, K | 1 |
| Ichihara, A | 2 |
| Sakoda, M | 2 |
| Mito, A | 1 |
| Kinouchi, K | 1 |
| Mori, F | 1 |
| Yagi, M | 1 |
| Watanabe, M | 1 |
| Inukai, K | 1 |
| Sumita, T | 1 |
| Ikebukuro, K | 1 |
| Ito, D | 1 |
| Kurihara, S | 1 |
| Ono, H | 3 |
| Awata, T | 1 |
| Katayama, S | 1 |
| Kabutoya, T | 1 |
| Kawamori, R | 1 |
| Murray, G | 1 |
| Boysen, G | 2 |
| Jatuzis, D | 2 |
| Kõrv, J | 2 |
| Richter, PS | 2 |
| Roine, RO | 2 |
| Terént, A | 2 |
| Thijs, V | 2 |
| Kuriyama, S | 2 |
| Otsuka, Y | 1 |
| Ueda, H | 1 |
| Sugano, N | 1 |
| Yoshizawa, T | 1 |
| Yamada, T | 2 |
| Ishimitsu, T | 3 |
| Ohno, E | 1 |
| Furukata, S | 1 |
| Sudo, Y | 1 |
| Nakano, N | 1 |
| Takahashi, T | 2 |
| Schweizer, J | 2 |
| Ulmer, HJ | 1 |
| Benduhn, H | 1 |
| Klebs, S | 2 |
| Yamashita, T | 4 |
| Inoue, H | 2 |
| Okumura, K | 2 |
| Kodama, I | 2 |
| Atarashi, H | 2 |
| Ohe, T | 2 |
| Ohtsu, H | 2 |
| Kato, T | 5 |
| Kamakura, S | 2 |
| Kumagai, K | 2 |
| Kurachi, Y | 2 |
| Koretsune, Y | 2 |
| Saikawa, T | 3 |
| Sakurai, M | 2 |
| Sugi, K | 2 |
| Hirayama, A | 2 |
| Fukatani, M | 2 |
| Mitamura, H | 2 |
| Yamazaki, T | 3 |
| Watanabe, E | 2 |
| Ogawa, S | 5 |
| Fogari, R | 5 |
| Zoppi, A | 3 |
| Mugellini, A | 4 |
| Lazzari, P | 3 |
| Santoro, T | 1 |
| Bian, SH | 1 |
| Yu, MY | 1 |
| Geng, Q | 1 |
| Hainer, JW | 2 |
| Jansson, SO | 1 |
| Malm, A | 1 |
| Fuller, JH | 1 |
| Matsuno, Y | 1 |
| Minatoguchi, S | 3 |
| Fujiwara, H | 2 |
| Grosso, AM | 1 |
| Bodalia, PN | 1 |
| Macallister, RJ | 1 |
| Hingorani, AD | 1 |
| Moon, JC | 1 |
| Scott, MA | 1 |
| Minhas, R | 1 |
| Pitt, B | 1 |
| Jia, XJ | 1 |
| Yu, SQ | 1 |
| Gu, Y | 1 |
| Wang, L | 1 |
| Guo, XM | 1 |
| Cheng, X | 1 |
| Wei, YM | 1 |
| Zhou, ZH | 1 |
| Fu, M | 1 |
| Liao, YH | 1 |
| Hankey, GJ | 1 |
| Murray, GD | 2 |
| Katayama, A | 1 |
| Otsuka, F | 1 |
| Tanabe, K | 1 |
| Tsukamoto, N | 1 |
| Yamanaka, R | 1 |
| Matsumoto, Y | 1 |
| Nasu, Y | 1 |
| Makino, H | 1 |
| Matsumoto, T | 2 |
| Palming, J | 1 |
| Renström, F | 1 |
| Johansson, A | 1 |
| Karlsson, C | 1 |
| Goette, A | 1 |
| Mitsuyama, S | 1 |
| Hedner, T | 2 |
| Narkiewicz, K | 2 |
| Okura, T | 1 |
| Kojima, M | 1 |
| Machida, H | 1 |
| Sugiyama, M | 2 |
| Komada, T | 1 |
| Miyazaki, T | 1 |
| Ninomiya, T | 1 |
| Ichikawa, T | 1 |
| Nakatani, K | 1 |
| Watanabe, Y | 3 |
| Dohi, Y | 2 |
| Kimura, G | 1 |
| Bekki, H | 1 |
| Yamamoto, K | 2 |
| Homma, T | 1 |
| Nakata, M | 1 |
| Nohara, M | 1 |
| Fukami, K | 1 |
| Okuda, S | 1 |
| Yamagishi, S | 1 |
| Yang, R | 1 |
| Smolders, I | 1 |
| Vanderheyden, P | 1 |
| Demaegdt, H | 1 |
| Van Eeckhaut, A | 1 |
| Vauquelin, G | 1 |
| Lukaszuk, A | 1 |
| Tourwé, D | 1 |
| Chai, SY | 1 |
| Albiston, AL | 1 |
| Nahmias, C | 1 |
| Walther, T | 1 |
| Dupont, AG | 1 |
| Rutkowski, P | 1 |
| Sebeková, K | 1 |
| Klassen, A | 1 |
| Bahner, U | 1 |
| Grupp, C | 1 |
| Heidland, A | 1 |
| Stopper, H | 1 |
| Arima, H | 1 |
| Chalmers, J | 1 |
| Belsey, JD | 2 |
| Mori, Y | 2 |
| Tanaka, T | 1 |
| Matsuura, K | 1 |
| Yokoyama, J | 1 |
| Tanaka, S | 2 |
| Fujisawa, Y | 1 |
| Nagai, Y | 1 |
| Lei, B | 1 |
| Nakano, D | 1 |
| Hitomi, H | 1 |
| Mori, H | 1 |
| Masaki, T | 1 |
| Nishiyama, A | 2 |
| Okumi, M | 1 |
| Kawada, N | 1 |
| Ichimaru, N | 1 |
| Kitamura, H | 1 |
| Abe, T | 1 |
| Imamura, R | 1 |
| Kojima, Y | 1 |
| Kokado, Y | 1 |
| Isaka, Y | 1 |
| Nonomura, N | 1 |
| Moriyama, T | 1 |
| Takahara, S | 1 |
| Simonenko, VB | 1 |
| Medvedev, IN | 1 |
| Tolmachev, VV | 1 |
| Khawaja, Z | 1 |
| Sezai, A | 1 |
| Hata, M | 1 |
| Yoshitake, I | 1 |
| Unosawa, S | 1 |
| Wakui, S | 1 |
| Shiono, M | 1 |
| Verlander, JW | 1 |
| Hong, S | 1 |
| Pech, V | 1 |
| Bailey, JL | 1 |
| Agazatian, D | 1 |
| Matthews, SW | 1 |
| Coffman, TM | 2 |
| Le, T | 1 |
| Inagami, T | 1 |
| Whitehill, FM | 1 |
| Weiner, ID | 1 |
| Farley, DB | 1 |
| Kim, YH | 1 |
| Wall, SM | 1 |
| Isa, K | 1 |
| Arnold, AC | 1 |
| Westwood, BM | 1 |
| Slany, J | 1 |
| Nirnberger, G | 1 |
| Pittrow, LA | 1 |
| Suzuki, O | 1 |
| Kobayashi, S | 1 |
| Sugiura, R | 1 |
| Oka, T | 1 |
| Castilla-Guerra, L | 1 |
| Fernández-Moreno, MC | 1 |
| Álvarez-Suero, J | 1 |
| Jiménez Hernández, MD | 1 |
| Mengden, T | 2 |
| Hübner, R | 1 |
| Hasegawa, H | 2 |
| Takano, H | 2 |
| Kameda, Y | 1 |
| Kubota, A | 1 |
| Kobayashi, Y | 1 |
| Komuro, I | 2 |
| Tota, S | 1 |
| Kamat, PK | 1 |
| Najmi, AK | 1 |
| Nath, C | 1 |
| Hart, M | 2 |
| Chen, YL | 2 |
| Mack, W | 2 |
| Milberg, W | 1 |
| Chui, H | 1 |
| Lipsitz, L | 2 |
| Fujiwara, W | 1 |
| Izawa, H | 2 |
| Ukai, G | 1 |
| Yokoi, H | 1 |
| Mukaide, D | 1 |
| Kinoshita, K | 1 |
| Morimoto, S | 4 |
| Ishii, J | 1 |
| Nomura, M | 1 |
| Shinohara, K | 1 |
| Ogawa, K | 1 |
| Bailey, KR | 1 |
| Chai, HS | 1 |
| Maeda, A | 1 |
| Kanaoka, T | 1 |
| Ohsawa, M | 1 |
| Haku, S | 1 |
| Azushima, K | 1 |
| Yanagi, M | 1 |
| Fujikawa, T | 1 |
| Mizushima, S | 1 |
| Ando, H | 2 |
| Ushijima, K | 1 |
| Hosohata, K | 1 |
| Saito, T | 1 |
| Fujimura, A | 1 |
| Kikuchi, F | 1 |
| Ishida, T | 1 |
| Konno, S | 1 |
| Frimodt-Møller, M | 1 |
| Kamper, AL | 1 |
| Strandgaard, S | 2 |
| Kreiner, S | 1 |
| Nielsen, AH | 1 |
| Foulquier, S | 1 |
| Dupuis, F | 1 |
| Perrin-Sarrado, C | 1 |
| Gatè, KM | 1 |
| Leroy, P | 1 |
| Liminana, P | 1 |
| Atkinson, J | 1 |
| Capdeville-Atkinson, C | 1 |
| Lartaud, I | 1 |
| Kwon, BJ | 1 |
| Jang, SW | 1 |
| Choi, KY | 1 |
| Kim, DB | 1 |
| Cho, EJ | 1 |
| Ihm, SH | 1 |
| Youn, HJ | 1 |
| de Lima, DC | 1 |
| do Nascimento, K | 1 |
| Kumagai, N | 1 |
| Hoshino, K | 1 |
| Nakamori, S | 1 |
| Kitai, T | 1 |
| Yazu, T | 1 |
| Oota, M | 1 |
| Ueda, Y | 1 |
| Hiraoka, N | 1 |
| Okamoto, S | 1 |
| Aoyama, T | 1 |
| Kawai, N | 1 |
| Iwasa, M | 1 |
| Oda, M | 1 |
| Kida, K | 1 |
| Kojima, S | 1 |
| Goto, N | 1 |
| Goto, M | 1 |
| Sugishita, F | 1 |
| Takai, K | 1 |
| Tanaka, R | 1 |
| Hiei, K | 2 |
| Minagawa, T | 1 |
| Yamamoto, N | 2 |
| Watanabe, I | 1 |
| Yasue, T | 1 |
| Novak, V | 1 |
| C Chui, H | 1 |
| Guo, Q | 1 |
| Hu, C | 1 |
| Ohsaki, Y | 1 |
| Yoneki, Y | 1 |
| Zhu, W | 1 |
| Jiang, Y | 1 |
| Endo, S | 1 |
| Nakayama, K | 1 |
| Nakayama, M | 1 |
| Miyata, T | 1 |
| Ito, S | 3 |
| Trenkwalder, P | 8 |
| Sakata, K | 2 |
| Kumagai, H | 3 |
| Osaka, M | 1 |
| Onami, T | 2 |
| Matsuura, T | 2 |
| Imai, M | 2 |
| Krum, H | 1 |
| Nolly, H | 1 |
| Workman, D | 1 |
| He, W | 1 |
| Roniker, B | 1 |
| Krause, S | 1 |
| Fakouhi, K | 1 |
| Nagata, K | 1 |
| Somura, F | 1 |
| Obata, K | 1 |
| Odashima, M | 1 |
| Ichihara, S | 1 |
| Nagasaka, T | 1 |
| Iwase, M | 1 |
| Yamada, Y | 2 |
| Nakashima, N | 1 |
| Yokota, M | 1 |
| Armstrong, PW | 1 |
| Lorell, BH | 1 |
| Nissen, S | 1 |
| Borer, J | 1 |
| Yamakawa, H | 2 |
| Bregonzio, C | 1 |
| Terrón, JA | 1 |
| Falcón-Neri, A | 1 |
| Saavedra, JM | 6 |
| Lo, KS | 1 |
| Sever, P | 2 |
| Fridman, KU | 1 |
| Wysocki, M | 1 |
| Friberg, PR | 1 |
| Andersson, OK | 1 |
| Kawai, A | 1 |
| Onimaru, H | 1 |
| Oshima, N | 1 |
| Fujii, K | 2 |
| Abe, I | 4 |
| Yamakado, M | 1 |
| Valagussa, L | 1 |
| Salvetti, M | 1 |
| Di Biagio, C | 1 |
| Agabiti-Rosei, E | 1 |
| Magnani, B | 1 |
| Mansour, G | 1 |
| Mansour, J | 1 |
| Meredith, P | 1 |
| Naito, Y | 3 |
| Tsujino, T | 4 |
| Fujioka, Y | 2 |
| Ohyanagi, M | 2 |
| Iwasaki, T | 2 |
| Tomonari, H | 1 |
| Tokudome, G | 1 |
| Horiguchi, M | 1 |
| Hayashi, H | 2 |
| Ishikawa, M | 1 |
| Turri, C | 1 |
| Magnoni, M | 1 |
| Grassi, G | 2 |
| Piuhola, J | 1 |
| Szokodi, I | 1 |
| Kinnunen, P | 1 |
| Ilves, M | 1 |
| deChâtel, R | 1 |
| Vuolteenaho, O | 1 |
| Ruskoaho, H | 1 |
| Mancini, GB | 1 |
| Ahmetoğlu, A | 1 |
| Erdöl, H | 1 |
| Simşek, A | 1 |
| Gökçe, M | 1 |
| Dinç, H | 1 |
| Gümele, HR | 1 |
| Elmarakby, AA | 1 |
| Morsing, P | 5 |
| Pollock, DM | 4 |
| Sjoelie, AK | 1 |
| Svensson, A | 1 |
| Peña-Penabad, C | 1 |
| Rodríguez-Lozano, J | 1 |
| del Pozo, J | 1 |
| García-Silva, J | 1 |
| Fonseca, E | 1 |
| Komiya, T | 1 |
| Okamura, M | 1 |
| Kawakami, K | 1 |
| Okazaki, M | 1 |
| Tsukamoto, J | 1 |
| Okada, S | 1 |
| Sumi, T | 1 |
| Negoro, N | 1 |
| Yoshikawa, J | 1 |
| Jezova, M | 1 |
| Mayorov, DN | 1 |
| de Wit, C | 1 |
| Roos, F | 1 |
| Bolz, SS | 1 |
| Pohl, U | 1 |
| Lithell, H | 7 |
| Hansson, L | 3 |
| Skoog, I | 6 |
| Hofman, A | 6 |
| Ciccarelli, L | 2 |
| Cediel, E | 2 |
| Sanz-Rosa, D | 2 |
| Oubina, MP | 2 |
| de las Heras, N | 2 |
| González Pacheco, FR | 1 |
| Vegazo, O | 3 |
| Jiménez, J | 2 |
| Cachofeiro, V | 3 |
| Lahera, V | 3 |
| Kawasaki, D | 2 |
| Okumura, T | 1 |
| Masai, M | 1 |
| Sakoda, T | 1 |
| Alföldi, S | 1 |
| Furuhashi, M | 1 |
| Ura, N | 2 |
| Higashiura, K | 2 |
| Murakami, H | 2 |
| Tanaka, M | 1 |
| Moniwa, N | 1 |
| Yoshida, D | 1 |
| Terra, SG | 1 |
| Norman, JT | 1 |
| Stidwill, R | 1 |
| Singer, M | 1 |
| Fine, LG | 1 |
| Sato, N | 1 |
| Kase, H | 1 |
| Kasai, K | 1 |
| Sidorenko, BA | 2 |
| Preobrazhenskiĭ, DV | 2 |
| Stetsenko, TM | 2 |
| Tarykina, EV | 1 |
| Tsurko, VV | 1 |
| Seravalle, G | 1 |
| Dell'Oro, R | 1 |
| Trevano, FQ | 1 |
| Bombelli, M | 1 |
| Scopelliti, F | 1 |
| Facchini, A | 1 |
| Yao, K | 1 |
| Sato, H | 2 |
| Sonoda, R | 1 |
| Ina, Y | 1 |
| Ohno, T | 1 |
| Ahn, JY | 4 |
| Jin, DK | 2 |
| Kim, HS | 2 |
| Shin, MS | 1 |
| Ahn, TH | 2 |
| Choi, IS | 1 |
| Schiffrin, EL | 1 |
| Touyz, RM | 2 |
| Adam, AG | 1 |
| Jaimes, EA | 2 |
| Kim, S | 3 |
| Leys, D | 1 |
| Umemoto, S | 1 |
| Kawahara, S | 1 |
| Hashimoto, R | 1 |
| Matsuzaki, M | 1 |
| Watanabe, H | 1 |
| Nishio, S | 1 |
| Hashimoto, H | 1 |
| Yamazaki, K | 1 |
| Dominiak, P | 1 |
| Häuser, W | 2 |
| Winkler, G | 1 |
| Jermendy, G | 1 |
| Matos, L | 1 |
| Wing, LM | 1 |
| Arnolda, LF | 1 |
| Upton, J | 1 |
| Molloy, D | 1 |
| Harrison-Bernard, LM | 1 |
| Ohashi, M | 1 |
| Takase, H | 1 |
| Sato, K | 1 |
| Ueda, R | 1 |
| Zhang, GX | 1 |
| Kimura, S | 1 |
| Shokoji, T | 1 |
| Rahman, M | 2 |
| Tokuda, K | 3 |
| Kuwahara, F | 3 |
| Yasukawa, H | 2 |
| Tahara, N | 2 |
| Takemiya, K | 2 |
| Morton, A | 1 |
| Muir, J | 1 |
| Lim, D | 1 |
| Little, WC | 1 |
| Wesley-Farrington, DJ | 1 |
| Hoyle, J | 1 |
| Brucks, S | 1 |
| Robertson, S | 1 |
| Kitzman, DW | 1 |
| Cheng, CP | 1 |
| Takeda, K | 3 |
| Higaki, J | 4 |
| Fukushima, M | 1 |
| Sakamoto, J | 1 |
| Morita, S | 1 |
| Fujishima, M | 2 |
| Mizukami, M | 1 |
| Kohro, T | 1 |
| Toko, H | 1 |
| Kudoh, S | 1 |
| Zou, Y | 1 |
| Aburatani, H | 1 |
| Panayiotou, B | 1 |
| Fotherby, M | 1 |
| Kansui, Y | 1 |
| Goto, K | 1 |
| Oniki, H | 1 |
| Shibata, Y | 1 |
| Iida, M | 1 |
| Soplevenko, AV | 1 |
| Ivanova, NA | 1 |
| Füessl, HS | 1 |
| Degl'Innocenti, A | 1 |
| Wiklund, I | 1 |
| Tanabe, A | 1 |
| Naruse, M | 1 |
| Hara, Y | 1 |
| Sato, A | 1 |
| Tsuchiya, K | 1 |
| Nishikawa, T | 1 |
| Imaki, T | 1 |
| Takano, K | 1 |
| Toblli, JE | 2 |
| Stella, I | 2 |
| Mazza, ON | 1 |
| Ferder, L | 2 |
| Inserra, F | 2 |
| Lochard, N | 1 |
| Thibault, G | 1 |
| Silversides, DW | 1 |
| Reudelhuber, TL | 1 |
| Kopkan, L | 2 |
| Kramer, HJ | 2 |
| Husková, Z | 2 |
| Vanourková, Z | 2 |
| Bäcker, A | 1 |
| Bader, M | 2 |
| Ganten, D | 2 |
| Cervenka, L | 2 |
| Diener, HC | 1 |
| Park, GS | 1 |
| Kang, WC | 1 |
| Takimoto, C | 1 |
| Iigaya, K | 1 |
| Arakawa, K | 3 |
| Papademetriou, V | 3 |
| Narayan, P | 1 |
| Kokkinos, P | 1 |
| Lackland, DT | 1 |
| Lindholm, LH | 1 |
| Ostergren, J | 1 |
| Nesbitt, S | 1 |
| Egan, B | 1 |
| Grozinski, M | 1 |
| Michelson, E | 1 |
| Kincaid-Smith, P | 1 |
| Fairley, KF | 1 |
| Packham, D | 1 |
| Kido, H | 2 |
| Sasaki, S | 2 |
| Oguni, A | 2 |
| Harada, S | 2 |
| Nakagawa, M | 3 |
| Owada, K | 1 |
| Stumpe, KO | 1 |
| Morgan, T | 2 |
| Anderson, A | 2 |
| Bertram, D | 1 |
| MacInnis, RJ | 1 |
| Farsang, C | 1 |
| Izzo, JL | 1 |
| Weinberg, MS | 1 |
| Kerkering, J | 1 |
| Tou, CK | 1 |
| Sano, N | 1 |
| Nobe, S | 1 |
| Ichinose, M | 1 |
| Yonemochi, H | 1 |
| Verma, S | 1 |
| Strauss, M | 1 |
| Duke, LM | 1 |
| Evans, RG | 1 |
| Omboni, S | 1 |
| Muda, P | 2 |
| Kampus, P | 2 |
| Zilmer, M | 2 |
| Ristimäe, T | 2 |
| Fischer, K | 2 |
| Zilmer, K | 2 |
| Kairane, C | 1 |
| Teesalu, R | 2 |
| Schram, MT | 2 |
| van Ittersum, FJ | 2 |
| Spoelstra-de Man, A | 1 |
| van Dijk, RA | 2 |
| Schalkwijk, CG | 1 |
| Ijzerman, RG | 2 |
| Twisk, JW | 2 |
| Stehouwer, CD | 2 |
| Andersen, NH | 2 |
| Poulsen, PL | 2 |
| Knudsen, ST | 2 |
| Poulsen, SH | 2 |
| Eiskjaer, H | 3 |
| Hansen, KW | 2 |
| Helleberg, K | 2 |
| Mogensen, CE | 3 |
| Tsunekawa, S | 1 |
| Taguchi, S | 1 |
| Eguchi, Y | 1 |
| Tomiyama, H | 2 |
| Motobe, K | 2 |
| Zaydun, G | 1 |
| Koji, Y | 2 |
| Yambe, M | 2 |
| Arai, T | 1 |
| Kushiro, T | 2 |
| Yamashina, A | 2 |
| Lundkvist, J | 1 |
| Ekman, M | 1 |
| Kartman, B | 1 |
| Carlsson, J | 1 |
| Jönsson, L | 1 |
| Matsui, Y | 1 |
| Morinari, M | 1 |
| Zeller, A | 1 |
| Battegay, E | 1 |
| Nishimura, M | 2 |
| Takahashi, H | 3 |
| Ono, T | 1 |
| Krimholtz, MJ | 1 |
| Karalliedde, J | 1 |
| Thomas, S | 1 |
| Viberti, G | 1 |
| Ohashi, H | 1 |
| Takagi, H | 1 |
| Skaroupková, P | 1 |
| Thurmová, M | 1 |
| Nishimura, T | 1 |
| Hashimoto, J | 1 |
| Totsune, K | 1 |
| Bald, M | 1 |
| Holder, M | 1 |
| Zieger, M | 1 |
| Vochem, M | 1 |
| Leichter, HE | 1 |
| Kanno, Y | 2 |
| Okuda, N | 2 |
| Inamoto, S | 1 |
| Okabe, M | 1 |
| Mieno, S | 1 |
| Horimoto, H | 1 |
| Kitaura, Y | 1 |
| Fujii, H | 1 |
| Nakahama, H | 1 |
| Yoshihara, F | 1 |
| Inenaga, T | 2 |
| Kawano, Y | 2 |
| Lu, Q | 1 |
| Zhu, YZ | 1 |
| Wong, PT | 1 |
| De Cavanagh, EM | 1 |
| Piotrkowski, B | 1 |
| Fraga, CG | 1 |
| Ogata, C | 1 |
| Kamide, K | 1 |
| Suzuki, Y | 1 |
| Sasaki, O | 1 |
| Kubota, Y | 1 |
| Takiuchi, S | 1 |
| Horio, T | 1 |
| Engelman, K | 1 |
| Kirpizidis, H | 1 |
| Stavrati, A | 1 |
| Geleris, P | 1 |
| Fujikawa, K | 1 |
| Hasebe, N | 2 |
| Minami, J | 2 |
| Kim, JA | 2 |
| Rayner, BL | 1 |
| Trinder, YA | 1 |
| Baines, D | 1 |
| Isaacs, S | 1 |
| Opie, LH | 1 |
| Xie, HH | 1 |
| Chen, YY | 1 |
| Miao, CY | 1 |
| Shen, FM | 1 |
| Su, DF | 1 |
| London, G | 1 |
| Schmieder, R | 1 |
| Calvo, C | 1 |
| Asmar, R | 1 |
| Hill, WD | 1 |
| Hess, DC | 1 |
| Kaĭdashev, IP | 1 |
| Rasin, MS | 1 |
| Savchenko, LG | 1 |
| Shlykova, OA | 1 |
| Iakimishina, LI | 1 |
| Nako, K | 2 |
| Takeuchi, K | 2 |
| Zhou, J | 1 |
| Pavel, J | 1 |
| Macova, M | 1 |
| Yu, ZX | 1 |
| Imboden, H | 1 |
| Ge, L | 1 |
| Nishioku, T | 1 |
| Dou, J | 1 |
| Delgiacco, E | 1 |
| Düsing, R | 1 |
| Spoelstra-de Man, AM | 1 |
| Kamp, O | 1 |
| Brouwer, CB | 1 |
| Mitka, M | 1 |
| Iwashima, Y | 1 |
| Okada, M | 1 |
| Haneda, M | 1 |
| Yoshida, T | 1 |
| Cheung, BM | 1 |
| Okazaki, H | 1 |
| Minamino, T | 1 |
| Tsukamoto, O | 1 |
| Kim, J | 1 |
| Okada, K | 1 |
| Myoishi, M | 1 |
| Wakeno, M | 1 |
| Takashima, S | 1 |
| Mochizuki, N | 1 |
| Cooper, CJ | 1 |
| Murphy, TP | 1 |
| Matsumoto, A | 1 |
| Steffes, M | 1 |
| Cohen, DJ | 1 |
| Jaff, M | 1 |
| Kuntz, R | 1 |
| Jamerson, K | 1 |
| Reid, D | 1 |
| Rosenfield, K | 1 |
| Rundback, J | 1 |
| D'Agostino, R | 1 |
| Henrich, W | 1 |
| Dworkin, L | 1 |
| Taniguchi, I | 1 |
| Kawai, M | 1 |
| Date, T | 1 |
| Yoshida, S | 1 |
| Seki, S | 1 |
| Taniguchi, M | 1 |
| Mochizuki, S | 2 |
| Ariff, B | 1 |
| Zambanini, A | 1 |
| Vamadeva, S | 1 |
| Barratt, D | 1 |
| Xu, Y | 1 |
| Stanton, A | 1 |
| Hughes, A | 1 |
| Thom, S | 1 |
| Masuyama, T | 2 |
| Imura, Y | 1 |
| Maitland, K | 1 |
| Bridges, L | 1 |
| Davis, WP | 1 |
| Loscalzo, J | 1 |
| Pointer, MA | 1 |
| Vetter, H | 1 |
| Tousset, E | 1 |
| Uen, S | 1 |
| Tomás, JP | 1 |
| Moya, JL | 1 |
| Campuzano, R | 1 |
| Guzman, G | 1 |
| Megías, A | 1 |
| Ruiz-Leria, S | 1 |
| Catalán, P | 1 |
| Marfil, T | 1 |
| Tarancón, B | 1 |
| Muriel, A | 1 |
| García-Lledó, A | 1 |
| Awad, AS | 1 |
| Kaplan, NM | 2 |
| Vidt, DG | 1 |
| Bakris, G | 1 |
| Kohara, K | 2 |
| Momomura, S | 1 |
| Messerli, FH | 3 |
| Bangalore, S | 1 |
| Reyes, AJ | 1 |
| Leary, WP | 1 |
| Jearnsujitwimol, V | 1 |
| Eiam-Ong, S | 1 |
| Kanjanabuch, T | 1 |
| Wathanavaha, A | 1 |
| Pansin, P | 1 |
| Kaneshiro, Y | 1 |
| Takemitsu, T | 1 |
| Persell, SD | 1 |
| Baker, DW | 1 |
| Meltzer, JI | 1 |
| Kotovskaia, IuV | 1 |
| Kobalava, ZhD | 1 |
| Hirono, Y | 1 |
| Yoshimoto, T | 1 |
| Suzuki, N | 1 |
| Sugiyama, T | 1 |
| Sakurada, M | 1 |
| Takai, S | 1 |
| Kobayashi, N | 3 |
| Shichiri, M | 1 |
| Usher-Smith, JA | 1 |
| Ramsbottom, T | 2 |
| Pearmain, H | 2 |
| Kirby, M | 2 |
| Sugi, Y | 1 |
| Fukui, D | 1 |
| Palma Gámiz, JL | 1 |
| Pêgo, M | 1 |
| Contreras, EM | 1 |
| Anglada, MP | 1 |
| Martínez, JO | 1 |
| Esquerra, EA | 1 |
| Sagastagoitia Gorostiza, JD | 1 |
| Fernandez, R | 2 |
| Asín, E | 1 |
| Schork, A | 1 |
| Fujii, S | 1 |
| Imagawa, S | 1 |
| Ohmura, K | 1 |
| Ohmura, Y | 1 |
| Andoh, Y | 1 |
| Dong, J | 1 |
| Ishimori, N | 1 |
| Furumoto, T | 1 |
| Tsutsui, H | 1 |
| García Donaire, JA | 1 |
| Ruilope, LM | 2 |
| Yamada, J | 1 |
| Shiina, K | 1 |
| Uemura, S | 1 |
| Kaibara, R | 1 |
| Tanaka, H | 2 |
| Node, K | 1 |
| Kosugi, K | 1 |
| Waki, H | 1 |
| Abe, C | 1 |
| Akashiba, A | 1 |
| Kameda, T | 1 |
| Schunkert, H | 1 |
| Hansen, HE | 1 |
| Madsen, JK | 1 |
| Kvist, S | 1 |
| Tsubono, Y | 1 |
| Hirschl, MM | 1 |
| Bur, A | 1 |
| Woisetschlaeger, C | 1 |
| Derhaschnig, U | 1 |
| Laggner, AN | 1 |
| Hass, E | 1 |
| Boaz, M | 1 |
| Zimlichman, R | 1 |
| Yamamoto, E | 2 |
| Kataoka, K | 2 |
| Tokutomi, Y | 2 |
| Dong, YF | 2 |
| Matsuba, S | 2 |
| Kim-Mitsuyama, S | 2 |
| Corradi, L | 1 |
| Preti, P | 1 |
| Rinaldi, A | 1 |
| Takeda, Y | 2 |
| Zhu, A | 1 |
| Yoneda, T | 2 |
| Usukura, M | 2 |
| Takata, H | 2 |
| Yamagishi, M | 2 |
| Hilsmann, U | 1 |
| Neumann, G | 1 |
| Handrock, R | 1 |
| Kottenberg-Assenmacher, E | 1 |
| Jakob, H | 1 |
| Peters, J | 1 |
| Shimosawa, T | 1 |
| Gohchi, K | 1 |
| Yatomi, Y | 1 |
| Fujita, T | 1 |
| Oda, N | 1 |
| Karashima, S | 1 |
| Marshall, TP | 1 |
| Blumenfeld, JD | 1 |
| Lumley, T | 1 |
| Rice, KM | 1 |
| Psaty, BM | 1 |
| Canzanello, VJ | 1 |
| Baranco-Pryor, E | 1 |
| Rahbari-Oskoui, F | 1 |
| Yu, Y | 1 |
| Yao, EH | 1 |
| Suzuki, R | 1 |
| Tahira, Y | 1 |
| Ueno, T | 1 |
| Matsumoto, K | 1 |
| Turner, MJ | 1 |
| van Schalkwyk, JM | 1 |
| Pearse, DD | 1 |
| Puzis, L | 1 |
| Grandi, AM | 1 |
| Solbiati, F | 1 |
| Laurita, E | 1 |
| Maresca, AM | 1 |
| Nicolini, E | 1 |
| Marchesi, C | 1 |
| Gianni, M | 1 |
| Guasti, L | 1 |
| Venco, A | 1 |
| Usher-Smith, J | 1 |
| Wolf, WP | 1 |
| Funken, C | 1 |
| Ferrer, E | 1 |
| Ohishi, M | 1 |
| Takagi, T | 1 |
| Ito, N | 1 |
| Tatara, Y | 1 |
| Hayashi, N | 1 |
| Shiota, A | 1 |
| Iwamoto, Y | 1 |
| Katsuya, T | 1 |
| Watanabe, K | 1 |
| Mizukusa, T | 1 |
| Kawasaki, H | 1 |
| Uno, T | 1 |
| Tsukamoto, T | 1 |
| Nakamoto, M | 1 |
| Mano, R | 1 |
| Kageyama, S | 1 |
| Saxby, BK | 1 |
| Harrington, F | 1 |
| Wesnes, KA | 1 |
| McKeith, IG | 1 |
| Ford, GA | 1 |
| Vraamark, T | 1 |
| Waldemar, G | 1 |
| Paulson, OB | 1 |
| Shi, SJ | 1 |
| Higashimori, K | 2 |
| Mikami, H | 3 |
| Nishikawa, K | 3 |
| Inada, Y | 4 |
| Shibouta, Y | 2 |
| Ojima, M | 2 |
| Kubo, K | 1 |
| Naka, T | 1 |
| Tojo, A | 1 |
| Hayakawa, H | 1 |
| Goto, A | 1 |
| Omata, M | 1 |
| Ideishi, M | 1 |
| Miura, S | 1 |
| Sakai, T | 1 |
| Maeda, H | 1 |
| Kinoshita, A | 1 |
| Sasaguri, M | 2 |
| Jimi, S | 1 |
| Kamitani, A | 1 |
| Sanada, T | 1 |
| Noda, M | 1 |
| Muratani, H | 2 |
| Sesoko, S | 2 |
| Teruya, H | 2 |
| Tozawa, M | 1 |
| Matayoshi, R | 1 |
| Moriguchi, A | 1 |
| Song, K | 1 |
| Kurobe, Y | 1 |
| Kanehara, H | 1 |
| Miyazaki, M | 1 |
| Inishi, Y | 1 |
| Katoh, T | 1 |
| Okuda, T | 1 |
| Yamaguchi, T | 1 |
| Kurokawa, K | 1 |
| Nyui, N | 1 |
| Hibi, K | 1 |
| Kobayashi, I | 1 |
| Sumida, Y | 1 |
| Kihara, M | 1 |
| Yabana, M | 1 |
| Takagi, N | 1 |
| Holzgreve, H | 1 |
| Chen, QH | 1 |
| Hosomi, H | 1 |
| Kosaka, H | 1 |
| Liu, Y | 1 |
| Tsuchihashi, T | 2 |
| Kagiyama, S | 2 |
| Matsumura, K | 2 |
| Ohtsuka, K | 1 |
| Nanbu, A | 1 |
| Nishimura, Y | 4 |
| Xu, T | 1 |
| Jöhren, O | 1 |
| Bunt, T | 2 |
| Fortepiani, LA | 1 |
| Rodrigo, E | 1 |
| Ortíz, MC | 1 |
| Atucha, NM | 1 |
| García-Estañ, J | 1 |
| Li, J | 1 |
| Zhao, H | 1 |
| Dipette, DJ | 1 |
| Supowit, SC | 1 |
| Wang, DH | 2 |
| Bennai, F | 1 |
| Paliege, A | 1 |
| Ketteler, M | 1 |
| Mayer, B | 1 |
| Tapp, R | 1 |
| Bachmann, S | 1 |
| Ruan, X | 1 |
| Purdy, KE | 1 |
| Oliverio, MI | 1 |
| Arendshorst, WJ | 2 |
| Brännström, K | 1 |
| Shibasaki, Y | 1 |
| Tsutumi, Y | 1 |
| Masaki, H | 1 |
| Sakamoto, K | 1 |
| Murasawa, S | 1 |
| Maruyama, K | 1 |
| Moriguchi, Y | 1 |
| Tanaka, Y | 1 |
| Iwasaka, T | 1 |
| Inada, M | 1 |
| Matsubara, H | 1 |
| Yazaki, Y | 1 |
| Miyazaki, Y | 1 |
| Buter, H | 1 |
| Navis, GY | 1 |
| Woittiez, AJ | 1 |
| de Jong, PE | 1 |
| Satoh, C | 1 |
| Hu, WY | 1 |
| Kubo, A | 1 |
| Kishioka, H | 1 |
| Izumi, Y | 2 |
| Kanmatsuse, K | 2 |
| Hiwada, K | 2 |
| Kirk, JK | 1 |
| Kulbertus, H | 1 |
| Barber, MN | 1 |
| Sampey, DB | 1 |
| Sasaki, K | 1 |
| Nakagawa, S | 1 |
| Spence, JD | 2 |
| Ghiadoni, L | 1 |
| Virdis, A | 1 |
| Magagna, A | 1 |
| Taddei, S | 1 |
| Salvetti, A | 1 |
| Cice, G | 1 |
| Ferrara, L | 1 |
| Tagliamonte, E | 1 |
| Russo, PE | 1 |
| Di Benedetto, A | 1 |
| Iacono, A | 1 |
| Zhan, Y | 1 |
| Iwao, H | 1 |
| Kimura, H | 1 |
| Obata, JE | 1 |
| Takeda, S | 1 |
| Hata, A | 1 |
| Shido, K | 1 |
| Yoshida, Y | 1 |
| Conlin, PR | 1 |
| Williams, B | 2 |
| Ribeiro, AB | 1 |
| Saito, I | 1 |
| Benedict, C | 1 |
| Bunt, AM | 1 |
| Grossman, E | 2 |
| Neutel, JM | 2 |
| Wong, W | 1 |
| Howes, L | 1 |
| Eshima, K | 1 |
| Shigematsu, H | 1 |
| Matsuo, I | 1 |
| Koike, G | 1 |
| Sakai, K | 1 |
| Takeshita, A | 1 |
| McMurray, J | 1 |
| Elliott, WJ | 1 |
| Fontes, MA | 1 |
| Baltatu, O | 1 |
| Caligiorne, SM | 1 |
| Campagnole-Santos, MJ | 1 |
| Santos, RA | 1 |
| Mallion, JM | 1 |
| Badguet, JP | 1 |
| Manolis, AJ | 1 |
| Jelakovic, B | 1 |
| Jacovides, A | 1 |
| Bernhardi, DC | 1 |
| Cabrera, WJ | 1 |
| Watanabe, LA | 1 |
| Barragan, J | 1 |
| Matadamas, N | 1 |
| Mendiola, A | 1 |
| Woo, KS | 1 |
| Zhu, JR | 1 |
| Mejia, AD | 1 |
| Dumortier, T | 1 |
| Smith, RD | 1 |
| Tikkanen, I | 1 |
| Oren, S | 1 |
| Viskoper, R | 1 |
| Watts, RW | 1 |
| Cooper, ME | 1 |
| Vallejo, I | 1 |
| García Morillo, S | 1 |
| Pamies, E | 1 |
| González-Jiménez, D | 1 |
| Varela, JM | 1 |
| Calderón, E | 1 |
| Galindo, J | 1 |
| González de la Puente, MA | 1 |
| Suzuma, I | 1 |
| Hata, Y | 1 |
| Clermont, A | 1 |
| Pokras, F | 1 |
| Rook, SL | 1 |
| Suzuma, K | 1 |
| Aiello, LP | 1 |
| Chen, BH | 1 |
| Philips, JC | 1 |
| Weekers, L | 1 |
| Scheen, AJ | 1 |
| Jiménez, AM | 1 |
| Montón, M | 1 |
| García, R | 1 |
| Núñez, A | 1 |
| Gómez, J | 1 |
| Rico, L | 1 |
| García-Colis, E | 1 |
| de Miguel, LS | 1 |
| Arriero, MM | 1 |
| Cabestrero, F | 1 |
| Farré, J | 1 |
| Casado, S | 1 |
| López-Farré, A | 1 |
| Zwanzger, P | 1 |
| Marcuse, A | 1 |
| Boerner, RJ | 1 |
| Walther, A | 1 |
| Rupprecht, R | 1 |
| Lin, Y | 1 |
| Derebail, VK | 1 |
| Pollock, JS | 1 |
| Hinsberger, A | 1 |
| Wingen, AM | 1 |
| Hoyer, PF | 1 |
| Chen, M | 1 |
| Hamada, M | 1 |
| Hiasa, G | 1 |
| Suzuki, M | 1 |
| Ikeda, S | 1 |
| Weber, MA | 1 |
| Vendetti, J | 1 |
| Wang, RY | 1 |
| Magometschnigg, D | 1 |
| Schnack, C | 1 |
| Schernthaner, G | 1 |
| Teramoto, S | 1 |
| Oashi, K | 1 |
| Saikai, T | 1 |
| Hashimoto, M | 1 |
| Abe, S | 1 |
| Huang, Y | 1 |
| Weisser, B | 1 |
| Tallam, LS | 1 |
| Jandhyala, BS | 1 |
| Zhuo, JL | 1 |
| Imig, JD | 1 |
| Hammond, TG | 1 |
| Orengo, S | 1 |
| Benes, E | 1 |
| Navar, LG | 1 |
| Saavedra, J | 1 |
| Spratt, JC | 1 |
| Webb, DJ | 1 |
| Shiels, A | 1 |
| Thurston, H | 1 |
| Miki, S | 1 |
| Hatta, T | 1 |
| Moriguchi, J | 1 |
| Kawa, T | 1 |
| Nakano, S | 1 |
| Mita, S | 1 |
| Kobayashi, T | 1 |
| Tsubokou, Y | 1 |
| Ortlepp, JR | 1 |
| Hanrath, P | 1 |
| Mevissen, V | 1 |
| Kiel, G | 1 |
| Borggrefe, M | 1 |
| Hoffmann, R | 1 |
| Rapi, J | 1 |
| Preston, RA | 1 |
| Baltodano, NM | 1 |
| Alonso, AB | 1 |
| Epstein, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX)[NCT01984164] | Phase 2 | 176 participants (Actual) | Interventional | 2014-08-20 | Completed | ||
| The Precision Hypertension Care Study[NCT02774460] | Phase 4 | 280 participants (Actual) | Interventional | 2017-02-20 | Completed | ||
| A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia.[NCT02770261] | Phase 3 | 219 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Scandinavian Candesartan Acute Stroke Trial[NCT00120003] | Phase 3 | 2,500 participants (Anticipated) | Interventional | 2005-06-30 | Completed | ||
| A Multicenter, Multifactorial, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study of Nifedipine GITS and Candesartan in Combination Compared to Monotherapy in Adult Patients With Essential Hypertension[NCT01303783] | Phase 2 | 1,381 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Effects of Angiotensin Converting Enzyme Inhibitors vs Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension[NCT01152567] | 50,000 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension[NCT03276598] | Phase 4 | 233 participants (Actual) | Interventional | 1999-11-25 | Completed | ||
| Heart Outcomes Prevention Evaluation-3[NCT00468923] | Phase 4 | 12,705 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Multi-center, Open-label, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Hemoglobin A1C Metabolism of Pitavastatin Therapy Versus Atorvastatin in Chinese Patients With Prediabetes and Hypertension[NCT03532620] | Phase 4 | 396 participants (Anticipated) | Interventional | 2018-08-09 | Recruiting | ||
| Polipill and RiscOMeter to Prevent StrOke and CogniTive ImpairmEnt in Primary Health Care[NCT05155137] | Phase 3 | 12,268 participants (Anticipated) | Interventional | 2021-12-20 | Recruiting | ||
| A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients With Mild to Moderate Essential Hypertension (Phase IIIb)[NCT01135212] | Phase 3 | 290 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397] | Phase 4 | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 2 Diabetic Patients With Retinopathy.[NCT00252694] | Phase 3 | 4,717 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients[NCT00125463] | Phase 3 | 3,200 participants | Interventional | 2001-09-30 | Active, not recruiting | ||
| A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to S[NCT00242346] | Phase 3 | 270 participants | Interventional | 2003-04-30 | Completed | ||
| An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of a 4 Week Therapy With Aliskiren 300 mg Plus Hydrochlorothiazide 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With Candesartan 32 mg Plus Hydrochlorothi[NCT00867490] | Phase 3 | 186 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients Without Retinopathy.[NCT00252733] | Phase 3 | 5,238 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| DIRECT: DIabetic Retinopathy Candesartan Trials. Effects of Candesartan Cilexetil (Candesartan) on Diabetic Retinopathy in Type 1 Diabetic Patients With Retinopathy.[NCT00252720] | Phase 3 | 1,850 participants (Actual) | Interventional | 2001-08-31 | Completed | ||
| [NCT00360763] | Phase 4 | 600 participants | Interventional | Recruiting | |||
| A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage[NCT02982655] | 500 participants (Anticipated) | Interventional | 2017-01-31 | Completed | |||
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE): The Role of Angiotensin-(1-7) in Hypertension and Hypertension-Induced Heart and Kidney Damage[NCT04752293] | 125 participants (Anticipated) | Observational | 2021-05-19 | Recruiting | |||
| The Role of the Renin-Angiotensin System in Pediatric Primary Hypertension (PHRAS)[NCT03310684] | 160 participants (Anticipated) | Observational | 2018-12-03 | Active, not recruiting | |||
| The Antihypertensives and Vascular, Endothelial and Cognitive Function Trial (AVEC Trial)[NCT00605072] | Phase 2 | 53 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Effect of Nighttime Losartan on Prognosis of Nocturnal Hypertension Patients Undergoing Continous Ambulatory Peritoneal Dialysis[NCT03692013] | Phase 4 | 68 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Effect of Nighttime Valsartan on Prognosis of Nocturnal Hypertension Patients Undergoing Maintenance Hemodialysis[NCT03594825] | Phase 4 | 68 participants (Anticipated) | Interventional | 2018-11-30 | Not yet recruiting | ||
| Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study[NCT00235287] | Phase 4 | 60 participants (Anticipated) | Interventional | 2005-09-30 | Recruiting | ||
| Pilot Study to Assess Blockade of Calcium Channels and Sodium Chloride Cotransporters for Physiologic Abnormalities in Liver Transplant Associated Hypertension[NCT05275907] | Phase 4 | 0 participants (Actual) | Interventional | 2022-07-12 | Withdrawn (stopped due to Screened participants did not meet inclusion criteria prior to study completion date) | ||
| Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170] | Phase 2 | 16 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Prevention of Hypertension Incidence and Diabetes Italian Assessment Study. Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects With Metabolic Syndrome and High-Normal Blood Pressure.[NCT00456963] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2007-09-30 | Terminated (stopped due to Because of delay in approval of the protocol by a number of Ethics Commitees the trial was terminated on March 4, 2010. No patient had received any study drug.) | ||
| Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833] | 35 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
| Walking Intervention in African American Adults With Newly Diagnosed Hypertension[NCT00298207] | 20 participants | Interventional | 2001-04-30 | Completed | |||
| Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)[NCT00081731] | Phase 3 | 947 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Valsartan 160 mg Plus HCTZ 25 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free Combina[NCT00360178] | Phase 3 | 198 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension[NCT01238705] | Phase 4 | 280 participants (Anticipated) | Interventional | 2008-04-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"EXecutive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research or EXAMINER tool box. This test batteryThe battery includes 11 tasks that generate 15 primary variables. Within this set, the EXAMINER includes: working memory, inhibition, set shifting, and fluency. The parts of EXAMINER that were used for this study include: Flanker task (inhibition) which involves responding to a central stimulus while ignoring flanking stimuli that are either compatible or incompatible with the central stimulus; Set-shifting, a measure of mental flexibility; Spatial 1-Back test assesses spatial working memory; Dot Counting test assesses verbal working memory; Verbal Fluency tested using a List Generation test which require the participant to generate words beginning with a specific letter, and category fluency in which the participant generates words from a specified category (e.g., animals, fruits). Higher are reflective of better executive function (-1 to +1)" (NCT01984164)
Timeframe: 12 months
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Candesartan | 0.07 |
| Lisinopril | 0.25 |
The Digit Span test is a subtest of both the Wechsler Adult Intelligence Scale (WAIS) and the Wechsler Memory Scales (WMS). For the digit span backwards, subjects are read a sequence of numbers and asked to repeat the same sequence back to the examiner in reverse order (backward span). Backward span is an executive task particularly dependent on working memory. The Digit Span backward is scored for backwards performance. Scale: 0 (minimum) to 16 (maximum). A higher score represents a better outcome. (NCT01984164)
Timeframe: 12 months
| Intervention | Number of correct responses (Least Squares Mean) |
|---|---|
| Candesartan | 5.14 |
| Lisinopril | 5.16 |
This will be measured using Digit Span Forward. The Digit Span test is a subtest of both the Wechsler Adult Intelligence Scale (WAIS) and the Wechsler Memory Scales (WMS). For the digit span forward, subjects are read a sequence of numbers and asked to repeat the same sequence back to the examiner in the correct order (forward span). Forward span captures attention efficiency and capacity. The Digit Span forward is scored for forwards performance. Scale: 0 (minimum) to 16 (maximum). A higher score represents a better outcome. (NCT01984164)
Timeframe: 12 months
| Intervention | Number of correct responses (Least Squares Mean) |
|---|---|
| Candesartan | 9.67 |
| Lisinopril | 8.93 |
ASL-MRI: Arterial Spin Labeling (ASL) MRI is non-invasive measure of perfusion that does not require contrast, and allows multiple brain regions mapping of perfusion and reserve. ASL-MRI provides measures of cerebral blood flow (CBF). Higher values indicates higher CBF. (NCT01984164)
Timeframe: 12 months
| Intervention | ml/100g/min (Least Squares Mean) |
|---|---|
| Candesartan | 45.48 |
| Lisinopril | 47.65 |
Executive function will be assessed using Trail Making Test (part B-A). Part A was collected to correct for motor speed and visual-perceptual demands on TMT by subtracting completion time for TMT Part A from completion time for Part B (TMT B - A). TMT Part B-A provides a relatively purer measure of executive functioning. It has a timed scale from 0 sec (min) to 300 secs (max). Along this scale, a lower score is better. (NCT01984164)
Timeframe: 12 months
| Intervention | seconds (Least Squares Mean) |
|---|---|
| Candesartan | 87.23 |
| Lisinopril | 111.37 |
This will be measured using the Boston Naming Test. BNT is a neuropsychological test used to assess visual confrontation naming and language performance in participants with cognitive decline. Its short 15-item version consists of drawings of objects ranging from common objects to less familiar objects. Scale: 0 (min score) to 15 (max score). For this test, a higher score/response represents a better outcome. (NCT01984164)
Timeframe: 12 months
| Intervention | number of correct responses (Least Squares Mean) |
|---|---|
| Candesartan | 13.42 |
| Lisinopril | 13.84 |
To assess episodic memory, the Hopkins Verbal Learning Test-Revised (HVLT-R) will be used. The retention (%) score is calculated by dividing the delayed recall trial by the higher of 3 learning trials. Each trial scores 0 (min) to 12 (max). The HVLT-R retention score is a percentage, and a higher percentage represents a better outcome. (NCT01984164)
Timeframe: 12 months
| Intervention | percentage of retention (Least Squares Mean) |
|---|---|
| Candesartan | 82.71 |
| Lisinopril | 79.47 |
White Matter Lesion volume: high-resolution anatomical images are acquired for the measurement of microvascular disease. WMH volumes will be obtained from Fluid attenuated inversion recovery (FLAIR) imaging sequence and reported as total volume (in mm3). Higher values means greater WMH (NCT01984164)
Timeframe: 12 months
| Intervention | mm^3 (Least Squares Mean) |
|---|---|
| Candesartan | 2.68 |
| Lisinopril | 5.73 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 161 |
| Placebo | 182 |
3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 180 |
| Placebo | 136 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252694)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 192 |
| Placebo | 193 |
An estimate of the slope from fitting a linear regression of log(UAER) over time (post-randomisation, yearly assessments) for each patient. (NCT00252694)
Timeframe: From Baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/1000 year (Least Squares Mean) |
|---|---|
| Candesartan | 656 |
| Placebo | 718 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | mmHg (Mean) |
|---|---|
| Phase 2 - Aliskiren+HCTZ | -3.12 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | mmHg (Mean) |
|---|---|
| Phase III - Aliskiren+HCTZ+Amlodipine | -5.87 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | mmHg (Mean) |
|---|---|
| Phase 2 - Aliskiren+HCTZ | -2.81 |
The arm in which the highest sitting diastolic pressures were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, systolic/diastolic blood pressure were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | mmHg (Mean) |
|---|---|
| Phase III - Aliskiren+HCTZ+Amlodipine | -9.20 |
Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | mmHg (Mean) |
|---|---|
| Phase 2 - Aliskiren+HCTZ | 0.31 |
Pulse pressure is systolic pressure (SP) minus diastolic pressure (DP). The arm in which the highest sitting DPs were found at study entry was the arm used for all subsequent readings. A calibrated sphygmomanometer and appropriate size cuff were used to measure arterial sitting blood pressure (BP) at trough with the arm supported at the level of the heart. At each study visit, after having the patient in a sitting position for at least 5 minutes, SP and DP were measured 3 times at 1-2 minute intervals. A mean was calculated from the 3 measurements. A negative change indicates improvement. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | mmHg (Mean) |
|---|---|
| Phase III - Aliskiren+HCTZ+Amlodipine | -3.33 |
Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | BPM (beats per minute) (Mean) |
|---|---|
| Phase 2 - Aliskiren+HCTZ | 0.27 |
Pulse rate was measured once for 30 seconds just prior to blood pressure measurements in the sitting position. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | BPM (beats per minute) (Mean) |
|---|---|
| Phase III - Aliskiren+HCTZ+Amlodipine | 0.03 |
Blood pressure response was defined as msSBP < 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 compared to Baseline in Phase 2 or a msDBP < 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | Percentage of patients (Number) | |
|---|---|---|
| msSBP response | msDBP response | |
| Phase 2 - Aliskiren+HCTZ | 37.4 | 34.1 |
Blood pressure response was defined as msSBP < 140 mmHg or a 20 mmHg decrease in msSBP at the end of Phase 2 compared to Baseline in Phase 2 or a msDBP < 90 mmHg or a 10 mmHg decrease in msDBP at the end of Phase 2 compared to Baseline in Phase 2. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | Percentage of patients (Number) | |
|---|---|---|
| msSBP response | msDBP response | |
| Phase III - Aliskiren+HCTZ+Amlodipine | 54.1 | 47.5 |
Normalized blood pressure was defined as a msSBP < 140 mmHg and/or a msDBP < 90 mmHg. (NCT00867490)
Timeframe: Baseline Phase 2 to end of Phase 2
| Intervention | Percentage of patients (Number) | |
|---|---|---|
| msSBP < 140 mmHg | msDBP < 90 mmHg | |
| Phase 2 - Aliskiren+HCTZ | 37.4 | 33.3 |
Normalized was defined as a msSBP < 140 mm Hg and/or a msDBP < 90 mm Hg. (NCT00867490)
Timeframe: Baseline Phase 3 to end of Phase 3
| Intervention | Percentage of patients (Number) | |
|---|---|---|
| msSBP < 140 mmHg | msDBP < 90 mmHg | |
| Phase III - Aliskiren+HCTZ+Amlodipine | 54.1 | 44.3 |
Two steps were defined as either a 1-step change in each eye or as a 2-step change in one eye only. ETDRS is a scale with 11 steps (1-11, where a score of 1 represents no retinopathy and a score of 11 represents proliferative retinopathy). A generalized log-rank test was used to test difference between treatments. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 178 |
| Placebo | 217 |
An estimate of the slope from fitting a linear regression of log(UAER) over time for each patient. (NCT00252733)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.510 |
| Placebo | 0.543 |
Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years, with visits after a half year, one year and thereafter one visit per year.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 127 |
| Placebo | 124 |
Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). (NCT00252720)
Timeframe: From baseline to the end of the study, i.e., 5 years
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 140 |
| Placebo | 139 |
Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs. (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | Participants (Number) |
|---|---|
| Candesartan | 110 |
| Placebo | 107 |
An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient (NCT00252720)
Timeframe: From baseline to end of study, i.e. 5 years.
| Intervention | log (µg/min)/year (Least Squares Mean) |
|---|---|
| Candesartan | 0.569 |
| Placebo | 0.642 |
This reports the change in the least square mean from baseline to 12 months, adjusted for age (NCT00605072)
Timeframe: Baseline-12 months
| Intervention | cm/sec (Least Squares Mean) |
|---|---|
| ACEI (Lisinopril) | -0.3 |
| ARB (Candesartan) | -2.85 |
| HCTZ | 0.35 |
Blood pressure was measured as follows: the participant was in the sitting position, rested for 5 minutes, no caffeine or smoking 2 hours prior to measurement, using appropriate cuff size (covering 60% of upper arm length and 80% of arm circumference), correct cuff placement (1-2 inches above brachial pulse on bare arm), and the bell of the stethoscope. The systolic blood pressure was defined as the pressure corresponding to the first korotkoff sounds (K1) and the diastolic as the pressure corresponding to the last korotkoff sound (K5). Blood pressure was measured in both arms and recorded (NCT00605072)
Timeframe: Baseline-12 months
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| ACEI (Lisinopril) | 28 |
| ARB (Candesartan) | 27 |
| HCTZ | 21 |
This test consists of series of digits of increasing length, some of which are recited as presented, and some of which are to be recited in reversed order. The forward digit span score ranges from 0 (ie cannot repeat two digits) to 8 ( participant can repeat up to 8 digits) (NCT00605072)
Timeframe: Baseline-12 months
| Intervention | number of digits repeated (Least Squares Mean) |
|---|---|
| ACEI (Lisinopril) | -0.3 |
| ARB (Candesartan) | 0.02 |
| HCTZ | -0.04 |
This is a 12-item list learning test in which individuals are presented three learning and recall trials followed by a delayed recall and 24 item recognition test. The HVLT-R has been identified as an ideal memory measure for elderly patients, and appropriate reliability and validity have been shown in older individuals. The test score is the number of correct answers in the delayed recall ( score range 0-12) (NCT00605072)
Timeframe: Baseline-12 months
| Intervention | number words remembered (Least Squares Mean) |
|---|---|
| ACEI (Lisinopril) | -1 |
| ARB (Candesartan) | -2 |
| HCTZ | -3 |
This test requires the connection of sequentially numbered circles (A), and the connection of circles marked by numbers and letters in alternating sequence (B). This test is considered a benchmark of executive function. The test score is the time required to complete the task in seconds. (NCT00605072)
Timeframe: Baseline-12 months
| Intervention | seconds (Least Squares Mean) |
|---|---|
| ACEI (Lisinopril) | -14 |
| ARB (Candesartan) | 17 |
| HCTZ | 4 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 77 |
| Stenting | 68 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 20 |
| Stenting | 20 |
Only the first event per participant is included in the composite (NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 169 |
| Stenting | 161 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 26 |
| Stenting | 27 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 27 |
| Stenting | 30 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 3 |
| Stenting | 4 |
(NCT00081731)
Timeframe: Measured at every 3 months for the first year and annually thereafter
| Intervention | participants (Number) |
|---|---|
| Optimal Medical Therapy | 16 |
| Stenting | 12 |
79 reviews available for candesartan and Hypertension
| Article | Year |
|---|---|
Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Topics: Acrylates; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzi | 2003 |
[Candesartan is the Basis of Therapy for Arterial Hypertension in Middle-Aged Women].
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Female; Humans; | 2017 |
Noncholestatic acute hepatocellular injury following candesartan administration.
Topics: Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2018 |
Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Benzoates; Biphenyl Compou | 2013 |
[What are the effects of fixed-dose combination of candesartan and amlodipine].
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Combinations; Humans; | 2016 |
Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertens | 2017 |
[Prevention of Cardiovascular Complications in Patients With Arterial Hypertension While Use of Angiotensin II Receptor Antagonists. Possibilities of Candesartan].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2016 |
[Role of RAS in prehypertension].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cardiovascular | 2008 |
[Oxidative stress and mild hypertension].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2008 |
[Prevension of hypertension by angiotensin receptor blockers in human--TROPHY study].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cardiovascular | 2008 |
Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; Bipheny | 2009 |
Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2010 |
Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Losartan; Randomi | 2010 |
Cardiovascular outcome of an angiotensin II receptor blocker, candesartan, in Japan.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2010 |
Cardio classics revisited--focus on the role of candesartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardi | 2010 |
Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2011 |
Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Case-Contro | 2011 |
A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Humans; Hypertension; L | 2011 |
An overview of candesartan in clinical practice.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2011 |
Combination therapy with AT(1)-receptor blockers.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diure | 2002 |
The retinal renin-angiotensin system: implications for therapy in diabetic retinopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compound | 2002 |
The SCOPE trial. Study on Cognition and Prognosis in the Elderly.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition Disorders; Humans; Hype | 2002 |
[Angiotensin II receptor antagonist improves age-related impairment of EDHF-mediated hyperpolarization].
Topics: Aging; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biological Factors; Biphenyl Compo | 2002 |
[Protective vascular effect of angiotensin receptor blocker (ARB)].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 2002 |
The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2002 |
[Angiotensin II receptor antagonists in arterial hypertension: new clinical evidence with candesartan].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biomedical Research; Biph | 1999 |
Emerging role of angiotensin II type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation.
Topics: Acrylates; Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Coronary A | 2002 |
[Diurnal blood pressure control in the optimal treatment of hypertension].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphen | 2003 |
[Effect of angiotensin II type 1 receptor antagonist on oxidative stress markers in type 2 diabetic patients with hypertension].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabe | 2003 |
[Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2003 |
Multiple actions of angiotensin II in hypertension: benefits of AT1 receptor blockade.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2003 |
Stroke prevention: is it possible? If so, which antihypertensive agent should be used?
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2003 |
Neurological protection provided by candesartan: reviewing the latest study results.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2003 |
[Angiotensin receptor blockers in chronic heart failure].
Topics: Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Heart Fai | 2003 |
[Cardiologic and diabetologic aspects of therapy with angiotensin receptor blocking agents].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Antihypertensive Agents; | 2003 |
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cerebral Hemorrhage; Cerebral Infarctio | 2003 |
[Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Bipheny | 2004 |
[Organ protection by angiotensin II receptor blockers].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2004 |
[Scope].
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2004 |
[Development of combined drugs (ARB and diuretics)].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2004 |
Candesartan for the treatment of hypertension and heart failure.
Topics: Administration, Oral; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus; Double-Blind Method; Dr | 2004 |
Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2004 |
[Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Angiotensin II; Angiotensin II Ty | 2005 |
[The Diabetic Retinopathy Candesartan Trials (DIRECT) programme].
Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agen | 2005 |
The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrophy; Benzimidazoles; Bip | 2006 |
Therapeutic potential of angiotensin receptor blockers in hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2006 |
Findings and implications of the Study on COgnition and Prognosis in the Elderly (SCOPE) - a review.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
[Circadian variations in gene expression of renin-angiotensin system].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2006 |
[Trend of research and development of antihypertensive agents].
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Angiotens | 2006 |
[Study on cognition and prognosis in the elderly].
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2006 |
[CHARM].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2006 |
[E-COST].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2006 |
Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Clinica | 2007 |
Treatment options for prehypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2007 |
Should the results of TROPHY affect the JNC 7 definition of prehypertension?
Topics: Advisory Committees; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Hu | 2007 |
Candesartan: from left ventricular hypertrophy to heart failure, a global approach.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2007 |
[NICE-Combi study: effect of nifedipine in combination with an angiotensin II receptor blocker on BP control and renal protection].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Doubl | 2006 |
[Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2008 |
[Significance of treating prehypertension with an angiotensin-receptor blocker--results from TROPHY study].
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl | 2008 |
[Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2008 |
Clinical efficacy of a new AT1 blocker.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Human | 1998 |
Candesartan: a new-generation angiotensin II AT1 receptor blocker: pharmacology, antihypertensive efficacy, renal function, and renoprotection.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1999 |
Role of tissue angiotensin II in myocardial remodelling induced by mechanical stress.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1999 |
[Comparison with other antihypertensive drugs, especially with ACEI].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; | 1999 |
Angiotensin and cerebral blood flow.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimid | 1999 |
Angiotensin-II receptor antagonists: their place in therapy.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 1999 |
[Pharma-clinics. The drug of the month. Candesartan (Atacand)].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Dose- | 1999 |
Angiotensin II receptor antagonists in the treatment of hypertension.
Topics: Algorithms; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazole | 1999 |
Angiotensin II antagonists for hypertension: are there differences in efficacy?
Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Humans; | 2000 |
Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
Topics: Acrylates; Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2000 |
Angiotensin receptor antagonists.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2000 |
Prehypertension: a possible target for antihypertensive medication.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2000 |
Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2000 |
[Candesartan, angiotensin II receptor antagonist].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Human | 2000 |
Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2000 |
[Angiotensin receptor blockers--significance for the therapy of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertens | 2001 |
[Angiotensin II type-1 receptor antagonists and diabetes mellitus].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2001 |
Dual angiotensin II blockade: a promise of enhanced renal protection?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihype | 2002 |
[Irbesartan: a new possibility in the treatment of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Benzimidazoles; Benz | 2002 |
205 trials available for candesartan and Hypertension
| Article | Year |
|---|---|
Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs: A Randomized Clinical Trial.
Topics: Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihyperten | 2023 |
Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment: A Randomized Clinical Trial.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Press | 2020 |
Comparison of ambulatory blood pressure-lowering effects of higher doses of different calcium antagonists in uncontrolled hypertension: the Calcium Antagonist Controlled-Release High-Dose Therapy in Uncontrolled Refractory Hypertensive Patients (CARILLON)
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Bl | 2017 |
ACE Phenotyping as a Guide Toward Personalized Therapy With ACE Inhibitors.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2017 |
Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2018 |
The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Bl | 2019 |
Beneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Case-Control Studies; Dihy | 2018 |
Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asia; Asian People; Benzimid | 2019 |
Efficacy and Safety of a Fixed-Dose Combination of Candesartan and Rosuvastatin on Blood Pressure and Cholesterol in Patients With Hypertension and Hypercholesterolemia: A Multicenter, Randomized, Double-Blind, Parallel Phase III Clinical Study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Double-Blind Meth | 2019 |
Relationships between metrics of visit-to-visit variability of blood pressure.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2013 |
Effects of candesartan in acute stroke on cognitive function and quality of life: results from the Scandinavian Candesartan Acute Stroke Trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition Diso | 2013 |
Diuretics enhance effects of increased dose of candesartan on ambulatory blood pressure reduction in Japanese patients with uncontrolled hypertension treated with medium-dose angiotensin II receptor blockers.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Benzimidazoles | 2014 |
Effects of antihypertensive drugs on central blood pressure in humans: a preliminary observation.
Topics: Aged; Amlodipine; Antihypertensive Agents; Aorta; Arterial Pressure; Benzimidazoles; Biphenyl Compou | 2013 |
Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Calcium Chan | 2013 |
Effect of azilsartan versus candesartan on nocturnal blood pressure variation in Japanese patients with essential hypertension.
Topics: Aged; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cir | 2013 |
Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1).
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Bipheny | 2013 |
Feasibility of regression of hypertension using contemporary antihypertensive agents.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressure D | 2013 |
In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; | 2014 |
Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2).
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2014 |
Effectiveness of using long-acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hypertension monitoring by using telemedicine system (FUJIYAMA study).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Benzimidazoles | 2014 |
Difference in the effects of switching from candesartan to olmesartan or telmisartan to olmesartan in hypertensive patients with type 2 diabetes: the COTO study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2014 |
Effect of azilsartan versus candesartan on morning blood pressure surges in Japanese patients with essential hypertension.
Topics: Aged; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dou | 2014 |
Renin-angiotensin system phenotyping as a guidance toward personalized medicine for ACE inhibitors: can the response to ACE inhibition be predicted on the basis of plasma renin or ACE?
Topics: Aged; Aldosterone; Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2014 |
Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Press | 2014 |
Blood pressure-lowering treatment with candesartan in patients with acute hemorrhagic stroke.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Female; Huma | 2014 |
Role of RAAS and adipokines in cardiovascular protection: effect of different doses of angiotensin II receptor blocker on adipokines level in hypertensive patients.
Topics: Adipokines; Adiponectin; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; | 2014 |
Effects of blood pressure lowering in patients with acute ischemic stroke and carotid artery stenosis.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2015 |
Correlation of Central Blood Pressure to Hypertensive Target Organ Damages During Antihypertensive Treatment: The J-TOP Study.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2015 |
Pharmacogenomics of hypertension: a genome‐wide, placebo‐controlled cross‐over study, using four classes of antihypertensive drugs.
Topics: Adult; Aldehyde Oxidoreductases; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2015 |
Effects of blood pressure-lowering treatment in different subtypes of acute ischemic stroke.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Brain Ischemia; D | 2015 |
Effect of angiotensin II receptor blockers, candesartan, on osteoprotegerin level in hypertensive patients: Link between bone and RAAS.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Bone and Bones; Female; | 2015 |
Randomized trial comparing the velocities of the antihypertensive effects on home blood pressure of candesartan and candesartan with hydrochlorothiazide.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Be | 2015 |
Impact of left ventricular ejection function on blood pressure-lowering therapy in hypertensive patients with coronary artery disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Coronary Artery D | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases; Choleste | 2016 |
Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiovascular Di | 2016 |
Renal resistance and long-term blood pressure in individuals genetically predisposed for essential hypertension: 10-year follow-up of the Danish Hypertension Prevention Project.
Topics: Adult; Angiotensin Receptor Antagonists; Antihypertensive Agents; Arterioles; Benzimidazoles; Biphen | 2016 |
A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2016 |
Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Channel Blocker | 2017 |
An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Double-Bli | 2008 |
Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro.
Topics: 3T3-L1 Cells; Adipocytes; Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Co | 2008 |
Exaggerated hypertensive response to exercise in patients with diastolic heart failure.
Topics: Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; B | 2008 |
Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Glucose Intolerance; Gl | 2008 |
Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles | 2008 |
Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes M | 2008 |
[Positive effects of angiotensin [corrected] receptor blockers on the course of microvascular complications of diabetes mellitus].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl | 2008 |
ARTA: AT1-receptor blocker therapy in patients undergoing coronary artery bypass grafting.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2009 |
ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2008 |
Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Compo | 2008 |
The short treatment with the angiotensin receptor blocker candesartan surveyed by telemedicine (STAR CAST) study: rationale and study design.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; R | 2008 |
Angiotensin II type-I receptor blocker, candesartan, improves brachial-ankle pulse wave velocity independent of its blood pressure lowering effects in type 2 diabetes patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Ankle Brachial Index; Benzimidazoles; Biphenyl Compou | 2008 |
Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.
Topics: Adipokines; Adiponectin; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Benzimidazoles; | 2010 |
Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Asian People; Benzimidazoles; Benzoates; | 2009 |
Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Be | 2008 |
Supramaximal dose of candesartan in proteinuric renal disease.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetic N | 2009 |
Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-co
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2009 |
Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphen | 2009 |
Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Angiotensin II Type 1 Receptor Blockers; Benzimidaz | 2009 |
Effects of angiotensin II receptor blockers on relationships between 24-hour blood pressure, autonomic function, and health-related QOL.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Autonomic Nervous System; Benzimidazoles; Benzoates; | 2009 |
Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood | 2009 |
A dose-response analysis of candesartan-hydrochlorothiazide combination therapy in patients with hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Clinical Laboratory Tec | 2009 |
Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Collagen; Elastin; Extracellular | 2009 |
Effects of AT1 receptor antagonism with candesartan on endothelial function in patients with hypertension and coronary artery disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl | 2009 |
[Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2009 |
Candesartan improves maximal exercise capacity in hypertensives: results of a randomized placebo-controlled crossover trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aspirin; Benzimidazol | 2009 |
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Complications; | 2009 |
Additive antihypertensive and antihypertrophic effects of long-acting Ca blockers in uncontrolled hypertensive patients with angiotensin-receptor blocker based treatment.
Topics: Aged; Amlodipine; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Drug Therapy, Combin | 2009 |
[Evaluation of antihypertensive effect of angiotensin II receptor blockers in patients with essential hypertension by self-measured home blood pressure--HACARARE 300 study].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2009 |
Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2010 |
Effects of angiotensin II receptor blockers on the relationships between ambulatory blood pressure and anti-hypertensive effects, autonomic function, and health-related quality of life.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood | 2009 |
Candesartan effect on inflammation in hypertension.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Glucose; Blood | 2010 |
Comparison of Candesartan versus Metoprolol for treatment of systemic hypertension after repaired aortic coarctation.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aortic Coarctation; Ben | 2010 |
Effects of a low-dose antihypertensive diuretic in combination with losartan, telmisartan, or candesartan on serum urate levels in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2010 |
Effect of dosing time of angiotensin II receptor blockade titrated by self-measured blood pressure recordings on cardiorenal protection in hypertensives: the Japan Morning Surge-Target Organ Protection (J-TOP) study.
Topics: Aged; Albuminuria; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphen | 2010 |
Angiotensin receptor blocker-based therapy and cardiovascular events in hypertensive patients with coronary artery disease and impaired renal function.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2010 |
Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Comp | 2010 |
Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Biphenyl Compou | 2010 |
Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angina, Unstable; Angiotensin II Type 1 Receptor Blocker | 2010 |
Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
Topics: Adiponectin; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2010 |
Angiotensin receptor blockade in acute stroke. The Scandinavian Candesartan Acute Stroke Trial: rationale, methods and design of a multicentre, randomised- and placebo-controlled clinical trial (NCT00120003).
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Double-Blind Method; Hu | 2010 |
Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (± amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg.
Topics: Adult; Aged; Algorithms; Amides; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compo | 2011 |
Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biph | 2011 |
Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension.
Topics: Adolescent; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Angiotensin Receptor Antagonists; Benzimidazoles; Bi | 2011 |
Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood | 2011 |
Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Autoantibodies; Benzi | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
Hydrochlorothiazide compared to candesartan treatment increases adipose tissue gene expression and circulating levels of serum amyloid A in hypertensive patients.
Topics: Adipose Tissue; Amyloid; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Female; Gene E | 2011 |
Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2011 |
Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidaz | 2012 |
Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
Topics: Adiponectin; Age Factors; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blocke | 2011 |
[Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial].
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Tetra | 2011 |
Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB trial of hypertension in obese patients with hyperinsulinemia assessed by oral glucose tolerance test (ATHLETE).
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Benzoates; B | 2011 |
Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood | 2011 |
Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Topics: Adolescent; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conver | 2011 |
Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2011 |
Effects of olmesartan on the renin-angiotensin-aldosterone system for patients with essential hypertension after cardiac surgery--investigation using a candesartan change-over study.
Topics: Aged; Aldosterone; Analysis of Variance; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; An | 2011 |
Cardiovascular risk stratification and antihypertensive therapy according to guidelines in the outpatient setting.
Topics: Age Factors; Aged; Ambulatory Care; Antihypertensive Agents; Austria; Benzimidazoles; Biphenyl Compo | 2011 |
Candesartan-based therapy and risk of cancer in patients with systemic hypertension (Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] substudy).
Topics: Age Factors; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Coronary Artery Dise | 2012 |
Office and ambulatory blood pressure control with a fixed-dose combination of candesartan and hydrochlorothiazide in previously uncontrolled hypertensive patients: results of CHILI CU Soon.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure Determination; Blood Pre | 2011 |
Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Asian People; Benzimidazoles | 2012 |
Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial.
Topics: Age Factors; Aged; Benzimidazoles; Biphenyl Compounds; Blood Pressure Determination; Cognition; Cogn | 2012 |
Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2013 |
Is home blood pressure variability itself an interventional target beyond lowering mean home blood pressure during anti-hypertensive treatment?
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2012 |
[Clinical implications from the results of the CASE-J extension].
Topics: Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Calcium Channel Bl | 2012 |
Genomic association analysis identifies multiple loci influencing antihypertensive response to an angiotensin II receptor blocker.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Black or African | 2012 |
Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ben | 2012 |
Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2012 |
Relationship between the receptor occupancy profile and pleiotropic effects of angiotensin II receptor blockers.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Area Under Curve; Benzimida | 2013 |
The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Topics: Aged; Albuminuria; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Aze | 2012 |
[The Heart Institute of Japan--candesartan randomized trial for evaluation in CAD (HUJ-CREATE)].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Coronary Artery D | 2011 |
Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Benzoates; Biphenyl Compounds; Bl | 2012 |
Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Benzoates; Biphenyl Compounds; Bl | 2012 |
Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Benzoates; Biphenyl Compounds; Bl | 2012 |
Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Benzoates; Biphenyl Compounds; Bl | 2012 |
Beneficial effects on arterial stiffness and pulse-wave reflection of combined enalapril and candesartan in chronic kidney disease--a randomized trial.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biph | 2012 |
Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Anti | 2012 |
Comparison of the efficacy between hydrochlorothiazide and chlorthalidone on central aortic pressure when added on to candesartan in treatment-naïve patients of hypertension.
Topics: Adult; Antihypertensive Agents; Arterial Pressure; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2013 |
Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Drug Subst | 2013 |
Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2013 |
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiot | 2002 |
The SCOPE trial. Study on Cognition and Prognosis in the Elderly.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cognition Disorders; Humans; Hype | 2002 |
Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients.
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl | 2002 |
Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Echocardiography | 2002 |
Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihy | 2002 |
The DIabetic Retinopathy Candesartan Trials (DIRECT) Programme, rationale and study design.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Retinopathy; Disease Progressi | 2002 |
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Bl | 2003 |
Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; | 2003 |
Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Benzothiadiazines; Biphenyl Compounds; Blood Pressure | 2003 |
A randomized, double-blind, controlled, parallel-group comparison of perindopril and candesartan in hypertensive patients with type 2 diabetes mellitus.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compound | 2003 |
Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
Topics: Angiotensin Receptor Antagonists; Angiotensins; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2003 |
Candesartan and hydrochlorothiazide in isolated systolic hypertension.
Topics: Aged; Aged, 80 and over; Australia; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressu | 2003 |
Candesartan reduces oxidative stress and inflammation in patients with essential hypertension.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2003 |
Effect of candesartan and verapamil on exercise tolerance in diastolic dysfunction.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Channel Blocker | 2004 |
Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE).
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2004 |
Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension.
Topics: Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Brachial Ar | 2004 |
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in African-American patients with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2004 |
Trial of preventing hypertension: design and 2-year progress report.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Double-Bli | 2004 |
The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiovascular Di | 2004 |
Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria.
Topics: Aged; Aged, 80 and over; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B | 2004 |
Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE).
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2004 |
Antihypertensive efficacy of candesartan-lisinopril in combination vs. up-titration of lisinopril: the AMAZE trials.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2004 |
Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure Determinati | 2004 |
Effect of antihypertensive treatment with candesartan or amlodipine on glutathione and its redox status, homocysteine and vitamin concentrations in patients with essential hypertension.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Female; Fol | 2005 |
Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized c
Topics: Adult; Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mell | 2005 |
Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus | 2005 |
Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benz | 2005 |
Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2005 |
The cost-effectiveness of candesartan-based antihypertensive treatment for the prevention of nonfatal stroke: results from the Study on COgnition and Prognosis in the Elderly.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2005 |
The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds | 2005 |
Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
Topics: Adult; Aged; Albuminuria; Amlodipine; Benzimidazoles; Biphenyl Compounds; Cross-Over Studies; Diabet | 2005 |
Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE).
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2005 |
Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pres | 2005 |
Anti-inflammatory and metabolic effects of candesartan in hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents; Benzimidazoles; Biph | 2006 |
AMAZE study--less than amazing results.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Drug Administ | 2005 |
Assessment of quality of life in a randomized clinical trial of candesartan only or in combination with DASH diet for hypertensive patients.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2005 |
Cost-effectiveness analysis of hypertension treatment: controlled release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension--the Nifedipine and Candesartan Combination (NICE-Combi) Study.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Ch | 2005 |
Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2006 |
Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diuretics; Female; Fibr | 2006 |
Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2006 |
[Clinical efficiency of candesatran depends on angiotension II receptor, type 1 gene polymorphism].
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; | 2005 |
Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimid | 2006 |
Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Compliance | 2006 |
Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy.
Topics: Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl | 2006 |
Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atenolol; Benzimi | 2006 |
Management of patients with uncontrolled arterial hypertension--the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCTZ.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pressure De | 2006 |
Effect of candesartan on coronary flow reserve in patients with systemic hypertension.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Flow Velocity; Carotid Arte | 2006 |
Randomized study of angiotensin II type 1 receptor blocker vs dihydropiridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl C | 2006 |
The effect of angiotensin II receptor blocker on peritoneal membrane transports in continuous ambulatory peritoneal dialysis patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biological T | 2006 |
[Is primary prevention of arterial hypertension with drugs possible? Results of the TROPHY Study].
Topics: Benzimidazoles; Biphenyl Compounds; Cholesterol, LDL; Female; Humans; Hypertension; Male; Middle Age | 2006 |
A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicent
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Double-Bli | 2006 |
Platelet aggregability in patients with hypertension treated with angiotensin II type 1 receptor blockers.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Aged; Angiotensin II Type 1 Rece | 2007 |
Discrepancy between improvement of insulin sensitivity and that of arterial endothelial function in patients receiving antihypertensive medication.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2007 |
Effects of candesartan for middle-aged and elderly women with hypertension and menopausal-like symptoms.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Female; Humans; Hypertension; Men | 2006 |
Effects of amlodipine and candesartan on oxidized LDL level in patients with mild to moderate essential hypertension.
Topics: Alkenes; Amlodipine; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Double-Blind Method; Female | 2006 |
Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients--reversal by chronic angiotensin II type 1A receptor blockade.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2007 |
Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Administr | 2007 |
Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients.
Topics: Adiponectin; Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dou | 2007 |
Treatment of young subjects at high familial risk of future hypertension with an angiotensin-receptor blocker.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; | 2007 |
Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2007 |
Effects of candesartan and lisinopril on the fibrinolytic system in hypertensive patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypert | 2007 |
High dose treatment with angiotensin II receptor blocker in patients with hypertension: differential effect of tissue protection versus blood pressure lowering.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Biphenyl Compounds; Blood P | 2008 |
Addition of manidipine improves the antiproteinuric effect of candesartan in hypertensive patients with type II diabetes and microalbuminuria.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2007 |
Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combination.
Topics: Benzimidazoles; Biphenyl Compounds; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hyperten | 2007 |
Chronic AT1-receptor blockade does not alter cerebral oxygen supply/demand ratio during cardiopulmonary bypass in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2008 |
Effectiveness of add-on low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs. candesartan/amlodipine.
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Diureti | 2007 |
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2007 |
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood | 2008 |
Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidaz | 2008 |
Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors | 2008 |
[Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2008 |
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Blood Pre | 2008 |
Renal protective effect in hypertensive patients: the high doses of angiotensin II receptor blocker (HARB) study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Com | 2007 |
Candesartan and cognitive decline in older patients with hypertension: a substudy of the SCOPE trial.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Antihypertensive Age | 2008 |
Candesartan cilexetil vs losartan.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; Losartan; Tetrazo | 1998 |
Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function.
Topics: Adult; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Bi | 1999 |
Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2000 |
[Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1999 |
Prehypertension: a possible target for antihypertensive medication.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2000 |
Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2000 |
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimi | 2000 |
[Clinical study of the month. The CALM study assessing the combination of an angiotensin-converting enzyme inhibitor and an angiotensin II receptor antagonist in the treatment of diabetic nephropathy].
Topics: Adult; Aged; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimi | 2001 |
Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. ACTION Study Investigators.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Female; Humans; Hypertensi | 2001 |
Effects of candesartan on cough and bronchial hyperresponsiveness in mildly to moderately hypertensive patients with symptomatic asthma.
Topics: Adult; Aged; Antihypertensive Agents; Asthma; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Br | 2001 |
Effects of candesartan on cardiac and arterial structure and function in hypertensive subjects.
Topics: Adult; Antihypertensive Agents; Arteries; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Compli | 2001 |
Variants of the CYP11B2 gene predict response to therapy with candesartan.
Topics: Aged; Analysis of Variance; Benzimidazoles; Biphenyl Compounds; Chi-Square Distribution; Cytochrome | 2002 |
A comparison of candesartan, felodipine, and their combination in the treatment of elderly patients with systolic hypertension.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2002 |
Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus.
Topics: Administration, Oral; Adult; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Con | 2002 |
316 other studies available for candesartan and Hypertension
| Article | Year |
|---|---|
Angiotensin II--AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Drug Desi | 2008 |
Renal Denervation in Combination With Angiotensin Receptor Blockade Prolongs Blood Pressure Trough During Hemorrhage.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2022 |
Study of possible sex features of ramipril and candesartan treatment under experimental arterial hypertension in rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 2022 |
Paeonol improves renal and vascular angiotensin II type 1 receptor function via inhibiting oxidative stress in spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Hypertension; Kidney; Oxidative Stress; Rats; Rats, Inbred SHR; Rats, Inbre | 2023 |
Effect of the structural modification of Candesartan with Zinc on hypertension and left ventricular hypertrophy.
Topics: Animals; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Hypertension; Hypertrophy, Lef | 2023 |
5-Aminolevulinic acid hydrochloride enhances bupivacaine-induced hypotension in spontaneously hypertensive rats.
Topics: Aminolevulinic Acid; Amlodipine; Animals; Antihypertensive Agents; Blood Pressure; Bupivacaine; Hype | 2023 |
A collaborative study of the impact of N-nitrosamines presence and ARB recall on ARB utilization - results from IQVIA™ Disease Analyzer Germany.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Germany; Humans; Hyperte | 2023 |
Effects of 5-fluorouracil Co-administration on Blood Pressure in Patients Maintained on Antihypertensives: a Retrospective Case Series.
Topics: Amlodipine; Antihypertensive Agents; Antineoplastic Agents; Blood Pressure; Cytochrome P-450 CYP3A; | 2023 |
Hypertensive APOL1 risk allele carriers demonstrate greater blood pressure reduction with angiotensin receptor blockade compared to low risk carriers.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Apolipoprotein L1; Benzimidazoles; Biphenyl Compound | 2019 |
Exploring the role of the membrane bilayer in the recognition of candesartan by its GPCR AT1 receptor.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; L | 2020 |
Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Canada; Cohort Studies; | 2020 |
Pharmacokinetic and pharmacodynamic evaluation of nano-fixed dose combination for hypertension.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Disease Models, An | 2020 |
ACE (Angiotensin-Converting Enzyme) Inhibition Reverses Vasoconstriction and Impaired Dilation of Pial Collaterals in Chronic Hypertension.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compound | 2020 |
Impact of age on clinical outcomes of antihypertensive therapy in patients with hypertension and coronary artery disease: A sub-analysis of the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease.
Topics: Age Factors; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2020 |
Rethinking of the hypertension management in the elderly with comorbidity: Should we forget the age in treating elderly hypertensives?
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Comorbidity; Coronary Artery Dise | 2020 |
TLR4/MyD88/NF-κB Signaling in the Rostral Ventrolateral Medulla Is Involved in the Depressor Effect of Candesartan in Stress-Induced Hypertensive Rats.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Hypertension; Medulla Oblongata; Myeloid Differentiatio | 2020 |
Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis.
Topics: Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Body Fluids; Chromatography | 2021 |
High Fructose-Induced Hypertension and Renal Damage Are Exaggerated in Dahl Salt-Sensitive Rats via Renal Renin-Angiotensin System Activation.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Enalapril; Fru | 2021 |
Mechanisms of acute neurovascular protection with AT1 blockade after stroke: Effect of prestroke hypertension.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; | 2017 |
Elastin insufficiency causes hypertension, structural defects and abnormal remodeling of renal vascular signaling.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2017 |
Angiotensin Receptor Blockade by Inhibiting Glial Activation Promotes Hippocampal Neurogenesis Via Activation of Wnt/β-Catenin Signaling in Hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Astrocytes; Benzimidazoles; Biphenyl Compounds; Bl | 2018 |
Impact of the Commercialization of Three Generic Angiotensin II Receptor Blockers on Adverse Events in Quebec, Canada: A Population-Based Time Series Analysis.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Datab | 2017 |
Topics: Actins; Albuminuria; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Comp | 2018 |
Angiotensin receptor blocker use and gastro-oesophageal cancer survival: a population-based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Benzimidazoles; Biphen | 2018 |
Blood Pressure Control by a Secreted FGFBP1 (Fibroblast Growth Factor-Binding Protein).
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2018 |
Role of angiotensin system modulation on progression of cognitive impairment and brain MRI changes in aged hypertensive animals - A randomized double- blind pre-clinical study.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2018 |
Inhibitory effects of candesartan on KCa3.1 potassium channel expression and cell culture and proliferation in peripheral blood CD4
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Case-Control Studies; CD4-Positi | 2018 |
Fixed-dose vs free-dose combinations for the management of hypertension-An analysis of 81 958 patients.
Topics: Age Factors; Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2018 |
PATHOMORPHOLOGY OF THE MYOCARDIUM, KIDNEY AND LIVER IN SPONTANEOUSLY HYPERTENSIVE RATS TREATED WITH SHORT AND LONG-TERM USE RAMIPRIL AND CANDESARTAN.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; | 2018 |
Long-term effects of antihypertensive therapy on cardiovascular events and new-onset diabetes mellitus in high-risk hypertensive patients in Japan.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardi | 2018 |
Angiotensin II upregulates CYP4A isoform expression in the rat kidney through angiotensin II type 1 receptor.
Topics: Angiotensin II; Animals; Arachidonic Acid; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cytoc | 2018 |
Unique mode of binding between angiotensin II type 1 receptor and its blockers.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Cells, Culture | 2019 |
Comparison of Candesartan and Angiotensin-(1-7) Combination to Mito-TEMPO Treatment for Normalizing Blood Pressure and Sympathovagal Balance in (mREN2)27 Rats.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Arterial P | 2019 |
Simultaneous transient global amnesia and Takotsubo syndrome after death of a relative: a case report.
Topics: Amnesia, Transient Global; Antihypertensive Agents; Aspirin; Atorvastatin; Benzimidazoles; Biphenyl | 2019 |
Candesartan attenuates hypertension-associated pathophysiological alterations in the gut.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Colon; Fatty Acids; Feces; Fibrosis; Ga | 2019 |
Spreading vasodilatation in the murine microcirculation: attenuation by oxidative stress-induced change in electromechanical coupling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Biphen | 2013 |
Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II-induced hypertension.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2013 |
The role of plasma renin activity, age, and race in selecting effective initial drug therapy for hypertension.
Topics: Adult; Age Factors; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Bla | 2013 |
Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report.
Topics: Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compound | 2013 |
Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2013 |
Drugs for treating hypertension.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drugs, Generic; Humans; Hydrochlorothia | 2013 |
Effects of angiotensin II type 1 receptor blocker and adiponectin on adipocyte dysfunction in stroke-prone spontaneously hypertensive rats.
Topics: Adipocytes; Adiponectin; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl | 2013 |
Influence of autoantibodies against AT1 receptor and AGTR1 polymorphisms on candesartan-based antihypertensive regimen: results from the study of optimal treatment in hypertensive patients with anti-AT1-receptor autoantibodies trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Autoantibodies; Benzimidazoles; Biphenyl Compounds; Enzyme- | 2014 |
Early treatment to prevent hypertension: a laudable goal.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Female; Humans; Hyperte | 2013 |
Superoxide dismutase mimetic, tempol, aggravates renal injury in advanced-stage stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; Benzimidazo | 2014 |
Suppression of advanced glycation and lipoxidation end products by angiotensin II type-1 receptor blocker candesartan in type 2 diabetic patients with essential hypertension.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; B | 2013 |
Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl | 2014 |
Female spontaneously hypertensive rats are more dependent on ANG (1-7) to mediate effects of low-dose AT1 receptor blockade than males.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl C | 2014 |
Benefit of azilsartan on blood pressure elevation around rest-to-active phase in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Hypertension; | 2015 |
Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology.
Topics: Aged; Amlodipine; Angiotensin Receptor Antagonists; Azetidinecarboxylic Acid; Benzimidazoles; Benzoa | 2015 |
Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2014 |
Bayesian sensitivity analysis of incomplete data: bridging pattern-mixture and selection models.
Topics: Antihypertensive Agents; Bayes Theorem; Benzimidazoles; Bias; Binomial Distribution; Biphenyl Compou | 2014 |
Oxidative DNA damage in kidneys and heart of hypertensive mice is prevented by blocking angiotensin II and aldosterone receptors.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; A | 2014 |
Oxidative stress causes imbalance of renal renin angiotensin system (RAS) components and hypertension in obese Zucker rats.
Topics: Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cyclic N-Oxides; Disease | 2015 |
Differences in 24-h blood pressure profile of Japanese hypertensive patients under ARB treatment.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Blood Pr | 2015 |
Development of Sustained Release "NanoFDC (Fixed Dose Combination)" for Hypertension - An Experimental Study.
Topics: Amlodipine; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Bl | 2015 |
β-Pro7Ang III is a novel highly selective angiotensin II type 2 receptor (AT2R) agonist, which acts as a vasodepressor agent via the AT2R in conscious spontaneously hypertensive rats.
Topics: Amino Acid Sequence; Analysis of Variance; Angiotensin II Type 2 Receptor Blockers; Angiotensin III; | 2015 |
Human GRK4γ142V Variant Promotes Angiotensin II Type I Receptor-Mediated Hypertension via Renal Histone Deacetylase Type 1 Inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2016 |
The velocity of antihypertensive effects of seven angiotensin II receptor blockers determined by home blood pressure measurements.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl | 2016 |
Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; | 2016 |
L/N-type Ca
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcium Channel Blocker | 2017 |
Combination candesartan-HCTZ did not reduce major CV events in patients at intermediate CV risk.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Humans; Hydr | 2016 |
Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; Hydrochlorothiazide; Hypertensi | 2016 |
Reninoma Masked by the Use of an Angiotensin Receptor Blocker.
Topics: Adenoma; Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Delayed | 2016 |
Partial adherence to antihypertensive therapy fails to achieve full cardiovascular benefits in hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Body Weight; Disease Models, A | 2008 |
Vascular protection with candesartan after experimental acute stroke in hypertensive rats: a dose-response study.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Dose-Response Relationship, Drug; Hyper | 2008 |
Combination therapy for treatment or prevention of atherosclerosis.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2008 |
Pemphigus foliaceus induced by an angiotensin II receptor blocker.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Female | 2008 |
Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2008 |
Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compou | 2008 |
The effect of recombinant aminopeptidase A on hypertension in spontaneously hypertensive rats: its effect in comparison with candesartan.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Ag | 2008 |
Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Press | 2009 |
The optimal target blood pressure for antihypertensive treatment in Japanese elderly patients with high-risk hypertension: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl | 2008 |
Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care.
Topics: Abdominal Fat; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Bl | 2008 |
Candesartan ameliorates cardiac dysfunction observed in angiotensin-converting enzyme 2-deficient mice.
Topics: Age Factors; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme | 2008 |
Candesartan-induced gene expression in five organs of stroke-prone spontaneously hypertensive rats.
Topics: Adipose Tissue; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimida | 2008 |
"Pulse" treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anim | 2009 |
A Bayesian sensitivity model for intention-to-treat analysis on binary outcomes with dropouts.
Topics: Adult; Aged; Antihypertensive Agents; Bayes Theorem; Benzimidazoles; Bias; Biphenyl Compounds; Blood | 2009 |
Intrarenal angiotensin III infusion induces natriuresis and angiotensin type 2 receptor translocation in Wistar-Kyoto but not in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin III; A | 2009 |
Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2009 |
Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension.
Topics: Acetylcholine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzi | 2009 |
Angiotensin blockade prevents salt-induced injury of the renal circulation in spontaneously hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Biphenyl Compounds; Body We | 2009 |
Intrathecal baclofen for autonomic instability due to spinal cord injury.
Topics: Abdominal Wall; Antihypertensive Agents; Autonomic Dysreflexia; Baclofen; Benzimidazoles; Biphenyl C | 2009 |
Regulation of angiotensin II type I receptor (AT1R) protein levels in the obese Zucker rat kidney and urine.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biomarker | 2009 |
[CASE-J: a large-scale clinical trial in hypertensive patients].
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Humans; | 2009 |
Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2009 |
Effects of cardiac complications on cardiovascular events in Japanese high-risk hypertensive patients: subanalysis of the CASE-J trial.
Topics: Adrenergic Antagonists; Aged; Amlodipine; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calciu | 2009 |
Candesartan for cardiovascular prevention in Japanese hypertensive patients with coronary heart disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2009 |
Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2009 |
Warnings against candesartan in pregnancy are not implemented in physicians' practice.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2009 |
Mid-term results, and therapeutic management, for patients suffering hypertension after surgical repair of aortic coarctation.
Topics: Adolescent; Antihypertensive Agents; Aortic Coarctation; Atenolol; Benzimidazoles; Biphenyl Compound | 2009 |
Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Benzimidazoles; B | 2009 |
Increased rhythmicity in hypertensive arterial smooth muscle is linked to transient receptor potential canonical channels.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Benzoates; | 2010 |
Tempol or candesartan prevents high-fat diet-induced hypertension and renal damage in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Antioxidants; Benzimidazoles; Biphenyl Compounds; Cyclic N-Oxides; | 2010 |
Blood pressure control determines improvement in diastolic dysfunction in early hypertension.
Topics: Antihypertensive Agents; Bendroflumethiazide; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Fe | 2009 |
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; F | 2010 |
Prehypertensive preconditioning improves adult antihypertensive and cardioprotective treatment.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; Benzi | 2010 |
Intrarenal aminopeptidase N inhibition restores defective angiontesin II type 2-mediated natriuresis in spontaneously hypertensive rats.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Com | 2010 |
[Preventive strategy for atrial fibrillation in arterial hypertension].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia A | 2009 |
Cardiovascular effects of inhibition of renin-angiotensin-aldosterone system components in hypertensive rats given salt excess.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimid | 2010 |
Reversible fetal renal failure after maternal treatment with Candesartan: a case report.
Topics: Adult; Amniotic Fluid; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Creatinine; Fema | 2010 |
Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients?: a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial.
Topics: Age of Onset; Aged; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Blood | 2010 |
Effects of antihypertensive drugs in the prevention of new-onset diabetes mellitus in patients with hypertension at high-risk of cardiovascular events in relation to aging.
Topics: Age Distribution; Age Factors; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl C | 2010 |
Regression of glomerulosclerosis in response to transient treatment with angiotensin II blockers is attenuated by blockade of matrix metalloproteinase-2.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensins; Animals; Antihypertensive Agents; Be | 2010 |
Health-care costs of losartan and candesartan in the primary treatment of hypertension.
Topics: Acute Coronary Syndrome; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimida | 2011 |
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2010 |
Involvement of angiotensin II in the remodeling induced by a chronic decrease in blood flow in rat mesenteric resistance arteries.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; A | 2010 |
Acute AT(1)-receptor blockade reverses the hemodynamic and baroreflex impairment in adult sheep exposed to antenatal betamethasone.
Topics: Age Factors; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Baroreflex; | 2010 |
[Suppression of renin-angiotensin system and cancer therapy (discussion)].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; B | 2010 |
Cardiovascular protection with candesartan in patients with metabolic disorders.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Cardiovascular Diseases | 2010 |
Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Co | 2010 |
Blood pressure-independent effect of candesartan on cardio-ankle vascular index in hypertensive patients with metabolic syndrome.
Topics: Ankle; Antihypertensive Agents; Arteries; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Caroti | 2010 |
Is very low dose hydrochlorothiazide combined with candesartan effective in uncontrolled hypertensive patients?
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure Monitoring, Ambula | 2010 |
Effects of renal dysfunction on cardiovascular events in diabetic patients with hypertension: challenge-DM Study subgroup analysis.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cardiov | 2011 |
Augmented antihypertensive effect of a fixed combination formula of candesartan and hydrochlorothiazide combined with furosemide in a patient on peritoneal dialysis.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Co | 2011 |
Year-long antihypertensive therapy with candesartan completely prevents development of cardiovascular organ injuries in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; D | 2010 |
[The relationship between the plasma concentration of urotension II (U II) and NO, NOS in spontaneous hypertensive rats and influence of candesartan].
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Hypertension; | 2009 |
Age-related differences in the effects of antihypertensive therapy on left ventricular hypertrophy in high-risk patients with hypertension-candesartan antihypertensive survival evaluation in Japan subanalysis.
Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Com | 2011 |
Waste not, want not: free money, moral hazard and value-based prescribing.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; | 2011 |
Easy money? Health cost savings resulting from the switch from a branded drug to a low-cost generic drug in the same class.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Heart Failure; | 2011 |
Lowering blood pressure in acute stroke: the SCAST trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2011 |
Unexpected occurrence of adrenal Cushing's syndrome in a patient with systemic lupus erythematosus.
Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Adenoma; Adult; Angiomyolipoma; Antihyperten | 2011 |
Angiotensin-converting enzyme inhibition and fibrinolytic balance.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2011 |
Cardiovascular events in subgroups of patients during primary treatment of hypertension with candesartan or losartan.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiovascular Di | 2011 |
The vanishing story of angiotensin II receptor blockers in the treatment of atrial fibrillation.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Benzimidazoles; Biphenyl C | 2011 |
[Prevention of hypertension by drugs and immunization against angiotensin II].
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibi | 2011 |
Treatment of high blood pressure in acute stroke--the SCAST study.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Humans; Hypertension; M | 2011 |
Angiotensin receptor blockade in diabetic women of childbearing potential: an acceptable risk?
Topics: Abnormalities, Drug-Induced; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; D | 2011 |
Pressor and renal hemodynamic effects of the novel angiotensin A peptide are angiotensin II type 1A receptor dependent.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Benzimidazoles; Biphenyl Compounds; | 2011 |
AT1 receptor antagonist candesartan attenuates genomic damage in peripheral blood lymphocytes of patients on maintenance hemodialysis treatment.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihyperte | 2011 |
Stroke: blood pressure lowering in acute stroke--scant joy from SCAST.
Topics: Acute Disease; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Bip | 2011 |
Choice of angiotensin receptor blocker in moderate hypertension. A UK-based cost-benefit comparison of olmesartan- and candesartan-based regimens.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl | 2011 |
Influence of coronary risk factors on coronary events in Japanese high-risk hypertensive patients. - Primary and secondary prevention of ischemic heart disease in a subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) tria
Topics: Aged; Amlodipine; Antihypertensive Agents; Asian People; Benzimidazoles; Biphenyl Compounds; Coronar | 2011 |
Roles of central renin-angiotensin system and afferent renal nerve in the control of systemic hemodynamics in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2011 |
Safety and efficacy of administering the maximal dose of candesartan in renal transplant recipients.
Topics: Adult; Aged; Albuminuria; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Benzimidazo | 2011 |
Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study.
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Urea Nitrog | 2011 |
[Dynamics of primary hemostasis activity in patients with arterial hypertension and metabolic syndrome treated with candesartan].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Female; | 2011 |
Angiotensin II acts through the angiotensin 1a receptor to upregulate pendrin.
Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Anion Transport Prote | 2011 |
Angiotensin-converting enzyme inhibition, but not AT(1) receptor blockade, in the solitary tract nucleus improves baroreflex sensitivity in anesthetized transgenic hypertensive (mRen2)27 rats.
Topics: Anesthesia; Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme In | 2011 |
Effects of an angiotensin 2 receptor blocker plus diuretic combination drug in chronic heart failure complicated by hypertension.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2011 |
[In view of the findings of the SCAST study, must the treatment of arterial pressure in the acute phase of stroke be changed?].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Clinical Trials as Topi | 2011 |
Angiotensin-(1-7) deficiency and baroreflex impairment precede the antenatal Betamethasone exposure-induced elevation in blood pressure.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Baroreflex; Benzi | 2012 |
Angiotensin-(1-7) deficiency and baroreflex impairment precede the antenatal Betamethasone exposure-induced elevation in blood pressure.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Baroreflex; Benzi | 2012 |
Angiotensin-(1-7) deficiency and baroreflex impairment precede the antenatal Betamethasone exposure-induced elevation in blood pressure.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Baroreflex; Benzi | 2012 |
Angiotensin-(1-7) deficiency and baroreflex impairment precede the antenatal Betamethasone exposure-induced elevation in blood pressure.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Baroreflex; Benzi | 2012 |
Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Avoidance Learning; Benzimidazoles; Biphenyl Compo | 2012 |
Association between asleep blood pressure and brain natriuretic peptide during antihypertensive treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood P | 2012 |
Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
Topics: Animals; Antihypertensive Agents; Azetidinecarboxylic Acid; Benzimidazoles; Biphenyl Compounds; Bloo | 2012 |
Sympathoinhibition caused by orally administered telmisartan through inhibition of the AT₁ receptor in the rostral ventrolateral medulla of hypertensive rats.
Topics: Acetophenones; Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertens | 2012 |
Differential effects of short-term treatment with two AT1 receptor blockers on diameter of pial arterioles in SHR.
Topics: Angiotensin Receptor Antagonists; Animals; Arterioles; Benzimidazoles; Benzoates; Biphenyl Compounds | 2012 |
Central angiotensin-(1-7) improves vagal function independent of blood pressure in hypertensive (mRen2)27 rats.
Topics: Angiotensin I; Animals; Antihypertensive Agents; Antioxidants; Baroreflex; Benzimidazoles; Biphenyl | 2012 |
Improving drug adherence using fixed combinations caused beneficial treatment outcomes and decreased health-care costs in patients with hypertension.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin Receptor Antagonists; Benzimidazoles; Benzoates; Bi | 2013 |
AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, West | 2013 |
Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; B | 2013 |
Potentiated sympathetic nervous and renin-angiotensin systems reduce nonlinear correlation between sympathetic activity and blood pressure in conscious spontaneously hypertensive rats.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Animals; Arginine; Benzimidazoles; Biphenyl | 2002 |
AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood | 2002 |
Candesartan.
Topics: Advisory Committees; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biph | 2002 |
Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2002 |
Angioedema associated with candesartan.
Topics: Angioedema; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Hypersensitivity; Fema | 2002 |
Rostral ventrolateral medulla neurons of neonatal Wistar-Kyoto and spontaneously hypertensive rats.
Topics: Action Potentials; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Newborn; Benz | 2002 |
Autoregulated glomerular filtration rate during candesartan treatment in hypertensive type 2 diabetic patients.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cross | 2002 |
Augmented diurnal variations of the cardiac renin-angiotensin system in hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Benzimidazoles; Biphenyl Compounds; Bloo | 2002 |
Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Animals, Genetically Mod | 2003 |
Effect of hypertension and candesartan on the blood flow velocity of the extraocular vessels in hypertensive patients.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Flow Velocity; Case-Control Studi | 2003 |
Enalapril attenuates endothelin-1-induced hypertension via increased kinin survival.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2003 |
Linear IgA bullous dermatosis induced by angiotensin receptor antagonists.
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2003 |
[Two cases of systemic lupus erythematosus accompanied by antiphospholipid syndrome nephropathy without immune complex nephritis].
Topics: Adult; Angiotensin Receptor Antagonists; Anticoagulants; Antigen-Antibody Complex; Antihypertensive | 2002 |
[New AT1 receptor antagonist. Rapid and effective blood pressure decrease].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clini | 2003 |
Normalization of endothelial and inducible nitric oxide synthase expression in brain microvessels of spontaneously hypertensive rats by angiotensin II AT1 receptor inhibition.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterial Occlusive Diseases; Ben | 2003 |
[AT1 blocker therapy of hypertension in seniors. Added protection for cerebral blood vessels?].
Topics: Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; | 2003 |
AT1 receptors in the RVLM mediate pressor responses to emotional stress in rabbits.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Angiotensin II; Angiotensin Receptor Antagonists; Animals; | 2003 |
Lack of vascular connexin 40 is associated with hypertension and irregular arteriolar vasomotion.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Animals; Arterioles; Benzimidazoles; Biphenyl Compo | 2003 |
Perindopril and candesartan comparative efficacy and safety in type II diabetic hypertensive patients.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mell | 2003 |
Effect of AT1 receptor blockade on hepatic redox status in SHR: possible relevance for endothelial function?
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Benzimida | 2003 |
Circadian gene expression of clock genes and plasminogen activator inhibitor-1 in heart and aorta of spontaneously hypertensive and Wistar-Kyoto rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Aorta; ARNTL Transcriptio | 2003 |
Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension.
Topics: Adiponectin; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2003 |
Cardiology patient page. Angiotensin receptor blockers.
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Benzoates; Bip | 2003 |
Angiotensin II blockade augments renal cortical microvascular pO2 indicating a novel, potentially renoprotective action.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 2003 |
[Fast-acting sartan. High blood pressure therapy without long waiting time].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2003 |
Effects of benidipine and candesartan on kidney and vascular function in hypertensive Dahl rats.
Topics: Albuminuria; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; C | 2003 |
In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Biphenyl Co | 2003 |
Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Area Unde | 2003 |
[Dosage equivalents of AT1-receptor antagonists available in Germany].
Topics: Acrylates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting E | 2003 |
Postovariectomy hypertension is linked to increased renal AT1 receptor and salt sensitivity.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2003 |
ROS during the acute phase of Ang II hypertension participates in cardiovascular MAPK activation but not vasoconstriction.
Topics: Acute Disease; Adrenergic alpha-Agonists; Angiotensin II; Animals; Antioxidants; Aorta; Benzimidazol | 2004 |
Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzimidazoles; Biphenyl Co | 2004 |
Rash and acute nephritic syndrome due to candesartan.
Topics: Acute Disease; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazole | 2004 |
Gene expression profile revealed different effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibitor on heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; B | 2003 |
Sub-depressor dose of angiotensin type-1 receptor blocker inhibits transforming growth factor-beta-mediated perivascular fibrosis in hypertensive rat hearts.
Topics: Administration, Oral; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Benzi | 2003 |
The ACCESS study.
Topics: Antihypertensive Agents; Autonomic Nervous System; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2004 |
Angiotensin II receptor blockade corrects altered expression of gap junctions in vascular endothelial cells from hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Antihypertensive | 2004 |
[Acute coronary syndrome you can hear the prognosis].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Clinical Trials as Topic; Coronary Arte | 2004 |
Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats.
Topics: Aldosterone; Angiotensin II; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; B | 2004 |
Candesartan cilexetil protects cavernous tissue in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2004 |
[AT-1 blockers are different in their effects. The forgetful patients begin to notice it especially].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2003 |
Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist.
Topics: 1-Sarcosine-8-Isoleucine Angiotensin II; Allosteric Regulation; Angiotensin II; Angiotensin II Type | 2004 |
Plasma and kidney angiotensin II levels and renal functional responses to AT(1) receptor blockade in hypertensive Ren-2 transgenic rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modified; Antihypert | 2004 |
[Treating high blood pressure in acute stroke].
Topics: Acute Disease; Adrenergic alpha-Agonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Conve | 2004 |
Hypertension control among African Americans: an urgent call for action.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2004 |
Valsartan treatment of hypertension--does VALUE add value?
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2004 |
Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2004 |
Effects of angiotensin II type 1 receptor antagonist on pressor responses to pulsatile compression of the rostral ventrolateral medulla in rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimida | 2004 |
Efficacy of candesartan in the treatment of migraine in hypertensive patients.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Female; Humans; | 2004 |
Effect of AT1 receptor antagonism on vascular and circulating inflammatory mediators in SHR: role of NF-kappaB/IkappaB system.
Topics: Animals; Aorta; Benzimidazoles; Biphenyl Compounds; Hypertension; Inflammation Mediators; Interleuki | 2005 |
Patients with mild hypertensive heart disease and left ventricular outflow tract obstruction: treatment with angiotensin II antagonists.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazo | 2004 |
Angiotensin receptor blockers and myocardial infarction.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphen | 2004 |
AT2 receptors contribute to acute blood pressure-lowering and vasodilator effects of AT1 receptor antagonism in conscious normotensive but not hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2005 |
Diabetic brain damage in hypertension: role of renin-angiotensin system.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspartic Acid; Benzimidazoles; Biphenyl Compounds; Bl | 2005 |
Chronic reductions in carotid blood flow cause salt-sensitive hypertension in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2005 |
The role of intrarenal angiotensin II in the development of hypertension in Ren-2 transgenic rats.
Topics: Angiotensin II; Animals; Animals, Genetically Modified; Antihypertensive Agents; Benzimidazoles; Bip | 2005 |
Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressu | 2005 |
Increased renal echogenicity in a preterm neonate. Kidneys with tubular dysplasia due to exposure to candesartan during pregnancy.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2005 |
Nifedipine enhances the cardioprotective effect of an angiotensin-II receptor blocker in an experimental animal model of heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Body Weight; C | 2005 |
Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diuretics; Drug Therapy | 2005 |
Neuroprotective effects of candesartan against cerebral ischemia in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Body Weight; B | 2005 |
Angiotensin II blockade improves mitochondrial function in spontaneously hypertensive rats.
Topics: Actins; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl C | 2005 |
Evaluation of intrarenal hemodynamics by Doppler ultrasonography for renoprotective effect of angiotensin receptor blockade.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Female; Hemodynamics; H | 2005 |
[Beneficial effects of combination therapy with losartan and low-dose hydrochlorothiazide in the treatment of essential hypertension].
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Pres | 2005 |
Effects of long-term treatment with candesartan on hemodynamics and organ damage in spontaneously hypertensive rats.
Topics: Administration, Oral; Animals; Aorta; Baroreflex; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2005 |
The X-cellent Study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Antihy | 2006 |
Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Benzimidazoles; Biphenyl Compounds; Blood Pressu | 2006 |
AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2006 |
[Preventing hypertension with drugs?].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases | 2006 |
[In high risk patients also treat high normal blood pressure values!].
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cardiovascular Diseases | 2006 |
Experts ponder treating prehypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2006 |
Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2006 |
Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial.
Topics: Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Benzimidazoles; Biph | 2006 |
An American TROPHY in the prevention of hypertension.
Topics: Benzimidazoles; Biphenyl Compounds; Disease Progression; Female; Humans; Hypertension; Male; Middle | 2006 |
Different effects of angiotensin receptor blockade on end-organ damage in salt-dependent and salt-independent hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2006 |
Role of AT1 receptors in permeability of the blood-brain barrier in diabetic hypertensive rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2006 |
TROPHY: a trial that may change clinical practice.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biph | 2006 |
Angiotensin-receptor blockers for prehypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biph | 2006 |
The continuum of blood pressure risk: when is the best time to intervene?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biph | 2006 |
Does life-long reduction in low-density lipoprotein cholesterol reduce the risk of new-onset hypertension?
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cholesterol, LDL; Humans; Hyperlipidemi | 2006 |
Hypertension, diuretics, and uric acid.
Topics: Antihypertensive Agents; Antioxidants; Benzimidazoles; Biphenyl Compounds; Cardiovascular System; Di | 2006 |
Treatment of prehypertension: how soon is soon enough? What therapy should be used?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biph | 2006 |
Benefits of candesartan on arterial and renal damage of non-diabetic hypertensive patients treated with calcium channel blockers.
Topics: Aged; Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Bloc | 2006 |
Studying interventions to prevent the progression from prehypertension to hypertension: does TROPHY win the prize?
Topics: Antihypertensive Agents; Benzimidazoles; Bias; Biphenyl Compounds; Epidemiologic Research Design; Hu | 2006 |
A specialist in clinical hypertension critiques the TROPHY trial.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Epidemiologic Research Design; Humans; | 2006 |
Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Bipheny | 2007 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Ben | 2007 |
Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds | 2006 |
Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug E | 2007 |
From TROPHY with pride.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2007 |
A dream yet to become true.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Genetic Predis | 2007 |
Role of xanthine oxidoreductase in the reversal of diastolic heart failure by candesartan in the salt-sensitive hypertensive rat.
Topics: Acetophenones; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; | 2007 |
Effects of aldosterone and angiotensin II receptor blockade on cardiac angiotensinogen and angiotensin-converting enzyme 2 expression in Dahl salt-sensitive hypertensive rats.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensinog | 2007 |
Blood pressure variability: the challenge of variation.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2008 |
Plasma renin activity for predicting antihypertensive drug efficacy.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Biomarkers | 2008 |
Carryover effects after cessation of drug treatment: trophies or dreams?
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2008 |
Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension.
Topics: Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biomarkers; Bi | 2008 |
Effects of an ARB on endothelial progenitor cell function and cardiovascular oxidation in hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antioxidants; Aorta; Benz | 2008 |
Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2008 |
Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agent | 2008 |
Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2008 |
Switch strategies in the management of hypertension: a cost minimisation analysis of angiotensin receptor blocker based regimen.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds | 2008 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidaz | 2008 |
[Treatment of hypertension. Effectiveness of sartans is far from exhausted].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; B | 2007 |
Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive | 2008 |
Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Fibrosis; Hypertension; Hypertrophy, Lef | 2008 |
Angiotensin II receptor antagonist CV-11974 and cerebral blood flow autoregulation.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood | 1995 |
Angiotensin II Receptor Antagonists: Can they Go Beyond ACE Inhibitors? Proceedings of a satellite symposium to the 15th scientific meeting of the International Society of Hypertension. Melbourne, Australia, March 1994.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 1994 |
Activated angiotensin II generation and regulation in rat mesenteric arteries following nephrectomy.
Topics: Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Feedback; Hypertension; Kidney; Male; M | 1994 |
Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1994 |
Effects of a calcium antagonist and an angiotensin II receptor antagonist on rat renal arterioles.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Arterioles; Benzimidazoles; Biph | 1994 |
Comparative effects of an angiotensin-converting enzyme inhibitor and an angiotensin II antagonist in Dahl rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Capto | 1994 |
The effects of central administration of angiotensin II type-1 receptor antagonist, CV-11974, in nephrectomized spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Hypertension; Injecti | 1994 |
Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone.
Topics: Administration, Oral; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Angiotensin III; Ang | 1994 |
Short-term effects of angiotensin II blockade on renal blood flow and sympathetic activity in awake rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Heart | 1994 |
Brain angiotensin II contributes to the development of hypertension in Dahl-Iwai salt-sensitive rats.
Topics: Angiotensin II; Animals; Arteries; Baroreflex; Benzimidazoles; Biphenyl Compounds; Blood Pressure; B | 1995 |
The effect of central amino acid neurotransmitters on the antihypertensive response to angiotensin blockade in spontaneous hypertension.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Hyper | 1995 |
Mapping of angiotensin II receptor subtypes in peripheral tissues of spontaneously hypertensive rats by in vitro autoradiography.
Topics: Adrenal Glands; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Autoradiog | 1995 |
Modulation of renal hemodynamics by IGF-1 is absent in spontaneously hypertensive rats.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Glucagon; Hemodynamics; Hypertension; In | 1997 |
Regulation of cardiac angiotensinogen mRNA in vivo and in vitro.
Topics: Angiotensinogen; Animals; Benzimidazoles; Biphenyl Compounds; Cells, Cultured; Dactinomycin; Hyperte | 1997 |
[Preferences in general practice. Interview by Christine Vetter].
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Famil | 1998 |
Is a hypertensinogenic factor present in the kidney of hypertensive dahl rats?
Topics: Angiotensin Receptor Antagonists; Angiotensinogen; Animals; Aorta; Benzimidazoles; Biphenyl Compound | 1998 |
Central and peripheral mechanisms involved in hypertension induced by chronic inhibition of nitric oxide synthase in rats.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Anima | 1998 |
Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arginine Vasopressin; Benzimidazoles; Bip | 1998 |
The angiotensin AT1 receptor antagonist CV-11974 regulates cerebral blood flow and brain angiotensin AT1 receptor expression.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1998 |
Candesartan for hypertension.
Topics: Administration, Oral; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; An | 1998 |
Pressure natriuresis in nitric oxide-deficient hypertensive rats: effect of antihypertensive treatments.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 1999 |
Reciprocal role of the AT1 receptor in modulating renal and neuronal AT1 mRNA expression.
Topics: Angiotensin I; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimida | 1999 |
Normalizing the expression of nitric oxide synthase by low-dose AT1 receptor antagonism parallels improved vascular morphology in hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Blood Pre | 1999 |
Combined treatment with ibuprofen and the AT1 receptor antagonist candesartan in young spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzimidazoles; | 1999 |
Effects of candesartan on angiotensin II-induced renal vasoconstriction in rats and mice.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Dose- | 1999 |
Candesartan normalizes exaggerated tubuloglomerular feedback activity in young spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Hyper | 1999 |
Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure.
Topics: Aged; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidaz | 1999 |
Effect of an angiotensin II receptor antagonist, candesartan, on insulin resistance and pressor mechanisms in essential hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1999 |
Production of angiotensin II by homogeneous cultures of vascular smooth muscle cells from spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; | 1999 |
AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1999 |
[Effects of angiotensin II receptor antagonist on insulin sensitivity and sympathetic activity in spontaneously hypertensive rats].
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 1999 |
Efficacy of angiotensin II antagonists in hypertension.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood | 1999 |
Cardiovascular effects of combination of perindopril, candesartan, and amlodipine in hypertensive rats.
Topics: Adrenergic beta-Antagonists; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2000 |
Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2000 |
Angiotensin in the nucleus tractus solitarii contributes to neurogenic hypertension caused by chronic nitric oxide synthase inhibition.
Topics: Angiotensin Receptor Antagonists; Angiotensins; Animals; Antihypertensive Agents; Benzimidazoles; Bi | 2000 |
ACE inhibition and AT(1) receptor blockers: efficacy and duration in hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimid | 2000 |
AT(1) receptor antagonists-beyond blood pressure control: possible place in heart failure treatment.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Bi | 2000 |
Angiotensin peptides acting at rostral ventrolateral medulla contribute to hypertension of TGR(mREN2)27 rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Animals, Genetically Modif | 2000 |
Angiotensin II AT(1) blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; | 2000 |
[Acute hepatitis induced by candesartan].
Topics: Acute Disease; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chemica | 2000 |
Candesartan and acute liver injury.
Topics: Acute Disease; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazol | 2000 |
AT1 receptor antagonist combats oxidative stress and restores nitric oxide signaling in the SHR.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2001 |
Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Captopril; Cat | 2001 |
Combination treatment effective option for hypertensive, diabetic patients with microalbuminuria.
Topics: Albuminuria; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetic Nephropathies; Do | 2001 |
Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Animals; Antihypertensive Agents | 2001 |
Lithium intoxication after administration of AT1 blockers.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Bipol | 2001 |
Antihypertensive effects of losartan and candesartan.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Therapy, Combination; Humans; Hype | 2001 |
The influence of chronic antihypertensive treatment on the central pressor response in SHR.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl | 2001 |
Combined effects of AT(1) and ET(A) receptor antagonists, candesartan, and A-127722 in DOCA-salt hypertensive rats.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Atrasentan; Benzimidazoles; Biphenyl Comp | 2000 |
Angiotensin-II-receptor inhibitors in pregnancy.
Topics: Abnormalities, Drug-Induced; Acute Kidney Injury; Adult; Antihypertensive Agents; Benzimidazoles; Bi | 2001 |
Coronary hemodynamic and ventricular responses to angiotensin type 1 receptor inhibition in SHR: interaction with angiotensin type 2 receptors.
Topics: Angiotensin Receptor Antagonists; Animals; Aorta; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2001 |
An angiotensin II type 1 receptor blocker, candesartan, increases myocardial apoptosis in rats with acute ischemia-reperfusion.
Topics: Acute Disease; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Apoptosis; bcl-2- | 2001 |
Role of AT1 and AT2 receptor subtypes in salt-sensitive hypertension induced by sensory nerve degeneration.
Topics: Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Calcitonin Gen | 2001 |
[Report of experiences. Walk in the woods by a retiree without leg edema].
Topics: Benzimidazoles; Biphenyl Compounds; Drug Combinations; Humans; Hydrochlorothiazide; Hypertension; Jo | 2001 |
Exaggerated natriuresis after selective AT1 receptor blockade in Dahl salt-sensitive rats.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compoun | 2001 |
Ang II accumulation in rat renal endosomes during Ang II-induced hypertension: role of AT(1) receptor.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antibodies; Antihypertensi | 2002 |
Pre-treatment with candesartan protects from cerebral ischaemia.
Topics: Angiotensin Receptor Antagonists; Animals; Arterial Occlusive Diseases; Benzimidazoles; Biphenyl Com | 2001 |
Comparative effects of candesartan and enalapril on augmented vasoconstrictive responses to endothelin-1 in coronary vessels of spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blood Pressur | 2002 |
Involvement of Rho-kinase pathway for angiotensin II-induced plasminogen activator inhibitor-1 gene expression and cardiovascular remodeling in hypertensive rats.
Topics: Amides; Angiotensin II; Animals; Benzimidazoles; Biphenyl Compounds; Body Weight; Hemodynamics; Hype | 2002 |